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Abstract
Lung cancer has the highest mortality among all human neoplasias and non-small cell lung 
cancers (NSCLC) comprise approximately 85% of all lung cancer cases. DNA methylation 
deregulation, reflected by both global hypomethylation and regional hypermethylation, 
appears to play a major role in lung tumour development. Global hypomethylation affects 
repeated DNA sequences as well as CpG poor regions and imprinted genes and is linked to re­
expression of embryonic genes and retro-transposable elements, loss of imprinting 
chromosomal instability and tumour formation. Regional hypermethylation involves in a great 
extent CpG islands of promoter regions and can promote carcinogenesis through the 
transcriptional silencing of multiple tumour-suppression genes (TSGs).
This study aims to elucidate some important aspects of DNA methylation deregulation in the 
development of NSCLC. In particular it was sought to: 1) explore the molecular mechanisms 
involved in the observed deregulation of DNA methylation and 2) measure the extent of 
global DNA hypomethylation in NSCLC and investigate its links with genomic instability and 
reactivation of retrotransposition.
In order to identify possible causes for the observed deregulation of DNA methylation 
patterns we have evaluated the mRNA expression levels of key players of the DNA 
methylation machinery (UHRF1, DNMT1, DNIVIT3A and DNMT3B) in primary non-small cell 
lung carcinomas by qPCR. The methylation status of two TSGs (CDKN2A and RASSF1) 
promoters was examined by pyrosequencing in the same set. In addition UHRF1 was knocked 
down by shRNA in A549 lung adenocarcinoma cells. All four genes were overexpressed in a 
coordinated manner in the lung tumour tissues and their expression correlated with that of 
E2F1. Higher UHRF1 expression in tumour tissues correlated with the hypermethylation of
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CDKN2A and RASSF1 promoters while the relationship with a combined epigenotype was even
stronger. DNMTs expression was also significantly higher in samples with either a 
hypermethylated RASSF1 or CDKN2A promoter. When UHRF1 was knocked down in A549 lung 
adenocarcinoma cells lower methylation levels of RASSF1, CYGB and CDH13 promoters were 
observed. Furthermore, UHRF1 knockdown clones demonstrated reduced proliferation and 
decreased cell migration properties. Our data demonstrate that UHRF1 is a key epigenetic 
switch, which controls cell cycle in NSCLC through its ability to sustain the transcriptional 
silencing of tumour suppressor genes by maintaining their promoters in a hypermethylated 
status.
Towards our second aim, we evaluated global DNA methylation by pyrosequencing, 
measuring the DNA methylation levels of LINE-1 and Alu transposable elements in primary 
non-small cell carcinomas and their paired adjacent tissues. We demonstrated a significant 
reduction of the methylation levels of both elements in a coordinated manner suggesting a 
possible common mechanism for their methylation maintenance. Genomic instability was 
assessed utilizing eleven fluorescent microsatellite markers located on lung cancer hot-spot 
regions such as 3p, 5q 9p, 13q and 17p. Hypomethylation of both transposable elements was 
associated with increased genomic instability. The reduction of the methylation index of L1NE- 
1 and Alu elements following treatment of three lung cell lines with a demethylating agent 
consistently resulted in increased expression of both elements. We have also demonstrated, 
utilising a construct which carries a full LINE-1 element tagged with a reporter cassette, that 
unmethylated LINE-1 can retrotranspose successfully in a lung cancer cell line. Our study 
demonstrates the strong link between hypomethylation of transposable elements with 
genomic instability in non-small cell lung cancer and provides early evidence for a potential 
active role of these elements in lung neoplasia.
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Chapter 1. Lung Cancer
1.1 Epidemiology
1.1.1 Incidence
Lung cancer is a global health threat. In the year 2002, more than 1.3 million people 
worldwide were diagnosed with lung cancer [Parkin, 2005]. In the United Kingdom it is the 
second most commonly diagnosed cancer, following breast cancer, with 39,027 new cases 
observed in the year 2006. Lung cancer has the second higher incident rates in men, after 
prostate cancer, with 22,381 new cases observed in the year 2006 in the UK. In woman it is 
the third most commonly diagnosed cancer, following breast and colorectal cancer, with 
16,646 new cases in the year 2006 in the UK [Cancer Stats, CRUK website, 2007] (Figure 1). In 
the United States lung cancer is the most commonly diagnosed cancer with an estimate of up 
to 219,440 new cases in 2009, with 116,090 cases for men and 103,350 cases for women 
[Jemal, 2009], In Europe, lung cancer is the secondly most commonly diagnosed cancer in 
men after prostate cancer with 292,200 cases in 2006. In women lung cancer rated fourth 
with 94,100 cases after breast cancer, colorectal cancer and cancer of the uterus in the year 
2006. Lung cancer is the third most commonly diagnosed cancer in Europe in both sexes 
(386,300) after breast and colorectal cancer in the year 2006 [Ferlay, 2007].
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Figure 1. Incidence rates for the 20 most frequently diagnosed cancer types for the year 2006 in the UK. 
Number of cases includes both sexes. Lung cancer is the second most frequent cancer type with 39,027 cases. 
(Figure adapted without permission by Cancer Stats, CRUK website, 2007).
1.1.2 Survival - Mortality
Lung cancer is the leading cause of cancer-related deaths worldwide. In the United Kingdom 
for the year 2007, lung cancer mortality accounted for 22% of all cancer related deaths with 
34,509 cases. It is of note that lung cancer mortality rates are more than two times higher 
than the next most common cause of cancer related death, colorectal cancer (Figure 2). 
Mortality rates are higher in men with 19,637 cases, compared to female mortality rates with 
14,872 cases in 2007 in UK [Cancer Stats, CRUK website, 2007]. In the United States lung 
cancer is estimated to be the cause of 159,390 deaths (88,900 for men and 70,490 for 
women) for the year 2009 alone [Jemal, 2009]. The situation is similar in Europe where lung 
cancer related deaths account for 253.300 cases in men and 81.500 cases in woman, totalling 
334.800 deaths in 2006 [Ferlay, 2007].
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Figure 2 Mortality rates for the 20 most common causes of cancer-related death for the year 2007 in UK. 
Number of cases includes both sexes. Lung cancer is the most frequent cause of cancer-related death with 
34,509 cases. (Figure adapted without permission by Cancer Stats, CRUK website, 2007).
The overall five-year survival after diagnosis of the disease has increased from 12.4% for the 
period 1974-1976 to 15% for the period 1996-2002 reflecting the limited advances in 
screening and treatment of lung cancer [Schwartz, 2007]. The poor 5 year-survival rates are 
mainly due to the late diagnosis of lung cancer cases combined with the failure of current 
therapeutic regimes to cure advanced disease [Breuer, 2005]. In the United States the 5 year 
survival rates are at 16% for 1996-2004 diagnoses, demonstrating an increase from 13% 
compared to the periods 1975-1977 and 1984-1986 [Jemal, 2009]. In England and Wales the 5 
year survival rates are significantly lower, remaining bellow 10% for both men and women 
[Cancer Stats, CRUK website, 2007].
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1.1.3 Risk Factors
The most important risk factor for lung cancer is long term exposure to inhaled tobacco 
smoke [Bruske-Hohlfeld, 2009]. Almost 87% of lung cancer cases are caused by cigarette 
smoking although only 20% of smokers will eventually get lung cancer [Hecht, 2002]. The risk 
of developing lung cancer is affected by smoking duration, level of consumption and tar 
content. However, the risk is much more dependent on duration of smoking rather than 
consumption. In addition, starting smoking at young age carries additional risks of lung 
damage [Cancer Stats, CRUK website, 2007].
The particulate phase of tobacco smoke contains more than 3500 chemical compounds, at 
least 55 of which have been identified as carcinogens. The two major classes of carcinogens 
are polycyclic aromatic hydrocarbons and tobacco-specific nitrosamines [Shields, 2002]. 
Tobacco induced carcinogenesis is a complex and multistep process. In general, tobacco 
smoking leads to increased carcinogen-DNA adduct formations which cause accumulating 
damage on the DNA of the pulmonary epithelial cells after a long latency period [Shields, 
2002], [Hecht, 2002]. Other risk factors of lung cancer include; (i) exposure to industrial 
carcinogens such as asbestos, arsenic, chromium, nickel, cadmium, radon, particulate air 
pollution and others [Bruske-Hohlfeld, 2009]; (ii) respiratory diseases such as COPD, chronic 
bronchitis, emphysema and tuberculosis [Littman, 2004], [Schabath, 2005]; and (iii) family 
history [Matakidou, 2005] and genetic background [McKay, 2008], [Bailey-Wilson, 2004].
1.1.4 The LLP project
The Liverpool Lung Project (LLP) is a large population study, funded by the Roy Castle 
Foundation. It aims to reduce lung cancer mortality by developing early detection and
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intervention schemes [Field, 2005]. LLP utilises epidemiological data and has developed a 5-
year absolute risk assessment model for predicting lung cancer development [Cassidy, 2008]. 
The LLP participated in a large international consortium undertaking a genome-wide 
association study (GWAS) to identify SNPs that may be responsible for increased lung cancer 
risk [Hung, 2008], [McKay, 2008], [Lips, 2010]. Currently genetic and epigenetic biomarkers 
are being integrated into the model in order to increase its prediction efficiency. In parallel, a 
number of projects relevant to the genetics and biology of lung cancer development are 
undertaken, the present thesis being among them.
1.2 Pathology
1.2.1 Histological subtypes
The majority of lung tumours are classified into four major types: squamous cell carcinomas, 
adenocarcinomas, large cell carcinomas and small cell carcinomas. The remaining malignant 
epithelial tumours include adenosquamous carcinomas, sarcomatoid carcinomas, carcinoid 
tumours and other [Beasley, 2005]. The WHO classification of epithelial lung tumours is 
provided in Table 1 [Beasley, 2005]. Apart from tumours of epithelial origin lung cancer 
includes tumours with neuroendocrine morphology such as low grade typical carcinoids (TC) 
and intermediate grade atypical carcinoids (AC), sarcomatoid carcinomas such as pleomorphic 
carcinomas, spindle cell carcinomas and carcinosarcomas, and other pulmonary tumours 
including mucoepidermoid carcinomas (MEC) and adenoid cystic carcinomas [Beasley,2005]. 
For practical therapeutic reasons epithelial tumours are divided in two main categories: small 
cell lung cancers (SCLCs) and non-small cell lung cancers (NSCLCs) which account for
16
approximately 75% of lung tumours and include squamous cell carcinomas, adenocarcinomas
and large cell carcinomas [Risch, 2008].
Table 1 2004 WHO Classification of malignant epithelial lung tumours (adapted without permission Beasley,
2005).
Squamous cell carcinoma
Variants 
Papillary 
Clear ceil 
Small cell 
Basaloid
Small cell carcinoma 
Variant
Combined small cell carcinoma 
Adenocarcinoma
Adenocarcinoma, mixed subtype 
Acinar adenocarcinoma 
Papillary adenocarcinoma 
Bronchioloalveolar carcinoma 
Nonmucinous 
Mucinous
Mixed nonmucinous and mucinous 
or indeterminate 
Solid adenocarcinoma with mucin 
production 
Variants
Fetal adenocarcinoma 
Mucinous {"colloid") carcinoma 
Mucinous cystadenocarcinoma 
Signet ring adenocarcinoma 
Clear cell adenocarcinoma
Large cell carcinoma 
Variants
Large cell neuroendocrine carcinoma 
Combined large cell neuroendocrine 
carcinoma 
Basaloid carcinoma 
Lymphoepithelioma-like carcinoma 
Clear cell carcinoma 
Large cell carcinoma with rhabdoid 
phenotype
Adenosquamous carcinoma 
Sarcomatoid carcinoma 
Pleomorphic carcinoma 
Spindle cell carcinoma 
Giant cell carcinoma 
Carcinosarcoma 
Pulmonary blastoma 
Carcinoid Tumour 
Typical carcinoid 
Atypical carcinoid 
Salivary Gland Tumours 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
Epithelial-myoepithelial carcinoma
Squamous cell carcinoma (SCC) is the most frequent lung cancer pathology in Europe 
[Hoffman, 2000]. The great percentage of squamous cell carcinomas (75%) usually occurs as 
central masses while the remaining carcinomas are normally located peripherally [Beasley, 
2005]. SCCs are usually associated with lobar collapse, obstructive pneumonia and 
haemoptysis and demonstrate late development of distant metastasis [Hoffman, 2000]. Figure 
3 depicts the morphology of a typical squamous cell carcinoma under microscopic 
examination demonstrating keratinisation or intercellular bridges [Beasley, 2005].
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Figure 3 Photo of a squamous cell carcinoma. The tumour cells demonstrate keratinisation and squamous 
pearls (adapted without permission from Beasley, 2005)
Adenocarcinomas are usually present as peripheral nodules and are quite often 
heterogeneous containing more than one subtype [Beasley, 2005]. They are characterised by 
early development of metastases and are associated with smoking in a lesser extend 
compared to squamous cell carcinomas [Hoffman, 2000]. There are a number of different 
subtypes of adenocarcinomas as seen in Table 1. The morphology of acinar and 
bronchioloalveolar carcinoma types are distributed in figure 4.
Figure 4 Subtypes of adenocarcinomas. A: Acinar adenocarcinomas. Tumour cells form glands or acini 
indicating adenocarcinomas differentiation. B:Nonmucinous type of bronchioloalveolar carcinoma (adapted 
without permission from Beasley, 2005)
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Small-cell lung carcinomas are neuroendocrine tumours with small cell cytological features,
oval shaped cells with scant cytoplasm and hyperchromatic nuclei and considered to be the 
most aggressive type of lung cancers (Figure 5) [Beasley, 2005], [Jackman, 2005]. They are 
strongly associated with smoking, they have a rapid growth rate and are characterised by 
early metastasis [Jackman, 2005] [Hoffman, 2000].
Figure 5 Small-cell lung cancer. The tumour demonstrates typical scant cytoplasm, increased mitotic index and 
spindling (adapted without permission from Jackman, 2005)
1.2.2 Symptoms and Treatment
Lung cancer patients present a variety of symptoms that may be associated with the primary 
tumour or mediastinal spread of the tumour, metastasis or paraneoplastic syndrome. 
Symptoms include dyspnoea, cough, haemoptysis, chest pain, loss of appetite and weight loss 
[Hamilton, 2005]. Lung cancer primary tumours can metastasise in many different sites 
including the brain, bone, liver, pleural cavity and skin [Hoffman, 2000].
Treatment differs for NSCLC and SCLC. Surgery is the main curative treatment for NSCLC 
patients, although the tumour may not be operable in many cases [Hoffman, 2000]. The five
19
year survival rates for stage I (UNO, T2N0) patients treated with radical surgery are between 
40%-67% [Hoffman, 2000]. Depending on the stage of the disease and patient's general health 
status, radical radiotherapy may be used instead of surgery but with a poorer outcome. Stage 
II (T1N1, T2N1, T3N0) patients have a 5 year survival rate of 25-55% after surgery. Surgery is 
also performed when possible, combined with radiotherapy and/or chemotherapy, for 
patients with advanced NSCLC (stage III), [Hoffman, 2000], [Burris, 2009].
In contrast, surgery for SCLC is rarely an option. Combined chemotherapy is the main 
treatment option with active drugs including cisplatin, etoposide, carboplatin and others while 
chest radiotherapy may also be applied in certain patients [Jackman, 2005]. 85-95% of 
patients with limited disease respond to combined chemotherapy with a median survival of 
14-20 months and 5-year cancer free survival of 12-25%. 75-80% of patients with extensive 
disease respond to combined chemotherapy with a median survival of 7-10 months and 5- 
year cancer free survival of 2% [Jackman, 2005] [Hoffman, 2000].
1.3 Molecular Pathogenesis
Transformation of normal lung cells into cancer cells is a multistep procedure. This includes 
multiple genetic and epigenetic changes and result in some form of growth or cellular survival 
advantage [Breuer, 2005]. Genetic studies in lung cancer tissues and cell lines have shown 
that the key events causing lung carcinogenesis, as in all cancers, include (proto)oncogene 
activation and tumour-suppression gene (TSG) inactivation. Oncogene activation usually 
occurs through a mechanism such as chromosome translocation, gene amplification or point 
mutation [Breuer, 2005], [Risch, 2008]. TSGs inactivation is believed to take place in a two- 
step process affecting both alleles [Breuer, 2005]. Inactivation may take place due to loss of
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heterozygosity (chromosomal deletion or translocation), point mutation or epigenetic changes 
such as silencing by hypermethylation or homozygous deletion [Breuer, 2005], [Risch, 2008]. 
The landscape of genetic and epigenetic changes across the complicated network of 
oncogenes and tumour suppressor genes involved in cancer development is massive. A small 
number of such representative gene changes are given below in the following paragraphs.
1.3.1 Oncogene activation
Proto-oncogene activation is a frequent phenomenon in lung cancers. Among the most 
frequently activated oncogenes observed are the RAS family proto-oncogenes. Usually 
activated due to point mutations, RAS family oncogene activation is detected in 15-20% of 
NSCLCs with K-RAS activation being the most frequent event [Aviel-Ronen, 2006]. Ras 
activated oncogenes induce the RAF1MEK/ERK pathway which is associated with 
transformation of cells and tumour progression [Sekido, 2003]. Genes of another proto­
oncogene family, the Myc family (comprised of the MYC, MYCN and MYCL genes) are 
frequently activated either by gene amplification or transcriptional deregulation in lung 
cancers [Sekido, 2003], [Breuer, 2005]. At least one member of the MYC family is activated in 
18% of SCLCs and 8% of NSCLCs [Richardson, 1993].
The receptor tyrosine kinases (RTKs) mediate cell signalling in response to extracellular growth 
factors. Members of this family, including the epidermal growth factor receptor (EGFR) and 
Heregulin receptor (HER2), are frequently deregulated in lung cancer and are associated with 
malignant transformation [Sharma, 2007], [Breuer, 2005]. EGFR is overexpressed in 
approximately 60% of NSCLCs, most frequently in squamous cell carcinomas, and is associated 
with poor prognosis [Sharma, 2007]. Heregulin receptor (HER2/neu) is overexpressed in 
approximately 30% of NSCLCs and is most frequent in adenocarcinomas and is also associated
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with poor survival [Sekido, 2003]. Furthermore, the GRP growth hormone and its receptors 
are found to be overexpressed in 20%-50% of SCLCs promoting the growth of this lung cancer 
type [Sekido, 2003].
1.3.2 Tumour suppressor gene inactivation
P53 protein is one of the most studied proteins due to its clear function as a tumour 
suppressor gene. It is responsible for the maintenance of genome integrity preventing the 
accumulation of genetic damage in daughter cells. Activated by various stress signals, such as 
DNA damage, hypoxia, oncogene activation and others, it acts mainly as a transcription factor 
regulating a number of responsive genes, mediating cell-cycle arrest, senescence, DNA repair, 
apoptosis and many more functions of the cell [Vousden, 2007] (Figure 6). P53 is the most 
frequently mutated TSG in human cancers with alterations observed in 75%-100% of SCLCs 
and in 47% of NSCLCs [Sekido, 2003].
Figure 6 P53: the guardian of the human genome. P53 expression is induced by a variety of stress signals (blue 
boxes). Acting mainly as a transcription factor, p53 transactivates a variety of molecules affecting many 
different cell processes (pink boxes)( Figure adapted without permission from Vousden, 2007).
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Inactivating mutations are the most frequent cause of p53 inactivation in lung cancers
[Hollstein, 1991]. Other molecules that are part of the p53 pathway either as p53 regulators 
or upstream and downstream targets and are frequently deregulated in lung cancers include 
p21, pl4ARF and MDM2 [Sekido, 2003].
The CDKN2Amk4a-cyclin D1-CDK4-RB pathway, which is critical in controlling the G1 to S phase 
transition of the cell, is also widely disturbed in lung cancers. Two out of the four main 
compounds of this pathway, CDKN2A and Rb, are widely affected. The CDKN2A gene is 
inactivated due to either hypermethylation of its 5' promoter or due to inactivating mutations 
that occur in approximately 30%-70% of NSCLCs. The Rb protein, in its hypophosphorylated 
form, binds and blocks on the transition transcription factors E2F1, E2F2 and E2F3 which are 
essential for the G1 to S phase transition of the cell cycle. Inactivation of pRb due to deletion, 
nonsense mutations and splicing abnormalities appear in almost 90% of SCLCs and in 15-30% 
of NSCLCs [Sekido, 2003].
Frequent homozygous deletions at chromosome region 3pl4.2 in lung cancers lead to the 
inactivation of the fragile histine triad (FRIT) TSG [Geradts, 2000]. In addition the FRIT gene is 
also silenced due to promoter hypermethylation in almost 50% of primary lung cancers 
[Zochbauer-Muller, 2001]. Other tumour suppressor genes that are frequently inactivated in 
cancers due to hypermethylation include RASSF1 which is inactivated in more than 90% of 
SCLCs and about 50% of NSCLCs [Sekido, 2003], [Vaissiere, 2009], CYGB [Xinarianos, 2006], 
and RAR-b [Virnani, 2000], [Risch, 2008].
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Chapter 2. DNA methylation
2.1 Cancer Epigenetics
Epigenetic changes are defined as heritable changes in gene expression that occur 
independent of any alterations on the DNA sequence [Esteller, 2008]. Most of these changes 
are established during differentiation and reflect the epigenome of a cell. They include 
methylation of the cytosine residues of DNA, post-translational modifications of histone 
proteins and positioning of nucleosomes along the DNA [Sharma, 2010]. The epigenome of a 
cell is maintained through cell divisions, while failure to do so can potentially lead to the 
activation or de-activation of signalling pathways resulting quite frequently in catastrophic 
results regarding the proper function of the cell. Epigenetic reprogramming of the cell is 
studied in a great extent in human tumours and is believed to play a crucial role in 
carcinogenesis and tumour progression [Jones, 2002], [Jones, 2007], [Esteller, 2008], [Sharma, 
2010]. In the following paragraphs we will study the role of DNA methylation in cancers while 
we will not stress out the other epigenetic changes observed in human cells.
2.2 DNA methylation
DNA methylation is probably the best studied epigenetic change in humans as yet. It involves 
the addition of a methyl group at the 5' site of a cytosine residue which, most of the times, is 
located prior to a guanidine residue (CpG dinucleotide) on the DNA chain [Cheng, 2008]. The 
addition of methyl groups does not occur randomly on CpG sites. It takes place mainly on 
stretches of DNA that include a great proportion of CpG sites, called CpG islands, and regions 
of large repetitive sequences (centromeric repeats, retrotransposable elements, satellite 
DNA). CpG islands can be found in the vicinity of about 76% of human promoters, their length
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is between 0.4-3 kb, they have a rich C-G content (>55%) and CpG sites in greater frequency 
compared to the rest of the human genome with an observed/expected ratio of >0.6 [Golf, 
2005]. While repetitive sequences are usually heavily methylated in normal tissues, CpG 
islands which are associated with both tissue-specific and housekeeping genes, are usually 
unmethylated or lightly methylated [Sharma, 2010], [Goll, 2005].
It is now well established that DNA methyiation causes transcriptional repression, especially 
when affecting CpG islands in the vicinity of gene promoters. This is accomplished either by 
blocking the binding of transcription factors on the 5' end promoters of genes or by the 
recruitment of methyl-binding proteins, such as MeCp2, which mediate transcriptional 
repression through the subsequent recruitment of a histone deacetylase (HDACs) containing 
complex [Jones, 1998], [Sharma, 2010], [Boyes, 1991], [Nan, 1998]. Apart from its role on 
transcriptional repression, DNA methyiation has others effects on the human genome. It is 
responsible for X chromosome inactivation, genomic imprinting, genome integrity and 
stability, for the maintenance of telomere length and normal development [Robertson, 2001], 
[Okano, 1999], [Brena, 2007], [Gonzalo, 2006]. The importance of the proper maintenance of 
methyiation patterns, which are established during development, is obvious in genetic models 
were DNA methyltransferases (DNMTs) knockouts, the enzymes responsible for the 
methyiation of DNA, can lead to genome instability [Brown, 2007] and tumour formation 
[Gaudet, 2003],
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2.3 DNA methyltransferases
Methylation of the human genomic DNA is undertaken by DNMTs. In brief, when DNMTs bind 
to DNA, the target cytosine is extruded from the double helix into the active site of the 
enzyme where the transfer of a methyl group from the Ado-Met substrate takes place (Figure 
7) [Cheng, 2001], [Cheng, 2008].
Figure 7 Crystal structure of the DNA (cytosine-5)-methyltransferase, M.Hhal (recognition sequence: GCGC) 
complexed with S-adenosyl-L-methionine. The core of the structure is dominated by sequence motifs 
conserved among all DNA (cytosine-5)-methyltransferases, and these are responsible for cofactor binding and 
methyltransferase function. Figure adapted without permission from Protein Data Bank (PDB file 1HMY, 
Cheng, 1993)
There are three DNMTs with proven de novo methylase activity; DNMT1, DNMT3A and 
DNMT3B [Bestor, 2000] while a fourth DNA methyltransferase DNMT3L appears to have an 
accessory function in de novo methylation, despite lacking itself any catalytic methylation 
activity [Cheng, 2008]. DNMT2 methylates cytosine 38 in the anticodon loop of tRNAasp while 
it has only a weak and ambiguous enzymatic activity on DNA substrate [Goll, 2006], [Hermann,
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2003]. DNMT3 methyltransferases can be grouped in two distinct structurally and functionally 
families compared to DNMT1 or DNMT2 as seen in Figure 8 [Cheng, 2008].
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Figure 8 Architectural structure of the human DNA methyltransferases. The methyltransferase (MTase) 
catalytic domain can be seen in the pink box. DNMT3L has only a small part of the MTase domain lacking 
methyltransferase activity. Different domains such as PWWP, PCNA and ZN binding domains are marked on 
each gene. DNMT3A and DNMT3B share great homology (Figure adapted without permission from Cheng, 
2008).
2.3.1 DNMT1
DNMT1 was the first methyltransferase to be identified [Bestor, 1988]. It is a large protein 
comprised of a 1616 amino acid sequence. At the C-terminal domain lays the catalytic centre 
(MTase catalytic domain) responsible for the methyltransferase activity of the enzyme. At the 
N-terminal part of the enzyme lie several individual domains, including the proliferating cell 
nuclear antigen (PCNA) binding domain, that are responsible for regulating the enzyme's 
activity (Figure 8)[Jeltsch, 2006].
DNMT1 is responsible mainly for maintaining methylation patterns during replication of DNA 
[Chen, 2006] and repair [Mortusewicz, 2005] demonstrating a thirty to forty fold preference 
for hemimethylated substrates compared to unmethylated substrates [Cheng, 2008] [Yoder,
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1997]. However, de novo methylation activity of the enzyme cannot be excluded since DNMT1
is the only methyltransferase that was purified and cloned on the basis of its ability for de 
novo methylation and since its specific activity on unmethylated DIMA is greater than the two 
main de novo methyltransferases DNMT3A and DNMT3B [Goll, 2005], [Cheng, 2008]. 
Additional features of DNMT1, supporting a maintenance methyltransferase character, are its 
ability to localise on replication foci via several independent domains and interact with the 
PCNA [Robertson, 2001].
DNMT1 expression is a prerequisite for proper embryonic development, imprinting, and X 
chromosome inactivation as demonstrated by DNMT1 knockout mice [Robertson, 2001] 
[Brown, 2007], In addition, genetic studies of DNMT1 demonstrate a link between DNA 
methylation and tumourigenesis. This subject will be discussed in a following chapter.
2.3.2 The DNMT3 family
The DNMT3 family consists of the DNMT3A, DNMT3B and DNMT3L proteins. DNMT3A and 
DNMT3B can catalyse CpG methylation and are considered as the main de novo 
methyltransferases [Okano, 1999] while DNMT3L lacks any methyltransferase activity and 
functions only as a regulatory factor in germ cells [Goll, 2005]. The structure of DNMT3A and 
DNMT3B proteins is very closely related. On the C-terminus lies the catalytic centre of the 
proteins with the methyltransferase activity (MTase catalytic domain). The N-terminal tails of 
both proteins contain a PWWP domain and a cysteine-rich zinc-binding region related to that 
of DNMTl and some of the methyl-binding proteins (MBPs) (Figure 8).
The two proteins can catalyse the transfer of methyl-group in unmethylated and 
hemimethylated substrates at equal rates and are expressed in a variety of adult tissues but in
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lower rates compared to DNMT1 [Goll, 2005]. Double knockout mice of either DNMT3A or
DNMT3B demonstrated global demethylation of the genome although in a lesser extent 
compared to DNMT1 knockout mice. In addition the inactivation of both genes blocks de novo 
methylation on embryonic stem cells and early mice embryos demonstrating that these 
proteins are essential for de novo methylation [Okano, 1999]. However, embryonic cells with 
no DNMT3B or DNMT3A activity demonstrate a mild demethylation which suggests that these 
two enzymes may also play a role in methylation maintenance assisting in a sense DNMT1 
[Chen, 2003], [Okano, 1999], [Liang, 2002].
It is also worth noting that point mutations in human DNMT3B are responsible for the human 
ICF (Immunodeficiency, Centromere instability and Facial anomalies) syndrome. This 
syndrome is caused by the hypomethylation of classical satellite DNA at the pericentromic 
regions of chromosomes 1, 9 and 16. These regions, following demethylation, demonstrate 
high rates of gains and losses of long arms and result in chromosomes with multiple long arms 
and single short arms [Goll, 2005], [Bestor, 2000],
DNMT3L is related to the other two proteins of the DNMT3 family in its C-terminal (MTase 
catalytic domain) and its N-terminal domain (cysteine-rich domain) but lacks the PWWP 
domain (Figure 8) [Goll, 2005]. It is expressed specifically in germ cells [Aapola, 2000] and as 
we already mentioned it lacks any methyltransferase activity [Aapola, 2000]. However 
DNMT3L co-localises with both DNMT3A and DNMT3B enhancing their de novo methylation 
enzymatic activity and is essential for the methylation of most imprinted loci and dispersed 
retrotransposons in germ cells [Bourc'his, 2004], [Webster, 2005], [Cheng, 2008].
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2.4 UHRF1
Although DNMT1 demonstrates a 30-40 fold preference for hemimethylated DNA in vitro, it is 
questioned whether this ability is enough to explain the high fidelity observed in the 
inheritance of DNA methylation patterns [Ooi, 2008]. UHRF1 (also known as ICBP90) is a 
protein that has recently been found to play an important part in methylation maintenance 
assisting DNMT1 [Bostick, 2007], [Ooi, 2008]. It binds hemi-methylated DNA through its SRA 
(SET and RING associated) domain [Arita, 2008], [Avvakumon, 2008] and subsequently 
facilitates the loading of DNMT1 onto the replicating heterochromatic regions [Sharif, 2007], 
[Bostick, 2007]. UHRF1 knockout derivatives of mouse embryonic stem cells exhibit significant 
loss of genomic methylation demonstrating the important role of UHRF1 in the maintenance 
of DNA methylation patterns [Bostick, 2007].
Based on structural data Arita and colleagues [Arita, 2008] have suggested a model according 
to which UHRF1 facilitates the work of DNMT1 by recruiting it and in a sense offering the 
target sequence. In brief, after the recognition and binding of UHRF1 onto a hemi-methylated 
sequence, the methyl-cytosine base is flipped out of the DNA helix in the SRA-DNA complex 
and fits tightly into a protein pocket on the concave surface. The successive flip out of the pre­
existing methylated cytosine and the target cytosine to be methylated is associated with the 
coordinated transfer of the hemi-methylated CpG site from UHRF1 to DNMT1 (Figure 9) (Arita, 
2008).
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Figure 9 Proposed model for the role of UHRF1 in methylation maintenance. The SRA domain of the UHRF1 
protein recognises hemimethylated CpG sites. The methylcytosine base is flipped out of the DNA helix in the 
SRA-DNA complex and fits tightly into a protein pocket on the concave surface of UHRF1. After recruitment of 
DNMT1, UHRF1 'offers' the target cytosine to DNMT1 (Figure adapted without permission from Arita, 2008)
It is worth noting that a recent study demonstrates strong interactions between the UHRF1 
protein and the de novo methyltransferases DNMT3A and DNMT3B. Apart from DNMT1 
mediated DNA methylation maintenance, this study suggests that UHRF1, together with 
DNMT3A and DNMT3B, can mediate promoter silencing through histone modification 
followed by DNA methylation [Meilinger, 2009].
2.5 Demethylases
DNA methylation can be removed passively by blocking methylation during DNA replication 
[Stresemann, 2008], [Wild, 2010]. However there have been several studies which suggest an 
alternative mechanism towards DNA hypomethylation. The general hypothesis is that methyl 
groups can be taken out of the CpG sites through active demethylation, a process which can 
be undertaken by specific demethylating proteins. Although this mechanism was proven in 
plants were active demethylation is undertaken by a family of m5C glycosylase, in mammals a 
similar mechanism has not been established yet [Ooi, 2008]. Nevertheless, several molecules 
such as thymine DNA glycosylase (TDG), methyl-binding domain 2 (MDB2) protein or
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GADD45a have been suggested to act as DNA demethylases in the literature post, 1993],
[Bhattacharya, 1999], [Hamm, 2008], [Barreto, 2007], although the field of active 
demethylation still remains unclear [for a review read Ooi, 2008]. It is of note that two recent 
studies suggest that the demethylation process is initiated by the same enzymes responsible 
for de novo DNA methylation, DNA methyltransferases DNMT3A and DNMT3B [Kangaspeska, 
2008], [Metivier, 2008].
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Chapter 3. DNA methylation in cancer
The spectrum of DNA methylation pattern alterations during cell transformation and tumour 
progression is wide. These changes are only a part of a fundamental epigenetic 
reprogramming that takes place in human cancers [Esteller; 2008]. DNA methylation changes 
can be classified into two major categories: global DNA hypomethylation and regional 
hypermethylation. Despite the plethora of studies exploring the causes and the effects of 
these two phenomena in cancer initiation and progression, the landscape remains far from 
being clear as to what is the biochemical relationship between them as well as their timing 
[Esteller, 2008], [Wild, 2010].
3.1 Global hypomethylation
The decrease in the overall 5-methylcytocine context of tumour cells was one of the first 
epigenetic changes to be observed in human cancers [Feinberg, 1983]. This is a common 
feature of human cancers affecting predominantly repeated DNA sequences such as 
LINES(long interspersed nuclear elements), SINES (short interspersed nuclear elements) and 
satellite repeats or CpG poor regions and imprinted genes [Ehrlich, 2002], [Sharma, 2010]. It is 
suggested that the degree of hypomethylation is related to the tumour progression. As 
tumour progresses from a benign to an invasive form hypomethylation increases [Esteller, 
2008], [Fraga, 2004].
The significance of hypomethylation is now well established, with experiments in animal and 
cell models demonstrating its capability of promoting chromosomal instability and tumour 
formation [Gaudet 2003], [Eden, 2003], loss of imprinting and oncogene re-activation 
[Esteller, 2008], [Feinberg, 2006]. One of the possible means by which DNA hypomethylation
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is suggested to promote carcinogenesis is by the 'unmasking' of repetitive sequences [Esteller,
2008]. Hypomethylation of repeated sequences can lead to genomic instability by promoting 
chromosomal rearrangements [Eden, 2003]. In addition, hypomethylation of 
retrotransposable elements which are part of the repeated sequences affected, may lead to 
their reactivation, translocation to other parts of the genome and finally to genomic instability 
[Howard, 2008], [Gaudet, 2003]. Retrotransposable elements and their possible reactivation 
in human cancer will be discussed in the following chapter. It is worth mentioning that, 
although DNA hypomethylation in cancers was observed earlier than regional 
hypermethylation, its relation with repeated sequences which pose technical difficulties, 
made this mechanism less popular and less studied than its counterpart [Ehrlich, 2006],
3.2 The human hypermethylome
Regional hypermethylation in human cancers affects in a great extend the CpG islands of 
promoter regions and is a major event in carcinogenesis, promoting the transcriptional 
silencing of many tumour-suppression genes (TSGs) [Esteller, 2008], [Feinberg, 2006]. To date, 
there is a large list of genes which have been shown to be at least partially silenced by 
promoter hypermethylation in human cancers, i.e. CDKN2A, Rb, BRCA1, VHL, RASSF1, RARB2, 
GSTP1, DAPK1, APC, and many more [Esteller, 2007], [Robertson, 2001], The affected TSGs 
are part of different cellular pathways including cell signalling, adhesion and invasion, cell 
cycle, angiogenesis, DNA repair and apoptosis all of which are involved in cancer development 
(Table 2) [Esteller, 2007]. It is of note that the profiles of hypermethylated TSGs are specific 
for the different cancer types (picture 10) [Costello, 2000], [Esteller, 2007].
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Table 2. Representative genes that are frequently hypermethylated in human tumours and affected pathways 
(Table adapted without permission from Esteller, 2007)
Pathways Representative hypermethylated genes
DNA repair hMLHl, MGMT, WRN, BRCA1
Hormone response Estrogen, progesterone, androgen, prolactin and thyroid-stimulating 
hormone receptors
Vitamin response RARB2, CRBP1,
Ras signalling RASSFIA, NOREIA
Cell cycle CDKN2AINK4a, pl5INK4b, Rb
P53 network pl4ARF, p73, HIC-1
Cell adherence and invasion E-cadherin, H-cadherin, FAT cadherin, EXT-1, SLIT2, EMP3
Apoptosis TMS1, DAPK1, WIF-1, SFRP1
Wnt signaling APC, DKK-l, 1GFBP-3
Tyrosine kinase cascades SOCS-1, SOCS-3, SYK
Transcription factors GATA-4, GATA-5, ID4
Homeobox genes PAX6, HOXA9
Other pathways GSTP1, LKB1/STK11, THBS-14, COX-2, SRBC, RIZ1, TPEF/HPP1, SLC5A8,
Lamin A/C
microRNAs miR-127 (targeting BCL6), miR-124a 
(targeting CDK6)
Lung cancer is affected, as all cancer types, by regional hypermethylation. Hypermethylation 
of a plethora of gene promoters such as RASSF1 [Vaissiere, 2009], CDKN2A [Esteller, 1999], 
[Zochbauer-Muller, 2001], CYGB [Xinarianos, 2006], EDNRB [Knight, 2009], RARbeta [Virnani, 
2000], MGMT [Zochbauer-Muller, 2001] and CDH13 [Vaissiere, 2009], [Kim, 2007] has been 
demonstrated indicating the key role of aberrant methylation into the progression of the 
disease.
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Figure 10 Frequently hypermethylated genes and their proteins in different cancer types (Figure adapted 
without permission from Esteiler, 2008)
3.3 DNMTs and UHRF1 in human cancers
The majority of studies in human cancer tissues suggest that the expression levels of most 
DNMTs are increased [el-Deiry, 1991], [Robertson, 1999], [Robertson, 2001]. A study in lung 
cancer primary tissues demonstrates overexpression of all DNMT1, DNMT3A and DNMT3B 
while DNMT1 overexpression correlated with a poor prognosis [Lin, 2007]. Another study in 
NSCLC suggests that the predominant form of DNMT3B is the ADNMT3B isoform [Wang, 
2006]. E2F1 can bind and regulate the expression of DNMT1 [Kimura, 2003], [McCabe, 2005]. 
It appears that the pRb/E2F pathway regulates the expression of DNMT1 increasing their
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abundance during S and G2 phases [Vogel, 1988], [Jeanblanc, 2005] in order to replicate the
DNA methylation patterns onto the newly synthesized strands.
Accumulated evidence suggests that UHRF1 has a putative oncogene function [Bronner, 
2007]. In normal cells, UHRF1 is expressed in late G1 and during G2/M transition, however, in 
contrast, it is expressed throughout the cell cycle in cancer cell lines [Mousli, 2003] and 
overexpressed in breast carcinomas [Hopfner, 2000], [Jenkins, 2005], [Unoki, 2004] and 
pancreatic adenocarcinomas [Crnogorac-Jurcevic, 2005]. The UF1RF1 gene is a target for the 
transcriptional activator E2F1 [Unoki, 2004], [Mousli, 2003] and its expression is associated 
with increased cell proliferation [Fujimori, 1998], [Hopfner, 2000]. Moreover, UHRF1 regulates 
the expression of topoisomerase II alpha and retinoblastoma genes, favouring cell entry into 
the S phase of the cell cycle [Jeanblanc, 2005], [Hopfner, 2000], [Hopfner, 2002]. In addition, 
UHRF1 expression knockdown leads to growth arrest [Arima, 2004], [Jenkins, 2005], 
[Bonapace, 2002], [Unoki, 2004]. There is limited information regarding the status of UHRF1 in 
lung cancer where overexpression of UHRF1 has been identified in the A549 cell line [Mousli, 
2003] and in a small number (n=10) of primary lung tumours [Jenkins, 2005].
3.4 DIMMTs, UHRF1 and aberrant methylation patterns
DNMT1, DNMT3A, DNMT3B and UHRF1 are the main molecules responsible for the 
generation and the maintenance of normal methylation patterns in human cells. This group of 
proteins may, therefore, provide a possible mechanism behind the aberrant methylation 
patterns observed in human cancers. A change in the expression levels of some of these 
proteins could potentially lead to the altered methylation profiles observed in cancers 
[Ehrlich, 2002]. In many cases the observed overexpression of DIMMTs in primary human
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tumours was analysed in comparison to the methylation status of several TSGs. Despite the
lack of correlation between overexpression of DNMTs and hypermethylation of specific TSGs 
in some studies [Ehrlich, 2006], [Sato, 2002], [Park, 2006], other reports demonstrate 
associations between expression of specific DNMTs with hypermethylation status of specific 
genes. Overexpression of a specific DNMT3B isoform (ADNMT3B) in NSCLC is responsible for 
the hypermethylation of RASSF1 promoter but not CDKN2A promoter, suggesting that 
ADNMT3B can regulate methylation in a promoter specific manner [Wang, 2006], [Wang, 
2007]. In addition DNMT1 overexpression correlates with hypermethylation of CDKN2A 
promoter [Lin, 2007], [Kim, 2006]. As already noted, UHRF1 is also overexpressed in many 
different cancer types. In a study in primary breast tumours, UHRF1 overexpression was found 
to be associated to BRCA1 promoter hypermethylation [Jin, 2009]. In addition, UHRF1 was 
found to be bound on methylated promoters of various tumour suppressor genes, including 
CDKN2A [Unoki, 2004].
The disruption of the activity of UHRF1 or any of the DNMTs in cell tissue models results into 
hypomethylation of the genome as previously discussed. Although primary tumours 
demonstrate global genomic hypomethylation, this cannot be connected to reduced or 
disrupted activity of DNMTs or UHRF1 since all these proteins tend to become overexpressed 
in human tumours. On the contrary, there is a report demonstrating that global 
hypomethylation correlates with overexpression of isoform DNMT3B4 in chronic myeloid 
leukaemia [Roman-Gomez, 2005]. It is also worth noting that there is a recent study 
suggesting that global hypomethylation, as measured by LINE-1 is inversely associated with 
CpG island methylator phenotype in colorectal cancer [Ogino, 2008]. However a study in
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ovarian epithelial tumours suggests that there is no such association between the two
phenomena [Ehrlich, 2002], thus the situation remains unclear.
3.5 Epigenetic cancer therapies.
Hypermethylation of TSGs is currently considered as a hallmark event in the tumour 
progression process [Esteller, 2007]. This notion has led to the use of hypomethylating agents 
for cancer treatment. The FDA has already approved the use of 5-azacytosine (azacytidine) 
and 2'-deoxy-5-azacytidine (decitabine) for the treatment of myelodysplastic syndromes 
[Plimack, 2007], [Issa, 2007].
Azacytidine and decitabine are nucleosidic analogs that cause hypomethylation in the same 
pattern. After cellular uptake, they are incorporated in the DNA during replication, where they 
substitute for cytosine. DNMTs recognise these nucleoside analogs as their normal substrate 
and initiate the methylation process by creating a covalent bond with their substrate. 
Although in the case of cytidine this bond is subsequently resolved and the enzyme is 
released, when either azacytidine or decitabine are present, this reaction is blocked and 
DNMT remains trapped on the DNA. This triggers DNA damage signalling and trapped DNMTs 
are being degraded. As a result hypomethylation occurs gradually during subsequent cycles of 
replication {Figure 11) [Stresemann, 2008], [Lyko, 2005].
Although azacytidine and decitabine act through the same mechanism, decitabine is believed 
to be more effective. This is a result of decitabine's ability to bind specifically on DNA while, 
on the contrary, azacytidine can be incorporated in high amounts (80-90%) into RNA [Li, 
1970]. it is important to note that the effectiveness of these nucleoside analogs towards
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demethylation of DNA is optimal in low doses while in higher doses, most probably due to cell
cycle arrest, no demethylation is observed [Qin, 2007].
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Figure 11 Azacytidine mechanism of DNMT depletion, (a) After binding, DNMT undertakes a nucleophilic 
attack at the C6 position of cytosine. Following, a methyl group from the methyl donor S-adenosyl-L- 
methionine is transferred through a covalent complex at position C6 between the DNA and the DNMT protein. 
A b-elimination reaction results in the resolve of the covalent complex and the subsequent release of the 
active DNA methyltransferase enzyme, (b) In the case of 5-azacytidine the covalent complex at C6 cannot be 
resolved through b-elimination because of the presence of a nitrogen atom at position 5. Covalently trapped 
DNMTs trigger DNA damage signalling which leads in the degradation of the enzymes (Figure adapted without 
permission from Stresemann, 2008)
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To date demethylating agents show some results of clinical relevance in patients with 
myelodysplastic syndromes (MDS) where they have been introduced [Issa, 2007]. It was 
demonstrated that decitabine can cause hypomethylation of DNA in vivo [Momparler, 1984], 
which was connected in some patients with hypomethylation and re-expression of TSGs such 
as CDKN2B/pl5mk4B [Daskalakis, 2002]. The molecular mechanisms behind the observed 
response of MDS patients to decitabine or azacytidine are not fully investigated and therefore 
it is still unclear at which extent toxicity of these substances to cells may cause this response 
[Lyko, 2005]. Possible molecular mechanisms suggested are the reactivation of TSGs due to 
hypomethylation and methylation-independent effects such as induction of p53 dependent 
DNA damage response [Santos, 2010], [Issa, 2009].
Although the use of demethylating agents in the treatment of MDS appears to be promising 
and there are a number of studies assessing the effect of this therapeutic option in other 
cancer types as well [Plimack, 2007], however the question remains as to the possible 
negative implications of global hypomethylation on human cells [see comments of Eden, 2003 
and Yang, 2003]. It has been previously discussed that hypomethylation may potentially 
result in oncogene activation or reactivation of retrotransposable elements and also 
correlates with genomic instability and tumour formation [Gaudet, 2003], [Eden, 2003], 
Although it is possible that the effect of demethylating agents may be favourable 
therapeutically, the need for further investigation into decitabine and other hypomethylating 
agent effects on the genome integrity is urgently required [Issa, 2007].
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Chapter 4. Retrotransposable elements
4.1 Introduction
The initial sequencing and analysis of the human genome revealed that almost half of its 
content is derived from transposable elements (Figure 12) [Lander, 2001]. Transposable 
elements are divided into two major classes namely DNA transposons and retrotransposons. 
DNA transposons can be excised from their specific location and be integrated into a different 
part of the genome by a cut and paste mechanism [Kazazian, 2004]. However these elements 
are currently considered to be inactive in the human genome [Lander, 2001].
Retrotransposons are transcribed into an RNA intermediate and through reverse transcription 
they are re-inserted into a new location of the genome, thereby duplicating themselves. They 
are further categorised into LTR retrotransposable elements (containing long-terminal repeats 
at both ends) and non-LTR retrotransposable elements (without long-terminal repeats but 
containing a polyadenylate sequence at their 3' end) [Kazazian, 2004]. LTR elements of the 
human genome are mainly endogenous retroviruses with limited activity of 
retrotransposition. Non-LTR retrotransposons include the LINE-1, ALU and SVA elements 
which account for the almost 30% of the human genome. These elements are currently active 
in the human genome resulting in different types of genetic disorders [Cordaux, 2009]. 
Retrotransposable elements are highly methylated in normal tissues while in human cancers 
they are affected by global hypomethylation. Since methylation is considered as one of the 
major mechanisms responsible for retaining their retrotransposition efficiency the next 
section will further describe in detail LINE-1 and Alu elements and explore their possible role 
in lung pathogenesis.
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Figure 12 The proportion of transposable elements in the human genome. In total, transposable elements 
account for about 45% of the human DNA. Non-LTR retrotransposons (LINE-1, Alu, SV40 and related elements 
comprise the bulk of transposable elements which accounts for almost 34% of human DNA while LTR 
retrotransposons and DNA transposons are significantly less frequent. (Figure adapted without permission 
from Cordaux, 2009).
4.2 LINE-1 and Alu elements
LINE-1 elements (long interspersed nuclear elements, also termed LINE-1) are non-LTR 
retrotransposons accounting for about 17% of the human genome [Cordaux, 2009]. Although 
most of these elements are 5' truncated and therefore incapable of retrotransposition, there 
are an estimated number of 80-100 elements which are considered to be potentially active in 
the human genome [Brouha, 2003].
Full length LINE-1 elements are about 6 kb, and consist of a 5' UTR (untranslated region), two 
open reading frames(ORF) and a 3' UTR with a functional polyadenylation signal (Figure 13). 
The two open reading frames, ORF1 and ORF2, give rise to two proteins both of them required 
for retrotransposition. ORFlp is a 40 ~kDA protein with RNA binding and nucleic acid 
chaperone activities. During the retrotransposition event ORFlp facilitates complementary 
strand annealing, melting and strand displacement in mispaired DNA duplexes. ORF2p has an
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endonuclease (EN) and a reverse transcriptase (RT) domain. The endonuclease domain is
responsible for DNA cleavage with preference for the 5' TTTT AA 3' sequence [Babushok, 
2007].
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Figure 13 Structure of full human LINE-1 and Alu elements. LINE-1 is 6kb and contains a 910 bp 5' UTR region 
with promoter activity (blue box), an ORF1 region encoding a 40-kDa RNA-binding protein, an ORF2 region 
encoding for a 150 kDa protein with endonuclease (EN) and reverse transcriptase (RT) activities and a 3' UTR 
region which contains a functional polyadenylation signal. The Alu element is about 300 bp and consists of two 
similar 150 bp monomers separated by an A-rich linker region. The 5'end left monomer has a functional pol III 
promoter (blue boxes) while the 3'end ends in an oligo(dA)-rich tail. (Figure adapted without permission from 
Cordaux, 2009).
Although retrotransposition events of LINE-1 elements lacking the endonuclease domain were 
identified at atypical sites in DNA-repair deficient cell lines and at mammalian telomeres, it is 
less efficient and rarely found in vivo, underlying the need of the endonuclease domain for 
successful retrotransposition [Morrish, 2002], [Morrish, 2007]. LINE-1 elements 
retrotranspose through a target primed reverse transcription (TPRT) mechanism. In brief, the 
endonuclease domain of the ORF2 protein nicks the host genome preferentially at a 5' TTTT 
AA 3' site. The RT domain then uses the free 3' hydroxyl group as a primer and polymerises a 
cDNA copy of the LINE-1 RNA. The next steps most likely include second strand cleavage, LINE- 
1 RNA cleavage and second strand synthesis but are less understood (Figure 15) [Kazazian, 
2004].
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Alu elements are of even higher copy number in the human genome with more than 106 
copies, comprising about 11% of the genome. The Alu consensus sequence is about 300 bp 
and consists of two similar 150 bp monomers with a 3' variable oligo dA tail. There is a 
functional pol III promoter in the left monomer (Figure 13) [Mighell, 1997]. Alu elements do 
not encode for specific proteins. It is thus suggested that their retrotransposition relies on 
other retrotransposable elements' machinery. The most likely candidate is LINE-1 element. 
There is a report demonstrating the ability of LINE-1 sequences to mediate retrotransposition 
of ALU sequences [Dewannieux, 2003]. This together with other data [Ostertag, 2001] suggest 
that ALU sequences use LINE-1 machinery in order to complete retrotransposition.
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Figure 14 Proposed model of LINE-1 integration reaction. A: EN domain of the ORF2 protein nicks the host 
genome preferentially at a 5' TTTT AA 3' site. B: The RT domain of ORF2 then uses the free 3' hydroxyl group as 
a primer and polymerises a cDNA copy of the LINE-1 RNA. C-G: The next steps include second strand cleavage, 
LINE-1 RNA cleavage and second strand synthesis leading to either classic or inverted insertion of the LINE-1 
sequence but are less understood (Figure adapted without permission from Progress in Understanding the 
Biology of the Human Mutagen LINE-1, Babushok, 2007)
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4.3 Retrotransposition capacity and implications on the human genome
In normal cells, LINE-1 and Aiu retrotransposition is rare. The UNE-1 promoter and the Alu 
sequences contain heavily methylated CpG islands, creating a condensed inaccessible form to 
the transcriptional machinery of the cells. The heavy methylated state of these elements also 
prevents recombination [Schulz, 2006].
Apart from the restriction of these elements' activities at the DNA level there are further 
barriers to their activity, at the RNA level. There are reports demonstrating inhibition of LINE-1 
element retrotransposition by specific siRNAs that are produced by its 5'antisense promoter. 
These siRNAs act through RNAi machinery reducing LINE-1 transcripts in the culture models 
[Yang, 2006], [Soifer, 2006]. In addition, it is considered that the transcriptional elongation of 
the LINE-1 element is inadequate, thus leading to poor expression [Han, 2004]. Alu element's 
retrotransposition is inhibited by the editing of its RNA by APOBEC3G, although the restriction 
mechanism remains unclear [Esnault, 2005]. Alu elements are widely edited in the human 
transcriptome and the above report indicates towards a protective role of adenosine-to- 
inocine nucleoside modification against retrotransposition [Levanon, 2005]. Furthermore, 
there are reports demonstrating protection against activation of these elements at the 
retrotransposition step, with cells carrying intact p53 undergoing apoptosis [Haoudi, 2004].
The restriction mechanisms of normal cells posed on retrotransposable elements are required 
to keep them constrained, as their activation has been proved to be destructive for a cell. 
There are a number of human genetic disorders such as Neurofibromatosis [Wallace, 1991] 
and beta-thalassemia that were caused by LINE-1 and Alu elements through unequal 
homologous recombination or direct retrotransposition into gene areas [Ostertag, 2001].
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Full LINE-1 elements have been studied in cell culture models were they were exogenously
introduced. Their overexpression has been found to cause chromosome breaks and 
translocations, promoting genomic instability of the cells [Symer, 2002], [Kazazian, 2002], 
[Gilbert, 2002]. Successful retrotransposition of LINE-1 elements in active genes or in the 
proximity of these genes may alter completely their expression either by inducing or 
decreasing transcription or by giving rise to premature and variant transcripts [Babushok, 
2007], They can also promote carcinogenesis through illegitimate and homologous 
recombination [reviewed in Schulz, 2006]. Apart from sharing the same potential negative 
effects regarding their retrotransposition events as LINE-1 elements, Alu sequences are more 
liable to homologous recombination, being responsible for chromosomal aberrations, and 
disease causing mutations [Kolomietz, 2002], [Ostertag, 2001]. The observations currently 
point towards a destructive potential of these elements, should they become unleashed 
[Kazazian, 2004]. In human cancers, their main restriction mechanism, methylation, in most 
cases is not present, thus enabling a potential reactivation of these elements.
4.4 LINE-1 and Alu elements in human cancers
It has already been previously discussed that LINE-1 and Alu elements are largely affected by 
DNA hypomethylation in many types of cancers. LINE-1 hypomethylation has been found in 
prostate, bladder, teratocarcinoma, renal and colorectal cancers [Schulz, 2006], [Suter, 2004], 
[Ehrlich, 2002], [Chalitchagorn, 2004], [Cho, 2007], [Wilson, 2007]. Hypomethylation of Alu 
elements has been reported in neuroendocrine tumours [Choi, 2007], colorectal carcinomas 
[Rodriguez, 2008], prostate cancer [Cho, 2007] and other types of tumours [Weisenberger, 
2005].
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Since methylation of these elements is one of the main restriction mechanisms for their
activity, it has been suggested that they may become reactivated in human cancers [Howard, 
2008]. This hypothesis is supported by a number of findings demonstrating increased LINE-1 
expression in cancers after hypomethylation of the LINE-1 sequences. LINE-1 expression was 
observed following hypomethylation in chronic myeloid leukaemias [Roman-Gomez, 2005] 
and urothelial carcinomas [Florl, 1999].
However, the available evidence on LINE-1 and Alu expression in human cancers is limited and 
as yet it is inconclusive to confirm their reactivation in neoplasia. It is possible that, even when 
methylation is absent as a restriction mechanism for these sequences, other mechanisms 
previously mentioned, can fully constrain their reactivation. Nonetheless, there are reports on 
a breast cancer case in which BRC2 gene was interrupted by an Alu sequence [Miki, 1996] and 
a colon cancer case where the ARC gene was interrupted by a LINE-1 element [Miki, 1992], It 
is of note that there is some data connecting LINE-1 activity in a cancer cell line with increased 
apoptosis [Belgnaoui, 2006]. In addition, a further study demonstrates that LINE-1 
retrotransposition induces apoptosis in cancer cells with intact p53 protein [Haoudi, 2004].
Further investigations are required to demonstrate the potential re-expression in the RNA and 
protein level (for LINE-1) of these elements in clinical samples, however, potential 
retrotransposition events, in contrast to cell lines, are difficult if possible to identify in clinical 
samples. PCR and sequencing approaches have been shown to have specific difficulties when 
targeting LINE-1 and Alu elements, mainly due to their presence in multiple copies but also 
due to the degeneracy of their sequences [Schulz, 2006].
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4.5 DNMTs, UHRF1 and retrotransposable elements
LINE-1 and Alu elements are mainly restricted by methylation and, as previously described, 
the molecules mainly responsible for the generation and maintenance of the methylation 
patterns are DNMTs and UHRF1. Although there is some data connecting specific DNMTs with 
the methylation of repeated elements [Bourc'his, 2004], it is more likely that DNMTs 
cooperate in order to maintain the methylation patterns of these sequences [Liang, 2002]. 
Double knockdowns of DNMT1 and DNMT3B in a cancer cell line have been shown to reduce 
the genome methylation up to 95% affecting repeated sequences including Alu [Rhee, 2002] 
and LINE-1 [Weisenberger, 2005].
Taking this evidence into account one would expect that the observed hypomethylation of 
LINE-1 and Alu elements in human tumours would be due to the inactivation of DNMT1 and 
DNMT3B. However this is not the case, at least regarding the mRNA levels of DNMTs, for 
clinical samples, where as we already mentioned DNMTs are usually overexpressed and no 
connection between low expression of DNMTs and retrotransposable elements 
hypomethylation has been established so far [Ehrlich, 2006]. On the contrary 
hypomethylation of LINE-1 elements have been found to correlate with overexpression of 
DNMT3B4 transcripts [Roman-Gomez, 2005].
In addition, it has been shown that UHRF1 knockout results in global hypomethylation and 
LINE-1 elements are greatly affected [Bostick, 2007], however, this situation cannot mimic the 
primary tissues environment, since UHRF1 protein is overexpressed in most cancer types 
studied, where at the same time LINE-1 hypomethylation is apparent. The observed 
hypomethylation of LINE-1 and Alu elements and global hypomethylation in primary tumours 
cannot be connected to the loss of activity of DNMTs or UHRF1 [Ehrlich, 2006].
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4.6 AIMS and OBJECTIVES of this study
Given the already evident abnormalities of the genome and epigenome of NSCLCs, this study 
had a two-fold aim:
1. To investigate the possible causes leading to the deregulation of the DNA methylation 
maintenance machinery in NSCLC and
2. To establish a link between global hypomethylation, retrotransposition and genomic 
instability in NSCLC development
To address these aims this study was organised to contain an observational (ex vivo) 
component and a functional [in vitro) one.
The specific objectives included:
a. Measure the expression of individual components of the DNA methylation machinery 
in primary NSCLC and investigate possible causes of transcriptional deregulation.
b. Examine the methylation status of retrotransposable elements which simultaneously 
provide a measure of global hypomethylation.
c. Investigate genomic instability utilising microsatellite markers at chromosomal loci 
shown to be hot-spots for loss of heterozygosity in NSCLC.
d. Examine the associations among variables established in a-c and investigate their 
potential clinical relevance.
e. Confirm hypomethylation-mediated activation of retrotransposable elements in vitro.
f. Assess the impact of alterations in the expression of UHRF1, a recently discovered 
methylation maintenance factor, in the regional hypermethylation of TSGs both in 
primary NSCLC tissue and in vitro.
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Chapter 5. Materials and methods
5.1 Human tissues
Two different set of tissues were used for this study. The first set consisted of forty eight 
NSCLCs (24 adenocarcinomas and 24 squamous carcinomas) and paired adjacent normal 
tissues. Twenty six (54%) patients were male and twenty two female (46%). Age ranged 
between 46 and 80 years (mean=64). Ali specimens were of advanced stage (43 T2, 4 T3 and 1 
T4). The second set consisted of 105 NSCLCs (55 adenocarcinomas and 50 squamous ceil 
carcinomas), as well as 50 adjacent normal lung tissues. Fifty seven patients were males and 
forty eight were females. Specimens comprised the following pathological stages (pT): ten Tl, 
eighty one T2, ten T3 and four T4. All tissues from both sets were obtained from Liverpool 
Heart and Chest Hospital (Liverpool, UK). Ethical approval has been obtained from Liverpool 
Ethics Committee for this study and informed consent was obtained from each individual.
5.2 Cell lines
Nine cell lines of lung cancer origin and one normal lung fibroblast cell line were examined in 
this study (Table 3). Cells were grown in DMEM: F12 medium supplemented with L-glutamine 
and 10% foetal bovine serum (FBS). In addition one immortalised - non tumourigenic lung 
epithelial cell line (HBEC 3KT - kindly donated by A. Gazdar was analyzed. This cell line was 
grown in Keratinocyte serum free medium (Keratinocyte-SFM medium, Invitrogen) 
supplemented with epidermal growth factor (EGF) and pituitary extract (Supplements for K- 
SFM medium, Invitrogen). All cells were grown at 37°C supplemented with 5% C02.
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Table 3 Cells lines used in this study and their histological type
Cell lines Histological type
CRL-5802 squamous cell carcinoma
SKMES squamous cell carcinoma
A549 adenocarcinoma
SKLU-1 adenocarcinoma
CALL)-3 adenocarcinoma
CRL-5935 adenocarcinoma
DMS-53 small cell carcinoma
CORL-23 large cell carcinoma
CALU-6 anaplastic carcinoma
IMR-90 normal lung fibroblast
5.3 DNA extraction
DNA extraction from primary tissues was undertaken utilising 20x40 pm sections which were 
cut from frozen tissue. The first and last sections underwent pathological review to ensure an 
at least 80% tumour cell content. DNA extraction of the samples was performed using the 
DNeasy kit (96-well protocol) (Qiagen) following the manufacturer's protocol. Briefly, tissue 
was lysed with 360 pi of ATL reagent and 40 pi of Proteinase K solution (Qiagen) and 
incubated at 55°C overnight in an orbital shaking incubator at 200rpm. 820 pi of premixed AL 
buffer with ethanol were added and after mixing, lysates were transferred in two "twin" 96- 
well plates with silica based membranes. The samples were then centrifuged at 4,000 g for 
lOmin and washed once with 500pl buffer AW1. After centrifugation at 4,000 g the samples 
were washed again with 500pl buffer AW2. After centrifugation at 4,000 g 55pl of AE buffer 
pre-warmed at 60°C were added to each sample and DNA was recovered by centrifugation at 
4,000 g for 5 min.
For the DNA extraction from cell lines the DNeasy kit (Spin column protocol) (Qiagen) was 
used. A maximum of 5x10s cells were pelleted at 300 x g for Sminutes and the pellet was re­
suspended in 200 pi PBS. 20 pi proteinase K and 4 pi of RNase A (100 mg/ml) (Qiagen) were
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added, the lysate was then mixed by vortexing and incubated at room temperature for 10
minutes. Subsequently 200 pi Buffer AL were added and the lysate was mixed thoroughly by 
vortexing and incubated at 56°C for 10 min. 200 pi of ethanol (96-100%) were added to the 
sample which was mixed thoroughly by vortexing. The mixture was transferred into the 
DNeasy Mini spin column (which carries a silica based membrane) placed in a 2 ml collection 
tube, and was centrifuged at 6000 x g for 1 min. 500 pi of Buffer AW1 were added, and the 
sample was centrifuged for 1 min at 6000 x g . 500 pi of Buffer AW2 were then added and the 
sample was centrifuged for 3 min at 20,000 x g to dry the DNeasy membrane. The DNeasy 
mini spin column was then placed in a 1.5 ml microcentrifuge tube and the DNA was 
recovered into 200 pi Buffer AE with centrifuging at 6000 x g for 1 min. DNA quality and 
quantity was assessed by spectrophotometry at 260/280 nm wavelength.
5.4 RNA extraction
Two different kits were used in this study for RNA extraction. RNA from tissues and from cell 
lines which was used for the study of LINE-1.2 and Alu-PV sequences was extracted using the 
RNeasy kit (DNAse digest protocol, Qiagen). Approximately less than <5 x 106 pelleted cells 
were disrupted in 350 pi of Buffer RLT and the pellet was mixed by vortexing. The lysate was 
directly transferred into a QIAshredder spin column which was placed in a 2 ml collection tube 
and centrifuged for 2 min at 8000 x g. 350 pi of 70% ethanol were added to the homogenized 
lysate and mixed well by pipetting. 700 pi of the sample were then transferred to an RNeasy 
spin column which was placed in a 2 ml collection tube and was centrifuged for 15 s at 8000 x 
g (10,000 rpm). 350 pi of Buffer RW1 were then added to the RNeasy spin column and the 
column was centrifuged at 8000 x g (10,000 rpm) for 15 sec. The DNase I incubation mix (10 pi
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of DNase I stock solution and 70 \x\ Buffer RDD) was added directly to the RNeasy spin column
and incubated at room temperature (20-30°C) for 15 min. 350 pi of Buffer RW1 were added 
to the RNeasy spin column which was centrifuged for 15 s at 8000 x g (10,000 rpm). 500 pi 
Buffer RPE were added to the RNeasy spin column which was centrifuged for 15 s at 8000 x g 
(10,000 rpm). Subsequently, 500 pi of Buffer RPE were added to the RNeasy spin column and 
the column was centrifuged for 2 min at 8000 x g (10,000 rpm). 50 pi of DNase/RNase-Free 
water were added directly to the spin column membrane which was following centrifuged for 
1 min at 8000 x g (10,000 rpm) to elute the RNA. An aliquot of each RNA was used for Agilent 
chip analysis in order to check its quality and quantity while the remaining RNA was stored at - 
80°C for future use.
RNA from cell lines that was used for the expression study of all other genes except for L1NE- 
1.2 and Alu-PV sequences was performed using the Mini RNA Isolation il Kit™ 
(ZymoResearch). Cells were lysed directly in the culture container by removing liquid medium 
and replacing with 600 pi ZR RNA. The lysate was then transferred with the help of a pipette 
into a Zymo-Spin™ Column which was placed in a collection tube. The sample was spun in a 
microcentrifuge at >7,000 g for 1 minute and flow through was discarded. Following, 350 pi 
of RNA Wash Buffer were added to the column which was subsequently centrifuged at >7,000 
g for 1 minute. The flow-through was discarded and the wash step with RNA wash buffer was 
repeated once more. After discarding the flow through the column was transferred to an 
RNase-free 1.5 ml microcentrifuge tube. 50 pi of DNase/RNase-Free water were added 
directly to the membrane of the column, and, after 2 minutes, the column was centrifuged at 
>7,000 g for 1 minute to elute the RNA. An aliquot of each RNA was used for Agilent chip 
analysis in order to check its quality and quantity while the remaining RNA was stored at -70°C 
for future use.
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5.5 Agilent RNA 6000 Nano kit
RNA quality and quantity was assessed by capillary electrophoresis on an Agilent 2100 
Bioanalyser (Agilent Technologies). In brief 550 pi of Agilent RNA 6000 Nano gel matrix were 
placed into the top receptacle of a spin filter. The spin filter was centrifuged for 10 minutes at 
1500 g ± 20 % and 65 pi filtered gel were used per each chip. RNA 6000 Nano dye concentrate 
was vortexed and 1 pi of RNA 6000 Nano dye concentrate was added to a 65 pi aliquot of 
filtered gel. The gel and dye mix was vortexed thoroughly and spun for 10 minutes at room 
temperature at 13000 g. 9.0 pi of the gel-dye mix were pippeted at the bottom of the well 
marked in a RNA Nano chip. The gel and dye mix was spread throughout the chip under air 
pressure using a syringe for 30 seconds. After 5 seconds^ the plunger of the syringe was slowly 
pulled back, the chip priming station was opened and 9.0 pi of the gel-dye mix were pipetted 
in each of the marked wells. Subsequently 5 pi of the RNA 6000 Nano marker were pipetted 
into the well marked with the ladder symbol and each of the 12 sample wells. To minimize 
secondary structure, RNA ladder and samples were heat denatured at 70oC for 2 minutes 
before loading on the chip.l pi of the RNA ladder was pippeted into the well marked with the 
ladder symbol and 1 pi of each sample into each of the 12 sample wells. The chip was placed 
horizontally in the adapter of the IKA vortex mixer and was vortexed for 60 seconds at 100 g. 
Finally the chip was inserted in the Agilent 2100 Bioanalyzer and the run started in the 
following five minutes.
5.6 TURBO DNA-free Procedure
RNA from cell lines in which the expression of retrotransposable elements (LINE-1.2, Alu-PV) 
were examined, were treated with TURBO DNAse (Ambion) before cDNA preparation, in
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order to eliminate the possibility of DNA carry over. TURBO DNA-/ree reactions were 
conducted in 0.5 ml tubes to facilitate removal of the supernatant after treatment with the 
DNase Inactivation Reagent. 5 pi of 10X TURBO DNase Buffer and 1 pi TURBO DNase were 
added to approximately 2 pg of RNA in a 0.5 ml tube and was mixed gently. The mixture was 
incubated at 37°C for 30 min and 5 pi of the re-suspended DNase Inactivation Reagent was 
added and the sample was incubated for 5 min at room temperature. The tube was flicked 2- 
3 times during the incubation period to re-disperse the DNase Inactivation Reagent. After 
incubation the mixture was centrifuged at 10,000 x g for 1.5 min and the supernatant, which 
contained the RNA, was carefully transferred without disturbing the pellet into a fresh tube.
5.7 cDNA preparation
Two different kits were used for the cDNA preparation. For cDNAs in which the expression of 
LINE-1.2 or Alu-PV elements expression was going to be measured, we used the Quantitect 
reverse transcription kit (Qiagen) following the manufacturer's protocol. This kit was selected 
as it includes an initial gDNA elimination step, minimizing the possibility of gDNA carry over 
into the produced cDNA. Briefly 1 pg of RNA was mixed with gDNA wipe-out buffer and RNase 
free water and was incubated at 42°C for 2 min. Quantiscript reverse transcriptase, 
Quantiscript RT buffer and RT primer mix were added, mixed and then incubated at 42 “C for 
30 min with a final incubation at 95°C for 3 min to inactivate Quantiscript reverse 
transcriptase.
For all other cDNAs that were used in this study the High-Capacity cDNA Reverse Transcription 
kit (Applied biosystems) was used following the manufacturer's protocol. Briefly 1 pg of RNA 
(10 pi) was mixed with 2 pi of lOx RT Buffer, 0.8 pi of dNTP Mix (100 mM), 2 pi of RT Random
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Primers, 1 nl of MultiScribe™ Reverse Transcriptase and 4.2 pi of Nuclease-free H20. After 
mixing by pippeting and centrifugation the reaction of the reverse transcription took place 
using a thermal cycler and performing the following steps: 10 min at 25 °C, 120 min at 37°C 
and a last step of 5 sec at 85 °C. cDNAs were diluted one time and 2 pi or 1.5 pi were used for 
the Quantitive PCR reactions.
5.8 Bisulphite treatment of DNA
In order to identify the methylation status of the different promoters and element's tested in 
this study, we have bisulphite treated our DNAs. 1 pg DNA from primary tissues was bisulphite 
treated using the EZ-96 DNA Methylation-Gold™ Kit, (Shallow-Well Format) (ZymoResearch) 
following the manufacturer's protocol.
The CT Conversion Reagent was prepared prior to use by adding 7.88 ml of water, 440 pi of M- 
Dissolving Buffer, and 2.63 ml of M-Dilution buffer. It was then mixed at room temperature by 
shaking for 15 minutes. The M-Wash Buffer was prepared by adding 144 ml of 100% ethanol 
to the 36 ml M-Wash Buffer concentrate. 130 pi of the CT Conversion Reagent were added to 
20 pi (1 pg) of each DNA sample in a Conversion Plate and samples were mixed by pipetting 
up and down. The plate was sealed, transferred to a thermal cycler and the following steps 
were performed: 98°C for 10 minutes, 64°C for 2.5 hours. The samples from the Conversion 
Plate were then transferred to the wells of the Silicon-A™ Binding Plate mounted on a 
Collection Plate, together with 400 pi of M-Binding Buffer. The plate was centrifuged at 3,000 
x g for 5 minutes and the flow-through was discarded. 400 pi of M-Wash Buffer were added to 
each well of the plate and it was then centrifuged at 3,000 x g for 5 minutes. 200 pi of M- 
Desulphonation Buffer were then added to each well and the plate was left at room
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temperature (20 °C - 30 °C) for 20 minutes. After the incubation, it was centrifuged at 3,000 x
g for 5 minutes, and the flow-through was discarded. 400 nl of M-Wash Buffer were added to 
each well of the plate, which was then centrifuged at 3,000 x g for 5 minutes, and the flow­
through was discarded. Another 400 pi of M-Wash Buffer were added and the plate was 
centrifuged at 3,000 x g for 10 minutes. The Silicon-A™ Binding Plate was then placed onto an 
Elution Plate and 35pl of M-Elution Buffer were added directly to each well. After 5 minutes, it 
was centrifuged at 3,000 x g for 3 minutes to elute the DNA. 3 pi of bisulphite treated DNA 
was used for each PCR reaction.
One pg DNA from cell lines was bisulphite treated using the EZ DNA Methylation-Gold Kit™ 
(Zymo Research) following the manufacturer's protocol. The CT Conversion Reagent was 
prepared prior to use by the addition of 900 pi of ddH20, 50 pi of M-Dissolving Buffer and 300 
pi of M-Dilution Buffer to a tube of CT Conversion Reagent. The mixture was dissolved at 
room temperature with intermittent, brief vortexing for a total of 10 minutes. The M-Wash 
Buffer was prepared by adding 24 ml of 100% ethanol to the M-Wash Buffer concentrate. 130 
pi of the CT Conversion Reagent solution were added to 20 pi of DNA (1 pg) sample in a PCR 
tube and the sample was mixed by pipetting. The sample tube was placed in a thermal cycler 
and the following steps were performed: 98°C for 10 minutes, 64°C for 2.5 hours. After 
incubation the sample was loaded into the Zymo-Spin iC™ Column containing 600 pi of the M- 
Binding Buffer, and the column was placed onto a provided Collection Tube. The mixture was 
centrifuged at full speed (>10,000 x g) for 30 seconds and the flow-through was discarded. 
100 pi of M-Wash Buffer were added to the column which was then spun at >10,000 x g for 30 
seconds. 200 pi of M-Desulphonation Buffer were then added to the column which was 
incubated at room temperature (20 °C - 30 °C) for 15-20 minutes. After the incubation, the 
column was spun at >10,000 x g for 30 seconds and the flow through was discarded. 200 pi of
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M-Wash Buffer were added to the column which was following spun at >10,000 x g for 30 
seconds. Another 200 pi of M-Wash Buffer were added and the column was spun at >10,000 x 
g for 2 minutes to ensure complete removal of alcohol traces. Finally 10 pi of M-Elution Buffer 
were added directly to the column matrix, the column was placed into a 1.5 ml tube and spun 
briefly at >10,000 x g to elute the DNA. 3 pi of bisulphite treated DNA was used for each PCR 
reaction.
5.9 Pyrosequencing Methylation Analysis (PMA).
Pyrosequencing (PSQ) is a method that can identify the sequence from small DNAs efficiently 
and with high fidelity. The procedure of the technique can be divided into two parts. The first 
part is the preparation of the samples that are to be sequenced. The target DNA sequence is 
amplified by PCR using primers that are generated by the pyrosequencing software. One of 
the two primers is biotinylated. After the examination of the product's quality in an agarose 
gel, the PCR products are mixed with the binding buffer, which contains sepharose 
streptavidin beads and buffer, and then are transferred into a 96 well PSQ, plate.
With the help of a tool that uses vacuum, the beads, in which the PCR product is bound, are 
held against a filter. The beads are then washed successively with ethanol, NaOH and wash 
buffer. NaOH denatures and separates the strands, while the wash buffer neutralises the 
immobilised strand. As a result, at the end of the above procedure, in the tool remain only the 
streptavidin beads with the biotinylated strand of the PCR products. The beads are then 
released in a new 96 well PSQ plate together with the annealing buffer which contains the 
sequencing primers.
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The second part of the technique takes place in the 96MA Pyrosequencer (Qiagen)
instrument. The template DNA together with the sequencing primer, are incubated with the 
enzymes DNA polymerase, ATP sulfurylase, lusiferase and apyrase, and the substrates 
adenosine 5' phosphosulfate (APS) and luciferin. The first of the four triphosphates (dNTPs) is 
injected into the reaction. DNA polymerase catalyses the incorporation of the first dNTP into 
the DNA strand if it is complementary to the base in the template strand. Each incorporation 
event is accompanied by release of pyrophosphate (PPi) in a quantity equimolar to the 
amount of incorporated nucleotide. ATP sulfurylase converts PPi to ATP in the presence of 
APS. This ATP drives the lusiferin to oxyluciferin that generates visible light in amounts that 
are proportional to the amount of the ATP. The light produced in the luciferase- catalysed 
reaction is detected by a charge coupled device (CCD) camera and seen as a peak in a 
pyrogram. The height of each peak (light signal) is proportional to the number of nucleotides 
incorporated (Figure 15).
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Figure 15 Nucleotide incorporation generates light seen as peak in the program (Figure adapted without 
permission from Qiagen website)
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Apyrase, a nucleotide degrading enzyme, continuously degrades ATP and unincorporated
dNTPs. This switches off the light and regenerates the reaction solution. The next dNTP is then 
added. The dNTPs are added one at a time. As the process continuous, the complementary 
DNA strand is built up and the nucleotide sequence is determined from the signal peaks in the 
pyrogram. An example is shown in Figure 16.
Pyrosequencing has applications in genetic variation (SNPs, haplotypes), in mutation detection 
(point mutations, insertions/deletions, known/unknown positions), quantification (allele 
frequency quantification, loss of heterozygosity, CpG methylation) and sequence analyses 
(viral/bacterial typing, clone checking, sequence identification). For the needs of this project
we used the pyrosequencing technique for methylation analysis.
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Cs(red) Into Us while methylated 
Cs (green) are preserved.
GGTU AGTG AU/mCG
u ">C
PCR amplification
T C
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percentage of methylated C (green) 
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Figure 16 An example of a DNA sequence, and its conversion by bisulphite treatment, with further 
amplification by PCR. By pyrosequencing, unmethylated cytosine C is measured as the relative content of T at 
the CpG site, and methylated cytosine, mC, is measured as the relative content of C at the CpG site (Figure 
adapted without permission from Qiagen website).
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Using the standard treatment of genomic DNA with bisulphite (described in the previous
paragraph), unmethylated Cytosine (C) is converted to Uracil (U), whereas methylated 
Cytosine (mC) remains unchanged. Using PCR, Uracil (U) is amplified to Thymine (T), whereas 
methylated Cytosine (mC) is amplified to Cytosine (C), Discrimination between mC and C is 
thereby achieved by transforming mC and C to appear as a C/T SNP (Figure 16).
5.9.1 UNE-1 and Alu assays
In order to identify the methylation status of UNE-1 and ALU elements in NSCLCs and cell lines 
we used the UNE-1.2 (Genebank accession no M80343) and the Alu-PV (Genebank accession 
no Z49816) as targets sequences. Those two sequences were specifically chosen as they 
belong to retrotranspositionally active families and there are published data on their ability to 
retrotranspose [Sassaman, 1997], [Wallace, 1991]. For the UNE-1.2 element a target region 
inside the CpG island of the 5' internal promoter including 6 CpGs was chosen while for the 
Alu-PV element we selected a target region in the CpG island near its 3' end encompassing 4 
CpG sites. All primers were designed using the Assay Design Software (Qiagen) and 
synthesized by MWG (Germany) (Table 4).
Table 4 Primers designed with Assay Design Software for UNE-1 and Alu-PV pyrosequencing assays. BIO: 
biotinylated end.
Promoter Forward primer (5'->3') Reverse primer (5'->3') Sequencing primer {5'->3'J
LINE-1 BIO-TAGGGAGTGTTAGATAGTGG AACTCCCTAACCCCTTAC CAAATAAAA CAATACCTC
ALU-PV GAGGTTGAGGTAGGAGAA BIO- CCCAAACTAAAATACAATAAC GTTGAGGTAGGAGAA
PCR amplifications were performed using Qiagen HotStarTaq Plus Master Mix Kit, 5pM 
biotinylated primer, 10 pM non-biotinylated primer and 3 pi (approximately 60ng) of 
bisulphite treated DNA. In order to avoid any biotinylated primer remains which could
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possibly cause problems during the pyrosequencing reaction we have used the non- 
biotinylated primer in excess. For the same reason we overcycled (40 cycles) our products. 
Thermal profiles for LINE-1 and Alu-PV amplification are shown in Tables 5 and 6 respectively.
Table 5 Thermal profile for UNE-1 amplification PCR reactions
Step Temperature (°C) Time No of cycles
Taq Activation 95 5 min
Denaturation 94 30 sec
Annealing 58 45 sec 40
Extension 72 45 sec
Final extension 72 10 min
Table 6 Thermal profile for ALU-PV amplification PCR reactions
Step Temperature (°C) Time No of cycles
Taq Activation 95 5 min
Denaturation 94 30 sec
Annealing 49 45 sec 40
Extension 72 45 sec
Final extension 72 10 min
The PCR product quality and quantity was confirmed by agarose gel (2%) electrophoresis UV 
visualisation on a UVP VisionWorks LS instrument prior to clean up and Pyrosequencing 
analysis. For the latter the SQA kit was used following the suppliers protocol (Qlagen) and the 
reaction was performed on a 96MA Pyrosequencer (Qiagen). The methylation index (Mtl) for 
the LINE-1 and Alu elements was calculated as the mean value of mC/(mC+C) for all examined 
CpGs in the elements.
5.9.2 DNMTs and UHRF1 assays
DNMTs are often aberrantly expressed in cancers. Interestingly, using the EMBOSS CpGPlot 
program (EBI) we have identified CpG islands in the promoter region of all DNMTs and the
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UHRF1 genes. In order to Investigate the potential epigenetic regulation of DNMTs and UHRF1 
in our lung cancer cell panel, we designed pyrosequencing assays for DNMT1, DNMT3A, 
DNMT3B and UHRF1. For DNMT1 (Genebank gene id: 1786) we have selected a target region 
inside the CpG island of the promoter including 5 CpGs (Figure 17). For DNMT3A (Genebank 
gene id: 1788) we have selected a target region inside the CpG island of the promoter 
including 6 CpGs (Figure 17). For DNMT3B (Genebank gene id: 1789) we have selected a target 
region inside the CpG island of the promoter including 9 CpGs (Figure 17). For UHRF1 
(Genebank gene id: 29128) we have selected a target region inside the CpG island of the 
promoter including 6 CpGs (Figure 17).
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Figure 17 Diagrammatic map of the DNMTs and UHRF1 promoter regions examined. CpGs are represented by 
vertical lines and primers as arrows. Numbering refers to the transcriptions start site depicted by the gamma­
shaped arrow.
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All primers were designed using the Assay Design Software (Qiagen) and synthesized by MWG
(Germany) (Table 7).
Table 7 Primers designed with Assay Design Software for DNMT1, DNMT3A, DNMT3B and UHRF1 
pyrosequencing assays, bio: biotinylated end.
Promoter Forward primer (5'-^3') Reverse primer (5'->3') Sequencing primer (5'->3')
DNMT1 GATATTTTGTGTAGAAGGATGGAA bio —ACCCACCTCCCAACAAAC ATTTTGTGTAGAAGGATG
DNMT3A GATTTTGGTTTTGTAGAGTAGAG bio -TCTACCTACCTCAACACTAAAACT ATTTTGGTTTTGTAGAGTA
DNMT3B GAGTTAGGTTTATTTG G GHAT bio -CTTCCTCCCAACAACTACT TTATTTGGGTTATTTAA
UHRF1 GGTTAATTAGGAGGTAGG bio -ACTCCACATTTAAAAATTAC GGTTAATTAGGAGGTAG
In order to avoid any biotinylated primer remains which could possibly cause problems during 
the pyrosequencing reaction we have used the non-biotinylated primer in excess. For the 
same reason we overcycled (40 cycles) our products. PCR amplifications were performed 
using Qiagen HotStarTaq Plus Master Mix Kit, 5 pM biotinylated primer, 10 pM non- 
biotinylated primer and 3 pi (approximately 60ng) bisulphite treated DNA. Thermal profiles for 
the different targets are seen in Table 8.
Table 8 Thermal profile for DNMT1, DNMT3A, DNMT3B and UHRF1 amplification PCR reactions
Step Target Temperature (°C) Time No of cycles
Taq Activation 95 5 min
Denaturation 94 30 sec
DNMTl 57
Annealing
DNMT3A
DNMT3B
54
57
30 sec 40
UHRF1 51
Extension 72 30 sec
Final extension 72 10 min
The PCR product quality and quantity was confirmed by agarose gel (2%) electrophoresis and 
UV visualisation on a UVP VisionWorks IS instrument prior to clean up and Pyrosequencing
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analysis. The methylation index (Mtl) was calculated as the mean value of mC/(mC+C) for all
examined CpGs in the target regions of the promoters.
5.9.3 Assays for frequently hypermethylated tumour suppressor genes
Regional hypermethylation is a common feature of human cancers which often affects
promoters of tumour suppressor genes. In this study we have examined using pyrosequencing 
the methylation status of the CDKN2A, RASSF1, CDH13 and CYGB promoters. These genes 
were chosen as they are known from the literature to be frequently hypermethylated in lung 
cancers. We have designed primers specific for target areas that are located on the promoters 
of these genes (Figure 18).
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Figure 18 Diagrammatic map of the promoter regions examined. CpGs are represented by vertical lines and 
primers as arrows. Numbering refers to the transcriptions start site depicted by the gamma-shaped arrow.
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Primers were designed using the Assay Design Software (Qiagen) and synthesized by MWG
(Germany) (Table 9).
Table 9 Primers designed using the Assay Design Software for RASSF1, CDKN2A, CDH13 and CYGB 
pyrosequencing assays, bio: biotinylated end.
Promoter Forward primer (5'->3') Reverse primer Sequencing primer (5'->3')
RASSF1 AGTATAGTAAAGTTGGTTTTTAGAAA bio-CCCTTCCTTCCCTCCTT AAGTTGGTTTTTAGAAATA
CDKN2A AGGGGTTGGTTGGTTATTAG bio-CTACCTACTCTCCCCCTCTC GGTTGGTTATTAGAGGGT
CDH13 bio-TTAG G GAAAATATGTTTAGTGTAGT ACCCCTCTTCCCTACCTA ACCCCTCTTCCCTACCT
CYGB bio-GGGAATTGATTTAAAGTTTA AAAAAACCCAACTAAATCCAC ACCCAACTAAATCCAC
In order to avoid any biotinylated primer remains which could possibly cause problems during 
the pyrosequencing reaction we have used the non-biotinylated primer in excess. For the 
same reason we overcycled (40 cycles) our products. PCR amplifications were performed 
using Qiagen HotStarTaq Plus Master Mix Kit, 5 pM biotinylated primer, 10 pM non- 
biotinylated primer and 3 pi (approximately 60ng) bisulphite treated DNA. Thermal profiles for 
the different targets are seen in Table 10:
Table 10 Thermal profile for RASSF1, CDKN2A, CYGB and CDH13 amplification PCR reactions
Step Target Temperature (°C) Time No of cycles
Taq Activation 95 5 min
Denaturation 94 30 sec
RASSF1 50
Annealing CDKN2A 55 30 sec 40CYGB 50
CDH13 52
Extension 72 30 sec
Final extension 72 10 min
The PCR product quality and quantity was confirmed by agarose gel (2%) electrophoresis UV 
visualisation on a UVP VisionWorks LS instrument prior to clean up and Pyrosequencing 
analysis. The methylation index (Mtl) was calculated as the mean value of mC/(mC+C) for all 
examined CpGs in the target regions of the promoters.
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5.9.4 Pyrosequencing assay for the LRE3 element 
To explore the effect of DNA methylation on LINE-1 retrotransposition in lung cancer we have
collaborated with Dr John V. Moran and utilised the KS-101 plasmid he kindly provided us 
with. The KS-101 plasmid contains a full length human retrotransposition competent LINE-1 
element (LRE3) tagged with a retrotransposition cassette and is cloned into a pBluescript 
backbone (Stratagene). Complete information on this construct is shown in paragraph 5.12.1. 
In order to investigate the methylation status of the LRE3 element after its insertion to 
mammalian cell lines we have designed primers that will specifically amplify the LRE3 element 
that is part of the construct and not some other LINE-1 homologous element. One of the 
primers was designed to anneal on the backbone of the pBluescript near the promoter of the 
LRE3 element while the second primer was designed to anneal in the promoter region of the 
LRE3 element (Figure 19).
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Figure 19 Primer design for IRES pyrosequencing analysis using the Assay Design software on the KS-101 
construct sequence. The sequence shown contains a part of the IRES 5'promoter (left side) and a small part of 
the pBluescript backbone (right side). The junction site is indicated with a blue arrow. The reverse biotinylated 
primer is designed to bind on the pBluescript region while the forward and sequencing primers are designed to 
bind on the 5-end LRE3 promoter. The target sequence inside the 5-end CpG island is marked as a grey zone 
and contains 6 CpG sites (blue strips).
Primers were designed using the Assay Design Software (Qiagen) and synthesised by MWG 
(Germany) forward primer: 5'-GGTAI I I l AGATGGAAATGTAGAA-3', reverse primer: 5'-bio- 
GGTGGAGTTTTAATTGGTTTTA -S', sequencing primer: 5'- AGATGGAAATGTAGAAATTA-3'. The 
reverse primer which was the one to anneal on the specific pBluescript backbone was
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designed with a slightly higher annealing temperature (Tm: 53.8) compared to the non specific 
forward primer (Tm: 52.4) in order to achieve maximum specificity. Moreover the reverse 
specific primer was chosen to be biotinylated so as to obtain only specific templates for the 
pyrosequencing reaction. In order to avoid any biotinylated primer remains which could 
possibly cause problems during the pyrosequencing reaction we have used the non- 
biotinylated primer in excess. For the same reason we overcycled (40 cycles) our products. 
PCR amplifications were performed using Qiagen HotStarTaq Plus Master Mix Kit, 5 pM 
biotinylated primer, 10 pM non-biotinylated primer and 3 pi (approximately 60ng) bisulphite 
treated DNA. The optimised thermal profile for the LRE3 amplification reaction is shown in 
Table 11.
Table 11 Thermal profile for the LRE3 amplification PCR reactions
Step Temperature (°C) Time No of cycles
Taq Activation 95 5 min
Denaturation 94 30 sec
Annealing 53 30 sec 40
Extension 72 30 sec
Final extension 72 10 min
The PCR product quality and quantity was confirmed by agarose gel (2%) electrophoresis UV 
visualisation on a UVP VisionWorks LS instrument prior to clean up and Pyrosequencing 
analysis. The methylation index (Mtl) was calculated as the mean value of mC/(mC+C) for all 
examined CpGs in the target regions of the promoters.
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5.10 Quantitative Real-Time PCR expression assays
5.10.1. LINE-1 and ALU-PV expression assays
In order to investigate the expression status of the LiNE-1 and Alu elements in our cell lines 
we used LINE-1.2 (Genebank accession no M80343) and the Alu-PV (Genebank accession no 
Z49816) as targets sequences. Those two sequences were specifically chosen as they belong 
to retrotranspositionally active families and there are published data on their ability to 
retrotranspose [Sassaman, 1997], [Wallace, 1991].
As Alu and LINE-1 sequences do not contain introns, the primers for the expression assays are 
unable to distinguish between the DNA sequences and the corresponding mRNA. Thus, an on 
column DNAse digestion step was included in the RNA extraction, extra DNAse treatment was 
performed on the extracted RNA and cDNA preparation encompassed an additional gDNA 
elimination step in order to ensure that no gDNA contaminants were carried over, in addition, 
control PCR reactions using primers for the p21 promoter sequence were carried in order to 
check for any gDNA contamination of the cDNAs prepared.
We have designed qPCR (real time) Taqman assays using the Primer Express v 2.0 software 
(Applied Biosystems) (Table 12). Primers were synthesized by MWG (Germany). The probes 
were labelled at the S7 end with FAM dye while the 3' end of the probe was labelled with 
TAMRA dye.
Table 12 Primers designed for the detection of LINE-1 and Alu-PV RNA sequences.
Target Forward primer (S'-^S1) Reverse primer (5'->3') probe (FAM labelled)
LINE-1 GAGAGGATGCGGAGAAATAGGA GGATG G CTGGGTCAAATGGT CAACCATTGTGGAAGTCAGTGTGGCG
Alu-PV GAGGCGGGCGGATCAC GTTTCACCGTTTTAGCCAGGAT AGGTCAGGAGATCGAG
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The amplicon size of LINE-1 primers was 131 bps while the amplicon size of Alu-PV primers 
was 58 bps. Primers and probe (labelled with VIC dye) amplifying the actin cDNA (Applied 
Biosystems, assay Id: 4326315E) with amplicon size 171 bps were used as endogenous control. 
The different dyes between our target and endogenous control enabled the identification of 
the target and endogenous control expression in the same reaction tube. Primers for LINE-1 
and Alu-PV elements had a smaller amplicon size compared to the amplicon size of the 
endogenous control in order to check for cDNA integrity. Assays were performed in a final 
reaction volume of 20 pi containing 10 pi of 2x TaqMan® Gene Expression Master Mix 
(Applied Biosystems), 900 nM of each primer and 250 nM probe (LINE-1 or Alu-PV primers), 
900 nM of each primer and 250 nM probe of the endogenous control ACTB-VIC (Applied 
Biosystems) and approximately 50 ng of cDNA following the universal conditions (2 min at 
50°C, 95 °C for 10 min, 50 cycles of 94 °C for 30 sec, 60 °C for 45 sec) on an Applied Biosystems 
7500 real time PCR machine. The assays' efficiency regarding reproducibility and robustness 
was tested over 5-logs of cDNA concentration.. The 7500 Software v2.0.1 (Applied Biosystems) 
was used for data analysis. RNA levels were expressed as relative quantification values (RQ) 
which were calculated as: RQ=2('MCt), where the mRNA expression of IMR-90 cells was used as 
a calibrator in each run. All assays were run in duplicate and the mean values were used for 
the analysis.
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5.10.2 UHRF1, MBD2, E2F1 and DNMTs assays.
In order to investigate the expression levels of the DNMT1, DNMT3A, DNMT3B, UHRF1 and
E2F1 in tissues and cell lines, we used off-the-shelf assays (Applied Biosystems) to reduce the 
optimisation times. The assay Ids for each gene and additional details are shown in Table 13.
Table 13 Ids and additional information for the assays used for examining expression levels of DNMT1,
DNMT3A, DNMT3B, UHRF1 and E2F1 genes.
GENE Assay Id DYE Unigene Id Amplicon length (bp)
DNMT1 Hs00945898_gl FAM FIs.202672 102
DNMT3A Hs01027167_gl FAM FIs.515840 65
DNMT3B Hs01003404_gl FAM Hs.643024, Hs.713611 74
UHRF1 Hs00273589_ml FAM FIs.108106 105
E2F1 HS01566605_gl FAM Hs.654393 66
ACTIN 4326315E VIC Hs.520640 171
ACTB-VIC (Applied Biosystems) was used as an endogenous control. Since its probe was 
labelled with a different dye (VIC) it was used in the same reaction tube with the target 
assays. The length of the endogenous control amplicon (171) was greater compared to the 
amplicon lengths of out targets enabling for an internal control of cDNA integrity. Assays were 
performed in a final reaction volume of 20 pi containing 10 pi of 2x TaqMan® Gene Expression 
Master Mix (Applied Biosystems), 900 nM of each primer and 250 nM probe, 900 nM of each 
primer and 250 nM probe of the endogenous control ACTB-VIC (Applied Biosystems) and 
approximately 50 ng of cDNA following the universal conditions (2 min at 50°C, 95 °C for 10 
min, 50 cycles of 94 °C for 30 sec, 60 °C for 45 sec) on an Applied Biosystems 7500 real time 
PCR machine. The 7500 Software v2.0.1 (Applied Biosystems) was used for data analysis. RNA 
levels were expressed as relative quantification values (RQ) which were calculated as: RQ=2(_ 
MCt), where the mRNA expression of IMR-90 cells was used as a calibrator in each run. All 
assays were run in duplicates and the mean values were used for the analysis.
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5.11 Microsatellite analysis
The microsatellite marker panel reaction was carried out in a multiplex fashion using the 
Qiagen Multiplex PCR Master Mix (Qiagen, UK). Primers were selected from the IMS High 
Density Panel set (Applied Biosystems) and were custom synthesized with 5' biotinylated 
reverse primers. These 11 microsateilite markers were chosen as they have been previously 
shown to be hot spots for loss of heterozygosity (LOH) in lung tumours [Liloglou, 2000] 
[Liloglou, 2001]. The microsateilite markers used were D3S1566, D3S1289, D9S161, D13S153, 
D13S171, D13S263, D3S1300, D3S1263, D9S157, D5S644 and D17S938.
The reaction mix was prepared using Qiagen Multiplex PCR Master Mix (Qiagen, UK), 200nmol 
of each primer, 50 ng of DNA and ddH20 in a total volume of 20 pi. The thermal profile is 
shown in Table 14.
Table 14 Thermal profile used for the amplification of the target microsateilite markers
Step Temperature (°C) Time No of cycles
Taq Activation 95 15 min
Denatu ration 94 30 sec
Annealing 56 90 sec 30
Extension 72 60 sec
Final extension 72 30 min
PCR products were cleaned using Streptavidin coated Dynabeads (Invitrogen, UK). 
Immobilized PCR products were washed with 200 pi 70% ethanol and dissolved in 4 pi loading 
buffer containing formamide: dextran blue: ROX400 size standard (Applied Biosystems) in a 
10: 2: 1.5 ratio. The mixture was denatured at 95 °C for 5 min, cooled on ice, and loaded on a 
4.2% denaturing polyacrylamide gel on a 377 ABI PRISM automated sequencer. Peak area 
analysis was undertaken using the GeneScan and Genotyper software (Applied Biosystems). 
The allelic imbalance index (All) was calculated for each sample as follows: All=
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(A1/A2)T/(A1/A2)N. The LOH threshold was calculated based on the 99% reference range
(=mean ± 3xSD) created by values produced by multiple repetition of normal blood DNA 
samples [Liloglou, 2000].
5.12 Vectors and constructs 
5.12.1 KS101 and KS105 vectors
In order to measure the retrotransposition ability of a full LINE-1 element in a lung cancer 
environment we collaborated with Dr Moran of the University of Michigan who has provided 
us with the KS-101 and KS-105 plasmids [Garcia-Perez, 2007]. The KS-101 plasmid is 
approximately 11.5 Kb and contains an 8.7 kb Noti-Sall fragment cloned into a pBluescript 
backbone {Stratagene). This fragment contains a full length human retrotransposition 
competent LINE-1 element (LRE3) tagged with a neomycin (NEO) retrotransposition cassette 
and a SV40 late polyadenylation signal in its 3' end. This element is located on chromosome 
2q24.1 on the human genome and is one of the most actively retrotransposing LINE-1 
elements [Brouha, 2002].The NEO retrotransposition cassette consists of the neomycin 
phosphotransferase gene interrupted by an intronic sequence, and has a CMV promoter in its 
3 end before the SV40 polyadenylation signal at the antisense direction. A graphic map of the 
plasmid can be seen in Figure 20.
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Figure 20 Graphic map of the KS-101 plasmid. The Not l-Sall fragment is cloned into the backbone of 
pBluescript. The different parts of the LRE3 element are shown. LREB contains an internal promoter at 5 UTR 
as all full LINE-1 elements. Between the SV 40 polyadenylation signal and ORF2 lies the neo gene sequence 
interrupted by an intronic sequence. The neo gene runs in the antisense direction under the regulation of a 
CMV promoter (blue arrow).
The KS-101 plasmid is used to demonstrate the ability of the cloned LINE-1.3 element to 
retrotranspose in a host cell line [Garcia-Perez, 2007]. The LREB element is under the 
regulation of its native 5'UTR promoter. The retrotransposition cassette becomes activated 
only if spliced LREB mRNA undergoes a successful round of retrotransposition. When this 
occurs, the neomycin gene is activated and the cell demonstrates resistance in the presence 
of G418 antibiotic. Therefore after transfection of a cell line with the KS-101 plasmid, the 
number of colonies that will appear, after selection with G418, stand for the number of cells 
where the LREB element completed at least a full cycle of retrotransposition. A detailed 
presentation of the activation of the retrotransposition cassette can be seen in Figure 21.
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Figure 21 Graphic representation of the KS-101 construct reporter cassette. A: the sequence of the LRE3 
element and the reporter cassette are shown. The reporter gene (neo) runs in the antisense direction and is 
interrupted by an intronic sequence with a splice donor (SD) and a splice acceptor (SA) arm. The CMV 
promoter is active but any product at the current stage will give rise to an interrupted NEO gene and therefore 
will not confer resistance to G418 antibiotic. B,C: When the LRE3 element is transcribed then the intronic 
sequence is excised from the reporter gene during splicing of the RNA. D: After a full retrotransposition cycle 
the LRE3 element is inserted to a new location in the genome carrying the intact neo gene and therefore 
conferring resistance to the cell after selection with G418 antibiotic. (Figure adapted without permission from 
Garcia-Perez, 2007).
The KS-105 vector is the same with the KS-101 vector except from the fact that it contains a 
missense mutation in the RT active site [Garcia-Perez, 2007]. Therefore, its LRE3 element is 
not capable for retrotransposition and the KS-105 plasmid can be used as a mock control.
5.12.2 Construction of the KS101B and KS105B vectors 
The KS-101 plasmid can be used to demonstrate the ability of a retrotransposition competent
IRES element to retrotranspose under the regulation of its own promoter in a cell line. 
However it has a specific limitation. No selection marker is available on the plasmid and 
therefore the transformation efficiency cannot be estimated. In order to be able to isolate
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colonies which have obtained the KS-101 plasmid, we have inserted a blasticidin resistance
marker in the KS-101 and KS-105 plasmids.
We have purchased from Invitrogen the pCMV/Bsd vector. This vector carries the blasticidin 
resistance gene under the regulation of a CMV and EM7 promoters followed by an SV40 polyA 
tail. The fragment carrying the blasticidin gene and its regulatory sequences is flanked by 
polylinker sequences enabling the excision of the desired fragment using different restriction 
enzymes (Figure 22).
pCMV/Bsd
3643 bp
Figure 22 Graphic map of the pCMV/Bsd vector.
The pCMV/Bsd vector was digested with Sal I. 2.4 pg of plasmid were digested with 60 units of 
Sal I (NEB) in lx NEB buffer 3 in a total reaction volume of 30 pi at 37 °C for 2 hrs. After 
digestion the linear vector was cleaned using the Qiaquick removal kit (Qiagen, see paragraph 
5.12.4). The vector was eluted in 30 pi ddH20 and was further digested with 100 units of Apa I 
(NEB) in lx NEB buffer 4 in a total reaction volume of 40 pi at 25 °C for 2 hrs. After incubation 
the reaction mix was loaded in a 1% low melting point agarose gel made with TAE buffer. 
Electrophoresis separated the two fragments of the CMV vector and the desired fragment
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carrying the blasticidin gene (1333 bp) was cut out from the gel using a scalpel, obtained using
the Qiaquick gel extraction kit (Qiagen, see paragraph 5.12.5) and eluted at 20 pi ddH20.
The KS-101 and KS-105 vectors were digested with Sal I and Apa I restriction enzymes (Figure 
23). 2.5 pg of plasmid were digested with 60 units of Sal I (NEB) in lx NEB buffer 3 in a total 
reaction volume of 30 pi at 37 °C for 2 hrs. After digestion the linear vector was cleaned using 
the Qiaquick removal kit (Qiagen). The vector was eluted in 30 pi ddH20 and was further 
digested with 100 units of Apa I (NEB) in lx NEB buffer 4 in a total reaction volume of 40 pi at 
25 °C for 2 hrs. The vector was cleaned using the Qiaquick removal kit (Qiagen) and eluted in 
20 pi ddH20.
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Figure 23 Graphic presentation of KS-101 and KS-101B constructs. A: The KS-101 plasmid and the recognition 
sites for Sail and Apal restriction enzymes. B: KS-101B plasmid after the insertion of the blasticidin fragment
from the pCMV.BSD vector.
The blasticidin fragment was ligated with the KS-101 and KS105 vectors using T4 ligase. I pi of 
the KS-101 and KS105 vectors were mixed with 5 pi of the blasticidin fragment, 1 pi of T4 DNA 
ligase (NEB) and 1 pi of lx T4 ligase reaction buffer (NEB) in a total reaction volume of 10 pi. In
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order to have approximately the same copy number of the KS-101 or KS105 and blasticidin
fragment and since the KS-101 and KS105 fragments are "“11.5 kb and the blasticidin fragment 
is ~1.4 kb we have used the blasticidin fragment in excess (5 times more than the KS-101/KS- 
105 plasmids). The reaction mix was incubated for 30 min at room temperature. After 
incubation, 2 pi of the ligation mix were transformed into One Shot* TOPIO Chemically 
Competent E. coli bacteria (Invitrogen) following the manufacturer's protocol for chemical 
transformation (see paragraph 5.12.6). The transformed bacteria were spread on labelled LB 
agar plates containing 50 pg/pl ampicillin. The plates were incubated at 37 °C overnight. 
Twenty five resistant colonies were picked up for each vector and minipreparation of the 
plasmids was undertaken utilising the Qiagen 96 prep kit as described in paragraphs 5.12.7. 
Plasmid DNA was digested using Sal I and ECOR I which were both one-cutter enzymes for the 
KS-101 plasmid while they do not cut into the blasticidin fragment. 17 pi of KS-101B and 
KS105B plasmid were mixed with 10 units of Sal I (NEB) and 10 units ECOR I (NEB) lx NEBuffer 
3 and dd2HO in a final volume of 20 pi. The reaction mix was incubated for 2 hrs at 37 °C. In 
addition approximately 500 ng of KS-101 were digested as described above in order to serve 
as controls. After incubation 5 pi of the reaction were run in a 1% agarose gel in TBE buffer 
and the cut plasmids were visualised using Safeview (NBS Biologicals) under UV lighting. The 
bacteria carrying the selected clones were grown in 150 ml liquid LB growth medium 
containing ampicillin (50 pg/pl) at 37 °C with shaking at 220 rpm. After 20-22 hrs 
maxipreperation of plasmid was undertaken using the using the Zyppy™ Plasmid Maxiprep Kit 
(Zymo Research, see paragraph 5.12.8) while 5 ml of the bacterial culture were used to create 
glycerol stock which was stored at -80 °C.
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5.12.3 Construction of the PAXUHRF1 vector
In order to investigate the effect of UHRF1 expression on regional hypermethylation and 
hypomethylation of cancer cells we have used an inducible shRNA system to silence the 
expression of UHRF1 in a lung cancer cell line. The shRNA inducible knockdown system was a 
generous gift from Dr Malliri (Paterson institute).
The system is based on two vectors. The first one is comprised of an engineered pGEM T-easy 
vector which carries the HI promoter and a Tet operator upstream of the position where the 
desired shRNA sequence is inserted. After insertion of the desired shRNA sequence in the 
pGEM T-easy vector, the shRNA module (HI promoter, Tet operator and shRNA) is excised 
and ligated into the vector backbone of the pNlp_actin“rtTA2S-M2-IRESEGFP plasmid [Welman 
et al. 2006] containing the tetracycline repressor. Dr Malliri also provided us with a ready to 
transfect final PA-1 vector which contains a scrambled shRNA sequence and can therefore be 
used as a mock control.
5.12.3.1 Preparation of UHRF1 shRNA oligo
The following DNA oligo sequence which carries a UHRF1 siRNA sequence (Qiagen) was 
designed and synthesised by MWG:
5'- GATCCCGGACGGCGCGGGAACTCTATTCAAGAGATAGAGTTCCCGCGCCGTCCTTTTTGGAAA- 3'
5'-AGCTTTTCCAAAAAGGACGGCGCGGGAACTCTATCTCTTGAATAGAGTTCCCGCGCCGTCCGG- 3'
5' GATCCCGGACGGCGCGGGAACTCTATTCAAGAGATAGAGTTCCCGCGCCGTCCTTTTTGGAAA 3'
3'GGCCTGCCGCGCCCTTGAGATAAGTTCTCTATCTCAAGGGCGCGGCAGGAAAAACCTTTTCGA 5'
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The DNA oligos carrying the UHRF1 shRNA sequence were annealed as follows. A 20 \x\ 
reaction mix was prepared with 400 pmol of each oligo, 3 pi PCR buffer (Roche), 6 pi of 
betaine (Sigma Aldrich) and 13 pi of ddH20. The mixture was incubated at 95°C for 5 minutes 
and then let to cool down at room temperature. The DNA oligo was analysed on a 4% TAB low 
melting point agarose gel, cut out, cleaned using Qiaquick nucleotide removal kit (Qiagen) and 
eluted at 20 pi ddi-hO.
5.12.3.2 Ligation of the UHRF1 shRNA sequence with the vector carrying the shRNA 
module
The pGEM T-easy shuttle vector containing the HI promoter and Tet operator was digested 
with Bgl II and Hind ill restrictive enzymes as follows. 500 ng of pGEM T-easy were mixed with 
2 pi of Buffer 2 (NEB), 20 U of Hind III, 20 U of Bgl II and ddH20 in a final volume of 20 pi. The 
reaction mix was incubated for 2 hrs at 37°C and subsequently cohesive ends were melted by 
incubating at 65 °C for 10 minutes. The mixture was then loaded and visualised on a 2% IxTAE 
low melting point agarose gel. The vector was cut out, cleaned using the Qiaquick gel 
extraction kit (Qiagen), and eluted in 20 pi ddH20.
The target DNA oligo sequence was subsequently ligated with the open pGEM T-easy shuttle 
vector using 1 pi of T4 DNA ligase (NEB), 1 pi of lx T4 ligase reaction buffer (NEB), 1 pi of 
open pGEM T-easy shuttle vector, 1 pi of oligo and ddH20 in a total reaction volume of 10 pi. 
The reaction mix was incubated for 30 min at room temperature. After incubation, 2 pi from 
the ligation mix was transformed in One Shot* TOPIC Chemically Competent E. coli bacteria 
(Invitrogen) following the manufacturer's protocol for chemical transformation. The 
transformed bacteria were spread on labelled LB agar plates containing ampicillin (50 pg/ pi) 
antibiotic.
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The following day 20 colonies were picked up and cultured for 16 hrs in LB growth medium 
containing ampicillin (50 pg/ pi) antibiotic. Plasmid extraction of the colonies took place the 
following day using Qiagen 96 prep kit. Positives colonies were checked by Xho I digestion and 
electrophoresis. The vector carrying the shRNA insert was larger (~500 bp) than the empty 
vector (~450 bp). Plasmids were digested with Xho I (5 pi DNA, 1 pi buffer 4 (NEB), 1 pi Xho I, 3 
pi ddH20) at 37°C for 2hrs and then run in a 2% agarose gel. In order to verify the inserted 
sequence positive plasmids were sequenced (see paragraph 5.12.9) using T7/SP6 primers that 
flank the target DNA oligo of interest.
5.12.3.3 Transfer of the UHRF1 shRNA module in the final PA-1 vector 
The next step was to transfer the UHRF1 shRNA module (HI promoter, Tet operator and
shRNA) to the pNlp_actin-rtTA2S-M2-lRESEGFP plasmid [Welman, 2006] vector containing the 
tetracycline repressor. Approximately 500 ng from the selected PGEM T-easy vector carrying 
the verified UHRF1 shRNA sequence and 500 ng of the pNlp_actin-rtTA2S-M2-IRESEGFP 
plasmid were digested using 20 U of Xho I, 2 pi buffer 3 (NEB) and ddH20 for 2 hrs at 37 °C in 
a final reaction volume of 20 pi. After incubation the pNlp_actin-rtTA2S-M2-IRE$EGFP vector 
was treated with alkaline phosphatase (NEB). Since the enzyme is working on the same buffer 
(buffer 3, NEB) as Xho I enzyme, 10 U of alkaline phosphatase were added in the pNlp„actin- 
rtTA2S-M2-IRESEGFP vector-Xho I digested mix and the new mix was incubated for an extra 
Ihrs at 37 °C. The Xho I digested vectors were separated on 2% 1 x TAE low melting point 
agarose gel. The desired Xho l-Xho I insert carrying the shRNA module and the Xho I digested 
vector were cut out and cleaned using the Qiaquick gel extraction kit (Qiagen) and eluted in 
20 pi of ddH20.
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2 \x\ of Xho l-Xho I insert carrying the shRNA module and 2 |il of Xho I digested vector were 
subsequently ligated using 1 ^il of T4 DNA ligase (NEB), 1 ^1 of lx T4 ligase reaction buffer 
(NEB) and ddH20 in a total reaction volume of 10 \jl\. The reaction mix was incubated for 30 
min at room temperature. After incubation, 2 pi from the ligation mix was transformed into 
One Shot* TOPIO Chemically Competent E. coli bacteria (Invitrogen) following the 
manufacturer's protocol for chemical transformation. The transformed bacteria were spread 
on labelled LB agar plates containing 50 pg/ pi Kanamycin. The following day 20 colonies were 
picked up and cultured for 16 hrs in LB growth medium containing kanamycin 50 pg/ pi 
antibiotic. Plasmid extraction of the colonies took place the following day using Qiagen 96 
prep kit (see paragraph 5.12.7). Positives were checked by Xho I digestion and gel 
electrophoresis. In order to verify the shRNA sequence and positive clones were sequenced 
utilising HI primers which flank the inserted oligo in the pNlp_actin-rtTA2S-IV12-lRESEGFP 
vector. The bacteria carrying the selected clones were grown in 150 ml liquid LB growth 
medium containing 50 pg/ pi kanamycin at 37 °C with shaking at 220 rpm. After 20-22 hrs 
maxi-preparation of plasmid was undertaken using the using the Zyppy™ Plasmid Maxiprep Kit 
(Zymo Research) while 5 ml of the bacterial culture were used to create glycerol stock which 
was stored at -80 °C. The constructed PAUHRF1 and a ready to transfect full PA-1 vector 
(carrying a scramble shRNA sequence and used as a mock control) were used for the 
transfection of the desired cell line.
5.12.4 DNA dean up from enzymatic reactions
In order to clean up DNA fragments from enzymatic reactions we have used the QIAquick 
Nucleotide Removal Kit (Qiagen) following the manufacturer's protocol. 500 pi of Buffer PN 
were added to a 50 pi enzymatic reaction sample and were mixed. A QIAquick spin column
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was placed in a provided 2 ml collection tube. In order to bind DNA, the sample was applied to
the QIAquick column and centrifuged for 1 min at 3000 g. The flow-through was discarded and 
the QIAquick column was placed into a new collection tube. To wash the QIAquick column, 
700 pi of Buffer PE were added and the column was centrifuged for 1 min at 3000 g. The flow­
through was discarded and the column was centrifuge for an additional 1 min at 17,000 g in 
order to completely remove residual ethanol from PE buffer. The QIAquick column was placed 
in a clean 1.5 ml microcentrifuge tube. To elute DNA, 50 pi of Buffer EB (10 mM Tris-Cl, pH 8.5) 
were applied to the centre of the QIAquick membrane and the column was centrifuged for 1 
min at 17,000 g.
5.12.5 DNA fragments extraction from agarose gels and clean up 
in order to extract and purify DNA fragments and vectors from low-melt TAE buffer agarose
gels we have used the QIAquick Gel Extraction Kit (Qiagen) following the manufacturer's 
protocol. The desired DNA fragment was excised from the agarose gel with a clean, sharp 
scalpel and in order to minimize the size of the gel slice, extra agarose was removed. The gel 
slice was weighed in a colourless 1.5 ml tube and 3 volumes of Buffer QG were added to the 
tube to 1 volume of gel (100 mg ~ 100 pi). For example, 300 pi of Buffer QG were added to 
each 100 mg of gel. The maximum amount of gel slice per QIAquick column is 400 mg, so for 
gel slices >400 mg more than one QIAquick column were used. The mixture was incubated at 
50°C for 10 min until the gel slice has completely dissolved. After the gel slice was completely 
dissolved, 1 gel volume of isopropanol was added to the sample and mixed. A QIAquick spin 
column was placed in a provided 2 ml collection tube and in order to bind DNA, the sample 
was applied to the column and centrifuged for 1 min. The flow-through was discarded and the 
QIAquick column was placed in a new collection tube. To wash the DNA fragment, 0.75 ml of
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Buffer PE were added to the QJAquick column and centrifuged for 1 min. The flow-through 
was discarded and the QIAquick column was centrifuged for an additional 1 min at 17,000 g 
to remove any residual ethanol from the PE buffer. The QIAquick column was placed into a 
clean 1.5 ml microcentrifuge tube. To elute DNA, 50 pi of Buffer EB (10 mM Tris-Cl, pH 8.5) 
were added to the centre of the QIAquick membrane and the column was centrifuged for 1 
min.
5.12.6 Transformation
For plasmid propagation the One Shot^ TOPIO Chemically Competent E. coli bacteria 
(Invitrogen) were used following the manufacturer's protocol for chemical transformation. 
One 50 pi vial of One Shot® cells was thawed on ice for each transformation. Following, 1 to 5 
pi of each ligation reaction or plasmid vector were transferred with a pipette directly into the 
vial of competent cells and mixed by tapping gently. The vials were incubated on ice for 30 
minutes and then for exactly 30 seconds in a 42°C water bath. Subsequently the vials were 
removed from the 42°C bath and placed on ice. 250 pi of pre-warmed S.O.C medium was 
added to each vial. The vial(s) were placed in a micro-centrifuge rack on its side and shaken at 
37°C for exactly 1 hour at 225 rpm in a shaking incubator.150 pi from each transformation vial 
were spread on separate, labelled LB agar plates containing 50 pg/ pi of the selection 
antibiotic (either ampiciliin or kanamycin). The plate(s) were inverted and incubated at 37°C 
overnight. The following day colonies were selected for miniprep isolation.
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5.12.7 Mini preparation of plasmid DNA
For the mini preparation of plasmid DNA two different kits based on alkaline lysis procedures, 
the R.E.A.L. Prep 96 Plasmid Kit (Qiagen) and the Zyppy Plasmid Miniprep kit (Zymo Research) 
were used following the manufacturer's protocols.
Utilising the R.E.A.L. Prep 96 Plasmid Kit (Qiagen), different colonies were grown in each well 
of a 96 square-well block in 1.3 ml LB growth medium containing the appropriate selective 
antibiotic (either kanamycin or ampiciliin). A single bacterial colony was inoculated in each 
well and the cultures were incubated for 20-24 h at 37°C with shaking at 220 rpm. The 
bacterial cells were harvested in the block by centrifugation for 5 min at 1500 x g in a 
centrifuge with a rotor for 96-well microplates and the medium was removed by inverting the 
block. Subsequently, each bacterial pellet was re-suspended in 0.3 ml Buffer R1 (containing 
RNase A) and mixed by vortexing. 0.3 ml of Buffer R2 were added to each well, the block was 
mixed gently but thoroughly by inverting 10 times and incubated at room temperature for 5 
min. 0.3 ml of Buffer R3 were added to each well, and the block was mixed immediately by 
inverting 10 times. The block was then placed in a boiling water bath for 5 min and then 
cooled at room temperature by incubating on ice for 10 min. The QIAfilter 96 plate was placed 
in the top plate of the QIAvac 96 manifold. A new square-well block was placed into the base 
and the manifold was reassembled. The lysates were transferred to the wells of the QIAfilter 
96 plate and vacuum (-200 to -300 mbar) was applied until the lysates were completely 
transferred to the square-well block in the QIAvac base. 0.7 volumes of room-temperature 
isopropanol were then added to each well and the block was mixed immediately by inverting 
3 times. Following, the block was centrifuged at 2500 x g for 15 min at room temperature to 
pellet the plasmid DNA and the supernatants were removed by quickly inverting the block 
over a waste container, then tapping the block firmly, upside down, onto a paper towel. Each
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DNA pellet was then washed with 0.5 ml of 70% ethanol and the block was centrifuged at 
2500 x g for 2 min to re-concentrate the pellets. The wash solutions were removed by 
inverting the block and the pellets were dried under vacuum for 10 min. The DNA pellets were 
then re-dissolved in 100 pi 10 mM Tris-CI, pH 8.5. The plasmid purity and plasmid DNA yield 
was assessed by spectrophotometry at 260/280 nm wavelength.
In order to use the Zyppy Plasmid Miniprep kit (Zymo Research) we have first prepared the 
Neutralization Buffer by adding RNase A at a final concentration of 50 pg/ml and the Zyppy™ 
Wash Buffer concentrate by the addition of absolute ethanol. 1.5 ml of bacterial culture was 
centrifuge for 30 seconds at maximum speed. The supernatant was discarded and the 
bacterial cell pellet was re-suspended in 600 pi of water. The mixture was transferred to a 1.5 
ml microcentrifuge tube, 100 pi of 7X Lysis Buffer (blue) were added and were mixed by 
inverting the tube 4-6 times. 350 pi of cold Neutralization Buffer (Yellow) were added and the 
mixture was mixed thoroughly. The sample turned yellow when the neutralization was 
complete and a yellowish precipitate formed. The sample was then centrifuged at 11,000 - 
16,000 x g for 2-4 minutes. The supernatant (~900 pi) was transferred carefully without 
disturbing the cell debris pellet into the provided Zymo-Spin™ IIN column. The column was 
then placed into a Collection Tube and centrifuged for 15 seconds. The flow-through was 
discarded and the column was placed back into the same Collection Tube. 200 pi of Endo- 
Wash Buffer were added to the column which was subsequently centrifuged for 15 seconds at 
top speed. 400 pi of Zyppy™ Wash BufferZ were added to the column another Centrifugation 
took place for 30 seconds at top speed. The column was transferred into a clean 1.5 ml 
microcentrifuge tube and 30 pi of Zyppy™ Elution Buffer were added directly to the column 
matrix and let stand for one minute at room temperature. Centrifugation for 15 seconds at
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top speed took place for the elution of the plasmid DNA. The plasmid purity and plasmid DNA
yield was assessed by spectrophotometry at 260/280 nm wavelength.
5.12.8 Maxi preparation of plasmid DNA
Maxi preparation of plasmids was undertaken using the Zyppy™ Plasmid Maxiprep Kit (Zymo 
Research) following the manufacturers protocol as follows. PI buffer was prepared by the 
addition of RNAse A at a final concentration of 50 pg/ml and Zyppy™ Wash Buffer by the 
addition of 96 ml of absolute ethanol. We have used the vacuum manifold protocol and all the 
steps were carried at RT. Up to 150 ml of fresh bacterial culture was centrifuged at > 3,400 x g 
for 10 minutes. The supernatant was discarded, 15 ml of PI Buffer (Red) were added to the 
bacterial cell pellet and it was re-suspended completely by vortexing. 15 ml of P2 Buffer 
(Green) were added, mixed immediately by inverting the tube 4-6 times and the tube was let 
to stand for one minute to lyse the cells completely. 20 ml of P3 Buffer (Yellow) were added, 
mixed thoroughly and the mixture was incubated on ice for 5 minutes. The Zymo-Maxi 
Filter™/Zymo-Spin™ VI column assembly was placed onto a vacuum manifold. And the entire 
mixture was added into the blue Zymo-Maxi Filter™ column. After the cell debris floated to 
the surface, the vacuum was turned on until all of the liquid had passed completely through 
both columns. The blue Zymo-Maxi Filter™ column was removed and discarded from the top 
of the Zymo-Spin™ VI column. 10 ml of Endo-Wash Buffer were added to the Zymo-Spin™ VI 
column and the vacuum was turned on. After the Endo-Wash Buffer had completely passed 
through the Zymo-Spin™ VI column, 10 ml of Zyppy™ Wash Buffer2 were added, the vacuum 
was turned on and the vacuum was let on for an additional 5 minutes to remove ail residual 
Zyppy™ Wash Buffer. The Zymo-Spin™ VI column was then transferred into a clean 50 ml
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conical tube and 3 ml of Zyppy™ Elution Buffer were added to the column. The column was
incubated at RT for one minute, and then centrifuged at > 3,400 x g for 1 minute to elute the 
plasmid DNA. The plasmid purity and plasmid DNA yield was assessed by spectrophotometry 
at 260/280 nm wavelength.
5.12.9 Sequencing of plasmids
The pGEM/UHRFl vector and the final PAUHRF1 plasmid were sequenced in order to verify 
correct inserts. Sequencing reactions were prepared as following. 10 pi from the plasmid DNA 
were incubated at 95 °C for 5 minutes then put on ice and spun at full-speed for 3 minutes. 
After centrifugation, 2.5 pi of plasmid DNA were taken from the top of the liquid and mixed 
with 8 pi BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), 3.2 pmol of HI 
primer and 8.5 pi ddH20 in a total reaction of 20 pi. The cycle sequencing was performed in an 
Applied Biosystems 7500 PCR machine using the following thermal profile. The reaction mix 
was heated at 95°C for 5 minutes followed by 30 cycles of 95 °C for 30 sec (denaturation), 58 
°C for 45 sec (annealing) and 60 °C (elongation) for 4 minutes.
After the sequencing reaction, the DNA fragments were precipitated using ethanol/EDTA 
method which produces consistent signal, while minimizing unincorporated dyes. Our samples 
were mixed with 5 pi of 125 mM EDTA. 60 pi of 100% ethanol were added, mixed and the 
tubes were incubated at room temperature for 15 min in the dark. Subsequently, the tubes 
were centrifuged for 15 min at 10.000 g and the supernatant was discarded using a pipette. 
60 pi of 70% ethanol were added to each tube which was subsequently centrifuged for 5 min 
at 10.000 g. Supernatant was discarded using a pipette and the precipitates were dried under 
vacuum for 5 min. Finally the samples were re-suspended in 10 pi HDF (Applied Biosystems),
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incubated at 95°C for 5 minutes and cooled on ice for 1 minute. Sample electrophoresis took 
place on an ABI prism 3700 DNA analyzer.
5.13 Transfection of cell lines
For the transfection of prepared plasmids into the desired cell lines we used two different protocols. 
For the transfection of the PAXUHRF1 and PA-1 mock plasmids we have used the Attractene 
Transfection Reagent (Invitrogen) following the manufacturer's protocol. Plasmid DNA
5
transfection was performed in 6-well plates. The day before transfection 5 x 10 cells were 
seeded per well in 2 ml of culture medium containing serum and antibiotics. Cells were 
incubated under normal growth conditions {typically 37 °C and 5% C02) until they reached
60%-80% confluence. On the day of transfection 1.2 pg of plasmid DNA was dissolved in 
medium without serum, proteins, or antibiotics to a total volume of 100 pi. 4.5 p of 
Attractene Transfection Reagent were added to the DNA solution and mixed by pipetting. The 
samples were incubated for 15 min at room temperature (15-25 °C) to allow complex 
formation. While complex formation took place, the medium from the cells was gently 
aspirated and 2 ml of fresh medium (containing serum and antibiotics) were added to the 
cells. Subsequently the transfection complexes were added drop-wise onto the cells and the 
plate was gently swirled to ensure uniform distribution of the transfection complexes and 
cells were incubated under their normal growth conditions.
For the transfection of cells with KS-101, KS105, KS101B and KS-105B plasmids we have used 
the Trons\J®-2020 Transfection Reagent (Mims) following the manufacturer's protocol.
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Plasmid DNA transfection was performed in 6-well plates. One day before transfection, 5 x 10 
cells were plated per well in 2.5 ml complete growth medium containing serum and
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antibiotics. Cells were incubated under normal growth conditions (typically 37 °C and 5% C02)
until they reached 60%-80% confluence. The Trans\T-2020 Transfection Reagent was pre­
warmed to room temperature and vortexed gently before being used. 2.5 pg of plasmid DNA 
were added to 250 pi of Opti-MEM®l Reduced Serum medium in a sterile polystyrene tube 
and mixed by pippeting. Subsequently, 7.5pl of Trans\T-2020 Transfection Reagent were 
added to the diluted DNA mixture and mixed by pippeting. The mixture was then incubated at 
room temperature for 30 minutes to allow sufficient time for the formation of complexes. 
The Trctn$\T-202Q Transfection Reagent: DNA complexes were added drop wise to different 
areas of the wells containing the plated cells. The culture vessel was gently rocked back and 
forth and from side to side to evenly distribute the Trans\J-2020 Transfection Reagent:DNA 
complexes and cells were incubated at normal conditions. As the Trans\T-2020 Transfection 
Reagent demonstrated minimum toxicity the complete growth medium was not replaced the 
following day with fresh medium.
5.14 Generation of A549 PAUHRF1 stable cell line clones
Screening of a panel of cell lines has demonstrated that A549 cells expressed the higher levels 
of UHRF1 mRNA and were therefore selected as the best candidates from UHRF1 
downregulation experiments. A549 cells were transfected with the PAXUHRF1 plasmid which 
carries the neomycin resistance gene, in order to determine the optimal concentration of 
G418 for selection we have examined the kill curve of A549 cells in the presence of various 
concentrations of G418. Cells were seeded in 24 well plates at low density and were grown in 
the presence of different concentrations (400 pg/ml -1.5 pg/ml) of G418 for two weeks. The 
lowest concentration of G418 that promoted complete death of A549 cells in less than two
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weeks was 600 ng/ml. 48 hours post transfection of A549 cells with the PAXUHRF1 and the 
PA-1 mock plasmids, cells were passaged in complete growth medium containing 600 pg/ml 
of G418. Growth medium and antibiotic was replenished every 2-3 days. After 2 weeks of 
selection colonies were isolated using cloning cylinders, trypsinised and grown in new flasks 
under normal growth conditions and in the presence of selection antibiotic. Twenty different 
clones were checked for UHRF1 downregulation at both RNA (qPCR) and protein {western 
blot) level in the presence/absence of 1 pg/ml Doxycycline for up to 96 hrs. Colonies 
demonstrating the highest UHRF1 knockdown efficiency were grown and used for further 
analysis.
5.15 Western blot
5.15.1 Protein extraction and total protein concentration measurement 
A549 cells were cultivated as described above until they reached 80% confluence. After two
washes with DPBS, the cells were harvested using 50pl of RIPA buffer (Table 15) 
supplemented with protease inhibitors {ImM PMSF (Sigma Aldrich), lOpg/ml leupeptin 
(Sigma Aldrich), lOmM NaF (Fluka), ImM Na3V04 (Sigma Aldrich)).
Table 15 Reagents used for the preparation of RIPA buffer
RIPA buffer
Tris-HCi pH 7.4 SOmM
NaCl 150m M
EDTA ImM
Nonidet P-40 1%
Deoxycholate sodium 0.1%
SDS 0.1%
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Cells were lysed for 15min on ice, spun at 4°C for 15min at 18.000 g and supernatant was 
stored at -20 °C until further analysis. Total protein concentration was measured with DC 
Biorad Assay (Biorad) using DU530 UV/VIS spectrophotometer (Beckman). Concentrations 
were read from a standard curve created from serial dilutions of fraction V BSA (Sigma 
Aldrich) prepared in RIPA buffer with protease inhibitors.
5.15.2 Protein electrophoresis
In order to prepare the samples for electrophoresis, 20 pg of total protein from A549 cells and 
clone derivatives were mixed together with 2.5 pg of (4x) NuPAGE* IDS Sample Buffer 
(Invitrogen), 1 pi of (lOx) NuPAGE Reducing Agent (Invitrogen) and ddH20 up to a total of 10 pi 
reaction volume. The mix was denatured by incubation at 70 °C for 10 minutes. For the 
electrophoresis of total protein we have used the 3-8% NuPAGE Novex Tris-Acetate Mini gels 
(Invitrogen). The gels were placed in the electrophoresis tank and the upper chamber was 
filled with 200 ml of lx NuPAGE Tris-Acetate SDS running buffer (Invitrogen) mixed with 500 pi 
of NuPAGE Antioxidant (Invitrogen), while the lower chamber was filled with 600 ml of lx 
NuPAGE Tris-Acetate SDS running buffer (Invitrogen).. After denaturation the samples were 
loaded on the gels together with Full Range Amersham™ Rainbow™ Marker (GE 
Healthcare). The gels were run at 150 V (40-55 mA gel start/ 25-40 gel end) for 1 hrs.
5.15.3 Electrotransfer, immunoblotting and detection.
For blotting of the electrophorised proteins we have used the iBLOT platform (Invitrogen).
After electrophoresis, the gels were removed and trimmed, put onto the membrane of Anode 
Stack (Invitrogen) and covered with pre-wet (in ddH20) blotting paper. The Cathode Stack
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(Invitrogen) was then added on top of blotting paper and a white sponge was placed on the 
inner side of the lid. The iBLOT platform was switched on at program 3 (P3-7min). After 7min 
the membrane was removed from the iBLOT and placed in the blocking solution for Ih at 
room temperature (blocking solutions: 5% milk in PBS-T; 3% BSA in PBS-T or Protobiock 
solution from National Diagnostics). The gels were rinsed in ddHaO water (3x Smin), stained 
with the Commassie Blue (e.g. Simple Blue SafeStain by Invitrogen), destained in water (3x 5 
min or more) and pictures were captured using the UVP VisionWorks LS instrument. After one 
hour of blocking, the membrane was incubated overnight with 2 pg/ml of the primary anti- 
UHRF1 mouse antibody (ab57083, Abeam) at 4 °C. The membrane was washed with three 
changes of PBS-T every lOmin and probed with HRP-rabbit anti-mouse secondary antibody 
(ab6728. Abeam) for Ih at room temperature. Membrane was then washed four times for 10 
min in PBS-T and the bands were visualised using the ECL western blotting detection kit 
(Amersham). Anti-Tubuline primary antibody (SC31779, Santa Cruz) was used as an internal 
control of total protein concentration.
5.16 Examination of cells phenotypic characteristics 
5.16.1 MTTproliferation assay
The viability of A549 parental and PAXUHRF1 knockdown clones was measured using the MTT 
proliferation assay. 5xl03 of A549 parental, mock, and clone derivative cells were seeded in 
12 well plates. The next day cells were washed with PBS and incubated with fresh medium 
containing 0.5 mg/ml of MTT (3-(4,5-dimethyl-2-thioazoyl) 2,5-diphenyltetrazolium bromide) 
(Sigma-Aldrich) for 2.5 hours at 37 °C supplemented with 5% C02. The medium was 
subsequently removed and cells were washed with PBS. The converted formazan was
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solubilised by the addition of 1 ml of isopropyl alcohol-0.04 M HCI and pipette mixing. After 
five minutes, viability of the cells was determined by measuring the difference in absorbance 
at 570 nm with reference at 630 nm (optical density 570-655). Time point measurements 
were performed every 24 hrs for 5 subsequent days. The average proliferation rate was 
deducted from three biological replicates.
5.16.2 Wound healing assay
Wound-healing capacity of the A549 parental, mock and clone derivative cells was measured 
using scratch assays. Approximately 3-5xl03 of A549 parental, mock, A549 PAXUHRF1 clone 1 
and clone 2 cells were seeded in 24 well plates. Next day when cells had reached confluence, 
monolayers were scratched using a tip and time lapsed images were digitally captured at 
different time points over a period of 24 hrs with a CCD camera. The open wound area was 
calculated using TScratch software [Geback, 2009].
5.17 Treatment of cell lines with decitabine and trichostatin-A
We have utilised decitabine, a known DNA demethylating agent and Trichostatin-A (TSA), a 
known histone de-acetylase (HDAC) inhibitor, in order to examine the effect of epigenetic 
changes on retrotransposable elements. The optimal amount of decitabine which yields 
maximum levels of global hypomethylation, was established by the use of different decitabine 
concentrations for treatment of a non tumourigenic (HBEC 3kt) and a cancer (CRL5802)_cell 
line. Cells were seeded so as to cover about 15% of the flask surface before the first day of 
treatment. On the day of treatment we changed medium and added the following amount of 
decitabine: 0.01 pM, 0.05 pM, 0.1 pM, 0.5 pM, 1 pM, 1.5 pM, 2 pM, 5 pM, 10 pM, 20 pM.
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Decitabine has a self-life time of 21 hrs at 37 °C [Stresemann, 2008] and therefore every 24 
hrs the medium was changed and fresh decitabine was added. Since decitabine blocks DNMTs 
and promotes hypomethylation during DMA replication, treatment was carried on until the 
cells had undergone at least two duplications. The concentration which demonstrated the 
highest degree of global demethylation as measured by the methylation status of LINE-1 
element was 0.1 pM. TSA was used at a concentration of 100 nM for 16 hrs. This dose for this 
period of time inhibits effectively the HDAC enzymes while it demonstrates low toxicity for the 
cells [Oyer, 2009].
DNA methylation/ histone acetylation inhibition experiments were carried out by treating 
A549, CRL5802 and HBEC3KT cell lines (one adenocarcinoma, one squamous and one non- 
tumourigenic respectively) with 5-aza-2,-deoxycytidine (Decitabine, Sigma-Aldrich, cat 
noll390) and TSA (Sigma-Aldrich, cat no T8552). Cells were seeded so as to cover about 15% 
of the flask surface. Four flasks were seeded for each cell line that we used; one served as a 
control; one was treated only with lOOnM decitabine; one was treated only with lOOnM TSA; 
one was treated with both chemical substances. Every 24 hrs the medium was changed and 
fresh decitabine was added. Treatment was carried on until the cells had undergone at least 
two cell divisions. TSA was added were applicable for the last 16 h prior to harvesting cells. 
When harvested cells from each flask were pelleted, split into two tubes and stored at -80 °C 
until DNA and RNA extraction. Observations were confirmed by triplicate experiments.
5.18 Transfection of different cell lines with KS-101 and KS-105 plasmids
In order to identify the retrotransposition ability of the LRE3 element in NSCLC and normal 
lung cell lines we have transfected IMR-90, A549, CRL5802, CRL5935, CALU-1 and CALU-6 cell
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lines with KS-101 and KS-105 plasmids. As we have described above, after transfection with
the KS-101 plasmid, cell will acquire resistance to G418 only after a full retrotransposition 
cycle. Therefore retrotransposition events can be visible in the number of colonies present 
after selection with G418.
In order to determine the optimal concentration of G418 for selection we have examined the 
kill curve of all different ceil lines in the presence of various concentrations of G418. Cells 
were seeded in 24 well plates at low density and were grown in the presence of different 
G418 concentrations (400 pg/ml - 1.5 mg/ml) for two weeks. The lowest concentration of 
G418 that promoted complete death of IMR-90, A549, CRL5935, CALU-1 and CALU-6 cells in 
less than two weeks was 600 pg/ml while for CRL5802 the optimal concentration of G418 was 
800 pg/ml.
The different cell lines were transfected with KS-101 and KS-105 plasmids as described in 
paragraph 5.13. 48 hrs post transfection cells were passaged in complete growth medium 
containing the optimal concentration of G418. Growth medium and antibiotic were 
replenished every 2-3 days. After 2 weeks of selection colonies were stained with 0.01% 
crystal violet, counted and photographed using the UVP VisionWorks LS instrument.
We have also examined the effect of decitabine on the retrotransposition capacity of L1.3 in 
these cell lines. After transfection with KS-101 and KS-105 plasmids, cells were passaged in a 
final confluence of approximately 20%. Treatment with decitabine was carried in half of the 
cells, as described in the previous paragraph until cells had undergone at least two 
duplications, while the rest were left untreated to serve as control. Subsequently the medium 
containing decitabine was subtracted from the cells and G418 selection took place in both 
decitabine treated and untreated cells as described above.
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5.19 Transfection of different cell lines with KS-101B and KS-105B plasmids
We have transfected CRL5802 cells using KS-101B and KS-105B plasmids. These two plasmids 
allow for selection of transfected colonies using blasticidin (see paragraph 5.12.2). The 
selected clones carry the KS-101 plasmid and can be studied regardless of the 
retrotransposition ability of the LI.3 element they carry on the KS-101 plasmid.
In order to determine the optimal concentration of blasticidin for selection we have examined 
the kill curve of the CRL5802 cell line in the presence of different blasticidin concentrations (2- 
10 pg/ml). Ceils were seeded in 24 well plates at low density and were grown in the presence 
of the different concentrations. The lowest concentration of blasticidin that promoted 
complete death of the CRL5802 cells in less than two weeks was 5 pg/ml.
Cell lines were transfected as described in paragraph 5.13. 48 hrs post transfection cells were 
passaged in complete growth medium containing 5 pg/ml of blasticidin. Growth medium and 
antibiotic was replenished every 2-3 days. After 2 weeks of selection colonies were isolated 
after trypsinization using cloning cylinders and were grown in new flasks under normal growth 
conditions and in the presence of selection antibiotic. DNA was extracted from each colony 
for methylation analysis of the LRE3 promoter. Colonies were examined for retrotransposition 
activity with or without decitabine as described in paragraph 5.18.
5.20 Statistical analysis
Q-Q plots and the one-sample Kolmogorov-Smirnof test were used to evaluate fitness to 
normal distribution of continuous parameters. Paired t-test was used to determine if there 
was a statistically significant change in the methylation status of LINE-1 and Alu-PV in primary 
NSCLC tumours. Depending on the fitness of parameters to normal distribution, the Pearson's
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(parametric) or Spearman's (non-parametric) tests were used to analyze correlations between 
LINE-1 and Alu-PV methylation and genomic instability. Non-parametric tests such as Mann- 
Whitney and Wilcoxon's were used to analyze expression values among different groups of 
DNMTs, E2F1 and UHRF1 expression. Spearman's correlation was employed to assess the 
relationship between continuous values. P<0.05 was considered statistically significant. All 
statistical tests were performed by SPSS16.0 (SPSS Inc. Chicago, IL, USA).
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Chapter 6. Deregulation of DNA methylation in lung cancer
The first aim of this study was to explore DNA methylation deregulation in lung cancer and 
identify potential causes behind this phenomenon. Towards this goal we have studied the 
expression of DNMTs and UHRF1, the proteins responsible for the establishment and 
maintenance of the methylation patterns, in a large set of primary tissues. In parallel, we 
identified in the same set the methylation status of particular TSG promoters bearing CpG 
islands and assessed global hypomethylation reflected by the methylation status of LINE-1 
element. Analysis demonstrated the importance of UHRF1, DNMT1 and DNMT3B in the 
promotion and maintenance of the hypermethylation of TSGs. Since this role is new and less 
studied for UHRF1, we further examined the effect of UHRF1 in TSG maintenance by knocking 
down its expression in a lung adenocarcinoma cell line.
6.1 Expression status of DNMTs, UHRF1 and E2F1 in primary tumours and cell lines
We examined by qPCR the mRNA expression levels of DNMTs, UHRF1 and E2F1 in a set of 105 
primary non-small cell lung carcinomas. RNA from paired normal adjacent tissues was 
available from 50 of these patients. RNA quality was examined on an Agilent Bioanalyser. The 
selection for the compilation of this set was based on a RIN value > 6 (Figure 24). 
Representative qPCR runs for UHRF1 and DNMT1 are shown in Figures 25 and 26 respectively.
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Figure 24 Total RNA electropherogram run on a Agilent Bioanalyser chip. The 18S and 28S peaks are clearly 
visible at 40 and 48 seconds, respectively. The examined lung tissue RNA set was constructed only with 
samples with adequate amount of RNA and a high RIN number (RIN>6, such as samples 4-7). Highly degrade 
RNAs (as in samples 11,12) were not included in the set.
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Figure 25 Representative amplification plot of UHRF1 gene on an Applied Biosystems 7500 real time PCR 
machine. The amplification curve of UHRF1 in a tumour and a corresponding adjacent normal sample are 
normalised to actin and superimposed in this plot. According to the threshold set, UHRF1 has a dCt value of 30 
in the tumour sample while at the corresponding normal a dCt value of 34.
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Figure 26 Representative amplification plot of DNMT1 gene on an Applied Biosystems 7500 real time PCR 
machine. The amplification curve of DNMT1 in a tumour and a corresponding adjacent normal sample are 
normalised to actin and superimposed in this plot. According to the threshold set, DNMT1 has a dCt value of 
32 in the tumour sample while at the corresponding normal a dCt value of 34.
RNA levels were expressed as relative quantification values (RQ) which were calculated as: 
RQ=2('AACt), where the mRNA expression of IMR-90 lung embryonic fibroblast cells was used as 
a calibrator in each run. All assays were run in triplicates and the mean value was used for the 
analysis. The mean RQ values of all genes in the examined set are available in the appendix.
We statistically compared the expression of these genes in tumour and adjacent normal 
tissues undertaking a non parametric test for paired analysis (Wilcoxon's). Analysis of 
normal/tumour paired tissue set demonstrated higher mRNA levels for UHRF1, DNMTs and 
E2F1 in the tumour samples (Table 16).
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Table 16 mRNA expression of examined genes in lung tumour and paired normal lung tissue (n=50).
mRNA expression (RQ values, mean ± SE)
Tumour Normal lung p-value (Wilcoxon's test)
UHRFl 3.9 ±0.4 0.5± 0.1 1.7xl0'9
DNMT1 9.8 ±0.8 5.8 ± 0.4 2.0 xlCT5
DNIVIT3A 47.9 ±7.4 32.9 ±4.5 3.9xl0'4
DNMT3B 89.0 ±16.7 31.8 ±5.8 4.4 xlO'6
E2F1 25.3 ±3.8 9.5 ±1.5 1.9 xlO"6
RQ=Relative quantification value= 2'MCt. The expression of IMR90 lung fibroblasts has been used as calibrator in all genes.
The mean value was deduced by two repeats.
Bivariate analysis (Spearman's correlation) of the expression levels of the above genes in the 
set of 105 tumours demonstrated significant correlations between all of them (Table 17).
Table 17 Coordinated expression of UHRF1, DNMTs and E2F1 in NSCLC (N=105)
DNMT1 DNMT3A DNMT3B E2F1
UHRFl 0.633* 0.583 0.514 0.754
4.5x10 13 6.6x10 11 2.4x10 8 1.5xl0'20
DNMT1 0.737 0.558 0.659
3.2xl0'19 7.3X10'10 2.3xl0'14
DNMT3A 0.688 0.744
6.9xl0'16 l.lxlO'19
DNMT3B 0.732
4 .............
l.lxlO’18
Spearman's correlation coefficient 
p-value
Expression of UHRF1, DNMTs and E2F1 was comparatively analyzed with the 
ciinicopathological data of this set. UHRF1 was found to be expressed at higher levels in 
squamous carcinomas compared to adenocarcinomas (Mann-Whitney test, p=0.019), whilst 
no other clinical association (age, gender, T stage, nodal metastasis or differentiation) was 
observed for the rest of the genes. Furthermore, we have analysed the expression levels of 
the above genes in comparison to survival data which were available for a subset of tumours 
(n=54) (Appendix). DNMT3B mRNA overexpression correlated with poor prognosis. In
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particular, patients with lower than median DNMT3B expression (RQ<26.6) had a mean
estimate survival of 70.2 ± 10.4 months while the corresponding figure for those with higher 
DNMT3B expression was 29.3 ± 5.7 months (Log rank test, p=0.013, Figure 27). The rest of the 
genes examined did not demonstrate any correlation with survival.
Low DNMT3B
> 0.6-
3 0.4-
High DNMT3B
FU (months)
Figure 27 Kaplan-Meier survival analysis of NSCLC patients in relation to the DNMT3B mRNA expression. X axis 
represents follow-up (FU) time while cumulative survival is represented on the Y axis. Tumours with DNMTBB 
RQ value >26.1 (median) demonstrate a lower survival rate than those with lower than the median DNMTBB 
expression. It must be noted that none of the patients received post-operative chemo- or radiotherapy.
6.2 Methylation status of DNMTs and UHRF1 promoters in primary tumours 
Bioinformatic analysis of the UHRF1 and all DNMTs promoters demonstrated the presence of 
CpG islands. This led us to investigate the potential epigenetic regulation of these molecules. 
Pyrosequencing assays were designed for each gene and used to identify the methylation 
status of their promoter in this normal and tumour set. Representative pyrograms for each 
gene are shown in Figure 28. The threshold for scoring hypermethylated samples was
105
conservatively set to 10%, which is higher to previously established threshold [Shaw, 2006],
[Hall, 2008], in order to increase the prospect of the detected methylation for biologically 
relevance. All four promoters were found to be completely unmethylated with a methylation 
index below 5% in all normal and tumour tissues examined.
H8 : GAAYGGAGT>GGnATGTTTAGGGAATAYSTATGYGTAAGGr'GGGTATATA
0*1 0*1 2% I%1 0*1
Q 50
CAS 3 C T A T G
A8 : TTTrAGMiTTGTYGSTYGjGTAGYGlTGTYGTTYGTTvGTTvGATYGTTAGGGAG
0*1 2*1 0*1 0*1 0*1 3*1 0*1 »*l 4*1
W A f 6 f'C G f A G f C t C f C G A T G - C & f A 6 C t &
C5 : GYG'TYGrTTTYGGTA'YGGTTTTTTIJrGGTTTYGTAATTTTTAAATGT
2*1 2*1 4*| 0*1 3*1 0*1
Figure 28 Representative pyrograms of DNMT1, DNMTBA, DNMT3B and UHRF1 promoter sequences examined 
in this study. The percentages in boxes represent the individual CpG methylation values. The methylation
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index (Mtl) is calculated as the average values of the examined CpGs. All gene promoters demonstrated low to 
methylation (less than 5%) DNMT1: Mtl 0%, DIM MTS A: Mtl 1% DNMT3B: Mtl 1%, UHRF1: Mtl 2%. The 
bisulphite control dispensed nucleotides are shown in the yellow column.
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6.3 Methylation status of CDKN2A and RASSF1 TSGs In primary lung carcinomas 
In order to examine the potential relationship between DNMTs and UHRF1 expression and 
frequently hypermethylated genes in lung cancer, we have identified the methylation status 
of CDKN2A and RASSF1 genes. The methylation levels of CDKN2A and RASSF1 promoters were 
measured by Pyrosequencing in this set of 105 NSCLC tumour and 50 normal tissues. The 
threshold for scoring hypermethylated samples was conservatively set to 10%, which is higher 
to previously established thresholds [Shaw, 2006], [Hall, 2008], in order to increase the 
prospect of the detected methylation for biological relevance. DNA hypermethylation was 
observed in 32.4% of the tumours for RASSF1 and 26% of the tumours for CDKN2A 
(Appendix). Representative pyrograms for each gene are given in photos 29 for CDKN2A and 
30 for RASSF1.
E7 : GQOSt'GGATYtjlrTiTTjrGTTYQjYaGrrTCSYOtiA
m] 2%] 2*J 2%) 1%I £*] MfcJ
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100-
25--------
Figure 29 Representative pyrograms of the CDKN2A promoter sequence examined in this study. Upper: 
CDKN2A adjacent normal, Mtl 0%. Lower: CDKN2A lung tumour, Mtl 45%. The percentages in boxes represent 
the individual CpG methylation values. The methylation index (Mtl) is calculated as the average values of the 
examined CpGs. The bisulphite control dispensed nucleotides are shown in the yellow column.
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H12 : Y GGG TAT T T TY GTY GTCSGTTGTTTT GYGGTYGTYGTYCTTr GTTGGTVGTTlf QGGGTGQQGT GTQAGGAQOQCK
oh] mj mj 3*1 3*1 3*1 0*1
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Figure 30 Representative pyrograms of the RASSF1 promoter sequence examined in this study. Upper: RASSF1 
adjacent normal, Mti 2%. Lower: RASSF1 lung tumour, Mtl 52%. The percentages in boxes represent the 
individual CpG methylation values. The methyiation index (Mtl) is calculated as the average values of the 
examined CpGs.
The methylation status of CDKN2A and RASSF1 promoter was analysed in comparison to 
clinicopathological data (age, gender, histological type, pTNM, differentiation). There was no 
significant association between the methylation status of either CDKN2A or RASSF1 promoters 
and clinicopathological data.
6.4 Relationships between UHRF1 and DNMTs expression with hypermethylation
The expression of the UHRF1 and DNMTs genes was analyzed in relation to the 
hypermethylation status of the TSGs (Appendix). Tumours with a hypermethylated CDKN2A 
promoter demonstrated higher levels of the DNMT1 (Mann-Whitney, p=0.018) and UHRF1 
(p=0.005) expression compared to the CDKN2A-unmethylated tumours. In addition, tumours 
with hypermethylated RASSF1 promoter demonstrated higher levels of DNMT3B (Mann-
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Whitney, p=0.043) and UHRF1 (p=0.034) expression. DNMT3A expression did not demonstrate 
a correlation with any of the two examined promoters. Interestingly, when combining the 
methylation status of both CDKN2A and RASSF1 (positive = at least one methylated) the 
correlation between UHRF1 expression and hypermethylation becomes more significant 
(p=2.3xl0'4, Table IS). The same stands for DNMT3B (p=0.037) while DNMT1 expression 
shows no significant difference between the combined group and unmethylated samples 
(Table 18).
Table 18 mRNA expression levels of UHRF1, DNMT1, DNMT3A and DIMMT3B in groups of NSCLCs with different
methylation status of CDKN2A and RASSF1
CDKN2A methylation RASSF1 methylation
CDKN2A and/or 
RASSF1
0 1 p-value 0 1 p-value 0 1 p-value
UHRFl 2.9±0.4 3.9+0.4 0.005 2.810.3 4.110.7 0.034 2.410.3 4.110.5 2.3x10'
DNMTl 6.5+0.8 8.8+1.2 0.018 6.8+0.7 8.1+1.3 0.301 6.010.7 8.211.0 0.058
DNMT3A 26.4±3.2 35.3±9.6 0.604 31.7+5.3 31.414.9 0.314 23.7+3.6 33.315.9 0.151
DNMT3B 59.5±10.0 73.1120.0 0.200 54.8+9.7 90.8119.8 0.043 41.9+6.1 84.6+16.8 0.037
Values are presented as mean relative quantification (RQ) ± standard error. P values originate from
Mann-Whitney tests.
6.5 Relationships between UHRF1, DNMTs expression and global hypomethylation
The LINE-1.2 methylation assay was utilised as a measure of global hypomethylation 
[Weisenberger, 2005] in the tumour samples of this NSCLCs set. Tumour samples of this set 
demonstrated a variable degree of hypomethylation in agreement to the findings of the 
second set (chapter 7) with a mean LINE-1.2 methylation index of 58.8% ± 0.9%. LINE-1.2 
hypomethylation was more apparent in squamous carcinomas (mean Mti: 55.9± 1.4) 
compared to adenocarcinomas (mean Mtl: 61.3± 1.1, Mann-Whitney test p= 0.002) (Figure
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31). No other association was observed between the methylation status of LINE-1.2 promoter
and clinicopathological data in this set.
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Figure 31 Box plot representation of LINE-1.2 methylation values in adenocarcinomas versus squamous ceil 
carcinomas. LINE-1.2 element demonstrates greater hypomethylation in squamous cell carcinomas.
The expression of the UHRF1 and DNMTs genes and regional hypermethylation of CDKN2A 
and RASSF1 was subsequently analyzed in relation to the global methylation as measured by 
LINE-1 assay. Firstly, we compared the continuous values performing Spearman's correlation 
test for non-parametric values. An inverse correlation was observed between global 
methylation and the methylation status of RASSF1 while there was no correlation with the 
methylation status of CDKN2A promoter. An inverse correlation was also observed between 
LINE-1.2 methylation and E2F1, UHRF1 and DNMT1 expression. There was also an inverse 
correlation between LINE-1.2 methylation and DNMT3A or DNMT3B expression, however, 
with really low correlation coefficient. The results are summarized in Table 19.
Ill
Table 19 Correlation between LINE-1, CDKN2A, RASSF1 methylation and DNMTs, UHRF1, E2F1.
LINE-1
(Mtl)
Correlation 
Coefficient 
Sig. (2-tailed) 
N
. , . methylation status
expression levels (RQ values) , .
DNMTl DNMT3A DNMT3B UHRF1 E2F1 CDKN2A RASSF1
-0.339 -0.198 -0.282 -0.491 -0.443 -0.126 -0.333
4xl0'4 0.044 0.004 IxlO*6 2.5xl0‘6 0.215 5xl0‘4
104 104 103 104 104 99 104
In order to gain a wider view on the observed correlation of hypomethylation with 
hypermethylation and higher expression of the studied genes we have dichotomized our 
samples into two distinct groups according to their LINE-1 methylation status. The expression 
status of DNMTs, UHRF1 and E2F1 was compared in these two group using Mann-Whitney 
test for non-parametric samples. The expression levels of DNMT1, DNMT3B, UHRF1 and E2F1 
were significantly higher in the group with lower LINE-1.2 methylation compared to that with 
higher LINE-1.2 methylation. The significance was higher for UHRF1 and E2F1 in accordance to 
the correlation results. The results are summarized in Table 20 and the differences in the 
mean expression values between the two groups can be seen in Figure 32.
Table 20 Expression of DNMTs, UHRF1 and E2F1 in high and low LINE-1 methylation groups
Examined
LINE-1 methylation N
Mean RQ Std. Asymp. Sig.
Genes value Error (2-tailed}
high 52 5.16 0.52
DNMTl 0.003
low 52 9.05 1.05
high 52 22.18 2.42
DNMT3A 0.174
low 52 40.08 7.19
high 51 39.26 5.83
DNMT3B 0.004
low 52 90.16 16.54
high 52 2.17 0.25
UHRF1 7xl0"5
low 52 4.27 0.50
E2F1
high 52 11.49 1.27
9x10
low 52 26.11 3.68
112
Figure 32 Bar representation of DNMT1, UHRF1 and DNMTBB mean expression between the lower and higher 
UNE-1.2 methylation groups. The Y-axis represents the mean expression in RQ values. Error bars represent 
standard error of the mean. The mean expression of DNMT1, DNMTBB and UHRF1 is higher in the group of 
patients with higher LINE-1 methylation
We have also examined the scored hypermethylated and unmethylated RASSF1 and CDKN2A 
samples with the two distinct groups of UNE-1.2 methylation. Since we wanted to compare 
ordinal values we performed chi square test. CDKN2A methylation status showed no 
difference between the two groups (Pearson chi-square p=0.78) while RASSF1 methylated 
samples were significantly more in the group with lower LINE-1.2 methylation (Pearson chi- 
square p=0.037)(Table 21). Furthermore, by using the assigned hypermethylated status, 
values were compared to the combined for both CDKN2A and RASSF1 phenotype with LINE- 
1.2 methylation status. Samples with CDKN2A and/or RASSF1 hypermethylated promoter
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were significantly more frequent in the group with lower LINE-1.2 methylation (Pearson chi-
square p=0.011) (Table 22).
Table 21 Tumour samples grouped according to the methylation status of LINE-1.2 and RASSF1.
LINE-1.2 methylation Total 
0 1
RASSFl 0 40 30 70
methylation 1 12 22 34
Total 52 52 104
Table 22 Tumour samples grouped according to the methylation status of LINE-1.2 and a combined
hypermethylation status of CDKN2A/RASSF1.
LINE1.2 methylation Total 
- -
CDKN2A/RASSF1 0 34 21 55
methylation 1 18 31 49
Total 52 52 104
6.6 UHRF1 downregulation leads to hypomethylation of TSGs in A549 cells
Following the observations regarding the relationship between UHRF1 expression, TSG 
hypermethylation and global hypomethylation in primary NSCLCs, we further investigated the 
role of the UHRF1 in a cell line model by knocking down UHRF1 in the A549 lung 
adenocarcinoma ceil line and acquiring stable cell transfectants.
We have inserted an shRNA oligo that specifically knockdowns UHRF1 expression in a shRNA 
inducible vector. The inserted sequence was verified by sequencing of the construct. The 
various clones were examined for their UFIRF1 knockdown efficiency under doxycycline
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induction. Clones demonstrating inducible knockdown of UHRF1 did not succeed more than 
45% reduction of the UHRF1 mRNA (Table 23).
Table 23 Expression of UHRF1 in A549 PAUHRF1 clones after induction with doxycyclin.
UHRF1 expression (RQ)
A549 PAUHRF1 Untreated supplemented with doxycyclin
24 hrs 48 hrs 72 hrs 96 hrs
clone 1 1 0.64 0.60 0.54 0.65
clone 2 1 1.20 1.12 1.25 1.21
clone 3 1 0.62 0.65 0.60 0.58
clone 4 1 0.85 0.87 0.84 0.80
clone 5 1 1.22 1.15 1.18 1.14
clone 6 1 1.30 1.18 1.20 1.22
clone 7 1 1.10 1.05 1.04 1.03
clone 8 1 1.09 1.08 1.03 1.10
clone 9 1 1.07 1.09 1.11 1.12
clonelO 1 0.97 0.95 0.90 0.92
clone 11 1 1.08 1.03 1.02 1.01
clone 12 1 1.30 1.23 1.21 1.32
clone 13 1 1.10 1.12 1.13 1.00
clone 14 1 0.55 0.60 0.55 0.57
clone 15 1 0.57 0.56 0.62 0.57
RQ=Relative quantification value= 2' . The expression of the untreated corresponding done has been used as calibrator.
The mean value was deduced by triplicate experiments.
In contrast, two clones (named clone 1 and 2 thereafter) demonstrated constitutive, non­
inducible >80% knockdown of UHRF1 mRNA compared to the parental and mock transfected 
A549 cells. Thus it was decided to proceed to the subsequent experiments with these two 
clones. Both derived clones demonstrated 80% knockdown at the RNA level (Figure 33A) while 
the protein was almost undetectable in western blotting (Figure 33B).
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Figure 33 qPCR (A) and western blotting (B) demonstrating UHRF1 mRNA and protein expression respectively 
of the A549-derived UHRF1 knockdown clones. A >80% reduction of mRNA levels is observed in both clones 
while UHRF1 protein is hardly detectable in the western blot in comparison to the strong UHRF1 expression in 
A549 and mock cells.
In order to investigate the UHRF1 knockdown effect on regional hypermethylation, we 
screened, using previously designed pyrosequencing assays, a number of frequently 
hypermethylated TSGs promoters in lung cancer including the promoters of CDKN2A, RASSF1, 
CYGB, and CDH13. CDKN2A was completely unmethylated in A549 parental, mock cells and 
UHRF1 knockdown derived clones. Representative pyrograms from CYGB and CDH13 are 
shown in Figure 34.
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Figure 34 Representative pyrograms of the CDH13 and CYGB promoter sequences examined in this study. The 
percentages in boxes represent the individual CpG methylation values. The methylation index (Mtl) is 
calculated as the average values of the examined CpGs. The bisulphite control dispensed nucleotides are 
shown in the yellow column.
While no difference was observed in the mock cell line, the methylation status of RASSF1, 
CYGB, and CDH13 promoters was consistently, although variably, reduced in both UHRF1 
knock down clones (Figure 35).
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Figure 35 Effect of UHRF1 expression knockdown on the DNA methylation levels of RASSFl, CYGB and CHD13. 
A consistent reduction of the DNA methylation of all three promoters is observed across biological replicates 
in both UHRF1 knockdown clones. The Y-axis represents the mean methylation index detected by triplicate 
pyrosequendng experiments. Error bars represent standard error of the mean.
Furthermore, we used the LINE-1.2 assay in order to detect any changes in global 
hypomethylation caused by UHRF1 downregulation. Indeed, UHRF1 knockdown clones 
demonstrated decreased mean methylation compared to parental and mock cells (Figure 36).
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Figure 36 Bar representation of LINE-1.2 methylation (global methylation) in A549, mock and UHRF1 
knockdown clones 1 and 2. The Y-axis represents the mean methylation index (Mtl) detected by triplicate 
pyrosequendng experiments. Error bars represent standard error of the mean. UHRF1 knockdown clones 
demonstrate a significant decrease in their LINE-1.2 methylation levels.
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In order to detect any changes in the expression levels of DNMTs in the derived clones we
have examined by qPCR the mRNA levels of al DNMTs in the control, mock and derived clones. 
The mRNA expression levels of DNMT1, and DNMT3A demonstrated no significant changes 
between A459, the mock and the UHRF1 knockdown clones. In contrast, DNMT3B was up- 
regulated in both UHRF1 knockdown clones (Table 24). UHRF1 and DNMT promoters were 
unmethylated in the A549 cells and no change was observed in the UHRF1 knockdown clones 
(Table 24).
Table 24 mRNA expression and DNA methylation status of DNMTs in UHRF1 knock-down clones.
mRNA expression (mean RQ ±SE) Promoter Methylation Index
DNMT1 DNMT3A DNMT3B UHRF1 DNMT1 DNMT3A DNMT3B
A549 1.00 ±0.21 1.02 ± 0.08 1.02 ± 0.08 2% 1% 0% 1%
mock 1.07+0.19 0.96+0.04 1.2±0.13 3% 2% 1% 0%
Clone 1 0.78 + 0.15 1.16 + 0.06 6.03 ± 0.39 2% 0% 2% 1%
Clone 2 0.94 ±0.18 1.27 ±0.06 4.15 ±0.19 2% 1% 1% 1%
RQ= relative quantification. Means and standard error (SE) have been calculated from 6 replicates (2 biological x 3 
technical). The average value of the A549 cells was used as calibrator for calculating RQ.
6.7 Phenotypic effects of UHRF1 downregulation
The phenotypic characteristics of the UFIRF1 knockdown clones were significantly different to 
those of A549 and mock cell lines. Proliferation of cells was measured using MTT assay for 5 
subsequent days. Both UHRF1 knock down clones demonstrated reduced proliferation rates 
compared to the parental and mock cells (Figure 37).
119
03-
Figure 37 Proliferation rates over 5 days, measured by MTT experiments. Proliferation is significantly reduced 
in both UHRF1 knock down clones in comparison to A549 cells and mock (scrambled shRNA) cell lines.
In addition, scratch assays demonstrated lower migration efficiency of the UHRF1 knockdown 
clones (Figure 38). In particular, TScratch software analysis demonstrated that after 24 hours, 
the open wound area was 10.5% ± 1.3% in the parental A549, 14.1% ± 1.1% in mock cells, 
71.9% ± 1.8% in UHRF1 clone 1 and 56.1% ± 1.8% in clone 2 (Figure 39).
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Figure 38 Scratch assays demonstrating the reduced migration efficiency of UHRF1 knock down clones in 
comparison to A549 cells and mock (scrambled shRNA) cell lines. Photographs of t=0 and t=24 hours are 
presented. The open wound area was quantified using TScratch software.
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Figure 39 Diagrammatic representation of the migration rates of parental, mock and UHRF1 knock down 
clones in scratch assays. The open wound area (OWA) was quantified using TScratch software. The increased 
OWA of the UHRF1 clones indicate their reduced migration capability.
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Chapter 7. Retrotransposons, DNA methylation and genomic instability
The second aim of this study was to measure the extent of global DNA hypomethylation in 
NSCLC and investigate its links with genomic instability and reactivation of retrotransposition 
We evaluated global DNA methylation by pyrosequencing, measuring the DNA methylation 
levels of LINE-1 and Alu transposable elements in primary non-smail cell carcinomas and their 
paired adjacent tissues. We demonstrated a significant reduction of the methylation levels of 
both elements in a coordinated manner suggesting a possible common mechanism for their 
methylation maintenance. Moreover we assessed genomic instability of this lung tumour set 
and demonstrated that hypomethylation of both transposable elements was associated with 
increased genomic instability. The reduction of the methylation index of LINE-1 and Alu 
following treatment of three lung cell lines with a demethylating agent, consistently resulted 
in increased expression of both elements. We have also demonstrated, utilising a construct 
which carries a full LINE-1 element tagged with a reporter cassette, that unmethylated LINE-1 
can retrotranspose successfully in a lung cancer cell line.
7.1 Methylation status of LINE-1 and Alu-PV in primary NSCLC tumours
Pyrosequencing assays were designed In order to examine the methylation status of LINE-1.2 
and Alu-PV elements in lung primary tissues. Both assays were used to identify the 
methylation status of these elements in the set of 48 paired tumour and adjacent normal 
NSCLC primary tissues. Representative pyrograms of the pyrosequencing runs are given in 
Figure 40 and 41 respectively. Detailed results are given in Table 25.
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Figure 40 Representative pyrograms of the LINE-1.2 promoter sequence examined in this study. A: LINE-1.2, 
adjacent normal, Mtl 69%. B: LINE-1.2, lung tumour, Mtl 31%. The percentages in boxes represent the 
individual CpG methylation values. The methylation index (Mtl) is calculated as the average values of the 
examined CpGs.
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GTAGTCGTGTATCGATGTCGAGTGCTAGTGATGTCGAG
Figure 41 Representative pyrograms of the Alu-PV promoter sequence examined in this study. A: Alu-PV 
adjacent normal, Mtl 56%. B: Alu-PV, lung tumour, Mtl 46%. The percentages in boxes represent the individual 
CpG methylation values. The methylation index (Mtl) is calculated as the average values of the examined 
CpGs.
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Table 25 Clinical samples of the utilized cohort and results for LINE-1 and Alu methylation and genomic 
instability (FAL).
Methylation Index (%)
Sample Gender Age Diagnosis LINE-1
Normal
LINE-1
Tumour
Alu
Normal
Alu
Tumour
FAL
1 F 74 AdenoCa 70.3 61.3 53.3 52.7 0.455
2 M 68 AdenoCa 69.7 58.0 55.0 53.2 0.857
3 F 50 AdenoCa 69.1 56.3 50.6 53.9 0.857
4 M 52 AdenoCa 69.6 65.6 57.4 54.1 0.375
5 F 68 AdenoCa 69.7 64.7 56.6 60.0 0.400
6 F 74 AdenoCa 69.4 47.0 56.6 55.0 0.625
7 F 67 AdenoCa 69.3 67.8 53.5 54.0 0.500
8 F 53 AdenoCa 70.0 60.8 58.2 52.8 0.778
9 F 73 AdenoCa 70.6 67.6 56.7 55.7 0.000
10 F 58 AdenoCa 70.2 54.0 58.4 55.2 1.000
11 M 74 AdenoCa 69.8 48.4 60.3 51.8 0.909
12 F 69 AdenoCa 69.6 34.8 59.0 56.5 1.000
13 M 63 AdenoCa 69.3 47.2 56.7 51.6 0.900
14 F 64 AdenoCa 69.8 51.3 56.2 50.7 0.889
15 F 66 AdenoCa 70.0 68.8 56.6 56.6 0.000
16 F 61 AdenoCa 68.3 57.4 58.8 55.7 0.600
17 M 67 AdenoCa 70.2 69.4 55.9 60.5 0.143
18 M 65 AdenoCa 69.3 62.4 58.8 52.2 1.000
19 F 68 AdenoCa 68.4 59.2 56.0 52.8 0.889
20 F 69 AdenoCa 69.5 52.2 ND ND 0.818
21 F 77 AdenoCa 69.7 54.5 55.7 54.3 1.000
22 F 53 AdenoCa 69.1 59.3 54.8 53.1 0.556
23 F 67 AdenoCa 68.1 52.1 56.9 48.6 0.500
24 F 45 SqCCL 69.4 66.8 55.3 53.4 0.250
25 M 62 SqCCL 69.7 30.9 56.4 46.3 0.833
26 M 68 SqCCL 69.9 70.3 58.7 54.5 0.000
27 M 78 SqCCL 67.1 48.2 58.7 59.9 0.556
28 M 68 SqCCL 70.8 41.5 58.8 54.1 0.375
29 M 60 SqCCL 70.2 62.7 53.4 52.4 0.333
30 M 62 SqCCL 69.5 40.8 59.9 51.7 0.556
31 M 60 SqCCL 70.3 43.9 58.2 52.2 0.636
32 M 70 SqCCL 69.6 63.1 56.5 54.4 1.000
33 F 70 SqCCL 69.6 40.0 55.4 51.2 0.900
34 M 83 SqCCL 69.6 49.8 56.4 53.8 0.900
35 M 83 SqCCL 70.5 56.8 56.5 48.8 1.000
36 M 66 SqCCL 68.3 41.0 60.6 47.6 1.000
37 M 65 SqCCL 70.4 50.5 53.0 55.9 1.000
38 M 58 SqCCL 69.0 48.2 55.6 51.8 0.714
39 M 66 SqCCL 70.1 60.3 57.2 53.4 0.182
40 M 72 SqCCL 69.8 61.9 62.5 54.9 0.300
41 F 66 SqCCL 68.8 57.1 53.9 50.9 0.667
42 M 47 SqCCL 69.4 38.6 55.7 53.4 0.700
43 M 69 SqCCL 70.3 66.4 57.2 54.1 0.636
44 M 68 SqCCL 73.5 67.7 55.2 55.1 0.100
45 F 48 SqCCL ND ND 56.6 57.5 0.182
46 M 63 SqCCL 65.4 34.6 55.6 52.6 0.714
47 F 71 SqCCL 69.1 41.6 54.4 53.7 0.778
48 F 69 SqCCL 70.1 52.1 ND ND 0.667
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LINE-1.2 promoter was highly methylated with minimal variability in normal lung tissues
(mean Mtl: 69.8%±0.14%). The corresponding tumour samples demonstrated a significant 
drop in the Mtl values (mean Mtl: 56.4%±1.4%, paired t-test, p=7.7xl0 14, Figure 42).
80 00'
70 00'
___  6000'
4-*
Ol
50 00'in
Z
=j
40 00'
30 00'
Normal Tumour
Figure 42 Box plot representation of LINE-1.2 methylation values observed in the first studied cohort. There is 
a profound hypomethylation of LINE-1.2 element in the lung cancer tissue compared to adjacent normal.
A highly significant difference between normal (mean Mtl:56.6%±0.3%) and tumour (mean 
Mtl: 53.5%±0.4%) tissue Mtls was found for Alu-PV promoter (paired t-test, p=9.6xl07, Figure 
43). Notably, LINE-1.2 and Alu-PV methylation indices in primary tumours correlated to each 
other (Pearson's correlation^.401, p=0.006). The methylation status of the two promoters 
was analysed in comparison to clinicopathological features such as histology, age, gender, T 
status, differentiation and nodal metastasis. Clinicopathological parameters such as age, 
gender, T status, differentiation and nodal metastasis did not demonstrate any significant 
association with LINE-1.2 and Alu-PV methylation. LINE-1.2 hypomethylation was more
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apparent in squamous carcinomas than adenocarcinomas, however only at borderline
significance (p=0.052).
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Figure 43 Box plot representation of Alu-PV methylation values observed in the first studied cohort. There is a 
profound hypomethylation of Alu-PV element in the lung cancer tissue compared to adjacent normal.
7.2 Correlation of LINE-1.2 and Alu-PV hypomethylation with genomic instability
We determined genomic instability in this tumour set utilising 11 microsatellite markers which 
have been previously shown to be hot spots for loss of heterozygosity (LOH) in lung tumours 
[Liloglou, 2000], [Liloglou, 2001]. Detailed results from individual microsatellites are given in 
appendix. Genomic instability for each sample was expressed as the fractional allele loss (FAL) 
value (Table 25). The fractional allele loss (FAL) value was used as an expression of overall 
genomic instability in each sample and was calculated as: FAL = [number of loci with 
loss]/[number of informative loci]. The bivariate correlation analysis between Mtl and FAL 
demonstrated that genomic instability is associated with hypomethylation of LINE-1.2
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(Pearson's correlation= -0.547, p=7.1xl05) and Alu-PV elements (Pearson's correlation= - 
0.392, p=0.008) (Figure 44).
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Figure 44 Scatter plot presentation of LINE-1.2 methylation values in comparison to genomic instability as
measured by FAL values.
7.3 Effect of demethylating and deacetylating agents on LINE-1 and Alu expression
We examined the methylation levels of the LINE-1.2 and Alu-PV elements in nine lung cancer 
cell lines and one immortalized non-tumourigenic bronchial epithelial cell line (HBEC3KT). 
Cancer cell lines demonstrated a variable degree of methylation at these elements, while the 
immortalised cell line methylation status was somewhat lower of the average index of surgical 
normal adjacent tissue (Table 26).
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Table 26 Methylation status of LINE-1.2 and Alu-PV promoters in different cell lines
Cell line LINE-1.2 Mtl Alu-PV Mtl
SKMES 58.71 45.93
CRL5802 36.63 37.01
CALU 6 49.52 45.45
A549 58.21 40.58
DMS 53 39.94 42.83
CALU 3 64.18 45.71
CRL 5935 63.8 43.91
CORL 23 63.4 47.68
SKLU-1 61.91 45.62
HBEC 3KT 62.73 44.08
We examined the possible epigenetic control of LINE-1 and Alu expression by using the 
demethylating agent 5-aza-2-deoxycytidine (decitabine) and a histone deacetylase inhibitor 
such as trichostatin (ISA). At first we identified the optimal concentration of decitabine to 
achieve maximum hypomethylation level, undertaking a dose-dependent experiment. The 
optimal amount of decitabine was found to be 0.1 pM (Figure 45). Our results are in 
agreement with a dose dependent experiment showing that low concentration of decitabine 
caused more hypomethylation than high concentrations of the drug [din, 2007].
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Figure 45 Dose-dependent effect of decitabine on the methylation status of LINE-1.2 and Alu-PV elements. 
HBEC-Bkt cells were treated with decitabine concentration as shown in the figure. The methylation levels 
measured by pyrosequencing for LINE-1.2 and Alu-PV are shown in the figure. Both elements seem to follow a 
similar pattern demonstrating higher hypomethylation with lower decitabine concentrations around 0.1 pM.
We applied the optimal dose of decitabine in the A549, CRL5802 and HBEC3KT lines (one 
adenocarcinoma, one squamous cell carcinoma and one non-tumourigenic respectively). 
Treatment with decitabine resulted in hypomethylation while addition of TSA did not affect, 
as expected, the methylation status. Decitabine and TSA increased the expression of both 
elements, with the exception of LINE-1 expression in HBEC3KT were TSA had no effect. As 
expected the combined use of both substances resulted in enhanced transcription compared 
to single substance use (Figure 46).
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Figure 46 Bar charts demonstrating the methylation (top panels) and expression (bottom panels) levels of 
LINE-1.2 and Alu-PV transcripts following treatment of lung cell lines with 5-aza-2'-deoxycitidine (Aza) and 
trichostatin (ISA). The addition of azacytidine reduces methylation and increases expression of both Alu-PV 
and LINE-1.2 elements. The addition of TSA does not affect methylation but has an effect in expression of both 
elements with the exception of UNE-1.2 in HBEC3KT cells. Simultaneous use of both compounds has a 
profound synergistic effect in expression of both elements. Expression is given in relative quantification (RQ) 
values which are calculated as RQ=2( value using the untreated control cell population as the calibrator. 
Means and standard error (SE) bars have been calculated fromB biological replicates.
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7.4 LINE-1 activity in lung cell lines.
In order to identify the retrotransposition ability of a full LINE-1 element in a lung cell 
environment we have utilised the KS-101 vector system (described in materials and methods). 
IMR-90, A549, CRL5802, CRL5935, CALU-1 and CALU-6 cell lines were transfected with the 
reporter plasmid KS-101. After selection with G418, formation of colonies was visible only in 
the CRL5802 cell line (Figure 47) while the rest of the cell lines did not demonstrate any 
colonies and therefore no retrotransposition events. As expected, transfection with the 
control retrotransposition-incompetent KS-105 vector did not demonstrate any colonies in 
any of the above cell lines (Figure 47).
Figure 47 CRL5802 cells transfected with KS-101 (left) and KS-105 (right) after two weeks selection with G418.
Interestingly the CRL5802 cell line which demonstrated LRE3 activity has the lowest LINE-1 
methylation levels as measured by pyrosequencing compared to the other cell lines (Table 
27).
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Table 27 Cell lines, methylation status of UNE-1.2 element and retrotransposition events of LRE3 element
Cell line UNE-1.2 Mtl UNE-1.3 retrotransposition
1 MR-90 60 N
CRL5802 37 Y
CALU-6 50 N
A549 51 N
CALU-3 64 N
CRL 5935 64 N
In order to identify the role of decitabine-induced global hypomethylation in the 
retrotransposition ability of the LRE3 element we have treated the above cell lines with 
decitabine after transfection with the KS-101 plasmid, allowed at least two cell duplications 
and then selected with G418. Again, only CRL5802 demonstrated the formation of colonies 
which in the presence of decitabine did not change significantly while at the rest of the cell 
lines no colonies were observed even after the addition of decitabine (Figure 48).
Figure 48 CRL5802 cells transfected with KS-101, untreated (left) and treated with decitabine (right) after two
weeks selection with G418.
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7.5 LINE-1 activity in cell lines utilising the KS101B and KS105B plasmids
The use of the KS101 plasmid in cell lines in order to identify the activity of LINE-1 element 
poses a significant limitation. No selection marker is available on the plasmid and therefore 
the transformation efficiency cannot be estimated. We have seen that LRE3 remains inactive 
in most cell lines even after decitabine treatment. In addition, it was observed that activity of 
the LRE3 element did not change significantly after decitabine treatment in the CRL 5802 cell 
line. Although these data suggest that global hypomethylation induced by decitabine does not 
affect LINE-1 activity, however we cannot be certain since transformation efficiency is 
unknown. Furthermore, the methylation status of the LRE3 element of the KS-101 plasmid can 
only be examined in selected colonies. To overcome these problems we have inserted the 
blasticidin resistance market in the KS-101 and KS105 plasmids in order to be able to examine 
the status of the plasmid before selection with G418 and to correct for transfection 
differences. The colonies with the new KS-101B and KS-105B plasmids carrying the blasticidin 
resistance gene can be seen in Figure 49.
Figure 49 KS-101B (lanes 1-6), and KS-105B (lanes 8-13) plasmids from minipreps digested with Sal I (NEB) and 
ECOR I run in a 1% agarose gel in TBE together with the X DNA-Hindlll marker (lanes 1,15). KS-101 (lane 7) was 
also digested with the two enzymes to serve as controls. The lower fragment is common in all minipreps and 
control while the upper fragment which carries the blasticidin fragment runs higher compared with the KS-101 
plasmid. All the minipreps carry the blasticidin fragment. Two plasmids were picked and grown further to 
generate the KS-101B and KS105B plasmids.
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The KS-101B and KS105B plasmids were transfected into the CRL5802 cell line and stable
colonies were obtained after selection with blasticidin. DNA was extracted from the colonies 
in order to identify the methylation status of the KS101B plasmids in each colony. Utilising the 
LRE3 methylation assay we have identified using pyrosequencing the methylation status of 
the LRE3 promoter in each colony. A representative pyrogram of LRE3 run is shown in Figure 
50.
HI : TYGTTTTTTGYGTYQTTTA'tBTTQQQAGTTGTAGATYQGAGTTGTTTTTATTYGGTTATTTTQGTTTTTTTTT
!*J ti*) ?*}
Figure 50 Representative pyrogram of the LRE3 promoter sequence examined in this study. Mtl: 8%. The 
percentages in boxes represent the individual CpG methylation values. The methylation index (Mtl) is 
calculated as the average values of the examined CpGs. Yellow column indicate the bisulphite control sites.
CRL 5802 KS101B colonies demonstrated variable methylation levels of the LRE3 element 
promoter which remained at low levels less than 10% (Table 28). In order to examine the 
effect of global hypomethylation on the retrotransposition efficiency of the LRE3 element in 
the selected CRL5802 clones, we have treated them with decitabine and then selected them 
using G418 in order to identify the number of retrotransposition events. Since the 
methylation status of each promoter was low, decitabine treatment would lead to global 
LINE-1 hypomethylation without affecting directly the methylation status of the LRE3
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promoter. As expected no colonies were observed in the CRL 5802 KS105B transfected cells
after selection with G418.
Table 28 Four CRL 5802 KS101B colonies and the corresponding methylation status of the LREB element.
CRL 5802 KS101B colonies LREB promoter Mtl (%)
1 8
2 5
3 10
4 9
Treatment with decitabine did not lead to any significant change in the number of colonies 
with retrotransposition events of the KS101B plasmid (Figure 51).
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Figure 51 Mean colony values of CRL5802 KS-101B transfected clones (A-B) with (green) and without (blue) 
decitabine treatment after selection for two weeks with G418. The number of retrotransposition events does 
not change significantly with decitabine treatment in any of the four clones.
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Chapter 8. Discussion
Lung cancer is among the most frequent cancer types and the number one cancer killer in the 
western countries. There is compelling evidence to demonstrate that epigenetic changes are 
of key importance in lung carcinogenesis, with DNA methylation taking up the largest part of 
the existing relevant literature on cancer epigenetics [Esteller, 2007], [Esteller,2008].
Human cancers are characterised by a somewhat paradoxical coincidence of global genome 
hypomethylation and regional hypermethylation and lung cancer is no exception to this. 
Global genome hypomethylation affects mainly repeat sequences like LINE-1 and Alu 
elements while hypermethylation of CpG island-bearing promoters frequent leads to TSGs 
transcriptional silencing. Our understanding of epigenetic deregulation is continuously 
advancing as the list of genes and mechanisms mediating the DNA methylation process is 
growing [Bestor, 2000], [Bird, 1999], [Webster, 2005], [Lopez-Serra, 2008], [Ooi, 2007].
The main objectives of this study was to explore further the molecular mechanisms involved 
in the observed deregulation of DNA methylation in lung cancer and to investigate the 
potential epigenetically controlled re-activation of retrotransposable elements and their 
implication in lung cancer development.
8.1 DNMTs and UHRF1 overexpression in lung cancer
DNMTs are the only enzymes up to date with known methyltransferase activity and are 
therefore considered as the main players in establishing and maintaining the methylation 
patterns. However, UHRF1 was also recently shown to exert critical function in DNA 
methylation maintenance [Bostick, 2007] by assisting the recruitment of DNMT1 on 
hemimethylated substrates. In order to identify potential causes of the observed methylation
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aberrations in lung cancers we have examined the expression status of DNMTs and UHRF1
genes.
The expression of DNMTs has been studied widely in various cancer types. Overexpression of 
DNMT1, DNMT3A and DNMT3B has been reported in human tumours [Girault, 2003], 
[Robertson, 2001], [Ehrlich, 2006]. In this study we observed that all three DNMTs are 
overexpressed in NSCLC tissues when compared to their normal adjacent tissues, in 
accordance with previous studies [Robertson, 1999], [Kim, 2006], [Vallbohmer, 2006J. We also 
demonstrated a significant overexpression of UHRF1 mRNA in NSCLC tumour tissues. Similar 
observations have been reported in a small set of human lung tumours [Jenkins, 2005], a 
cDNA microarray study in breast tumours [Unoki, 2004] and proteomic analysis in breast 
[Hopfner, 2000] and pancreatic carcinomas [Crnogorac-Jurcevic, 2005]. The expression of 
UHRF1 was higher in squamous carcinomas underlying further the differences in the 
molecular evolution of these tumour types. Further research is required to provide evidence 
on whether this difference could be utilized in the clinical management of these two 
histological types.
A strong correlation between the expression levels of all the DNMTs was observed in our 
primary lung tumours set suggesting a coordinated expression of DNMTs in cancers 
[Robertson, 1999], [Lin, 2007]. The E2F1 transcription factor, which is most frequently 
overexpressed in cancers, has been shown to regulate expression of both DNMT1 [Kimura, 
2003], [McCabe, 2005] and UHRF1 [Mousli, 2003] [Unoki, 2004]. In order to find out whether 
up-regulation of DNMT1 and UHRF1 was due to E2F1 regulation, we examined the levels of 
E2F1 in our tissue set. We found a strong relationship between the expression of E2F1 and 
both DNMT1 and UHRF1 suggesting that this transcription factor is, at least partially, 
responsible for the observed overexpression of DNMT1 and UHRF1 in lung cancers. It appears
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that the pRb/E2F pathway regulates the expression of DNMT1 and UHRF1 increasing their
abundance during S and G2 phases [Vogel, 1988], [Jeanblanc, 2005] in order to replicate the 
DNA methylation patterns onto the newly synthesized strands. Furthermore, the expression 
levels of DNMT3A and DNMT3B examined in this set correlated with the expression of E2F1. 
Our data suggest that DNMT3A and DNMT3B may be also regulated by E2F1. Recent evidence 
on the participation of DNMT3A and DNMT3B in DNA methylation maintenance following 
DNA replication [Liang, 2002], [Jones, 2009] provides a biological reason behind the E2F1 
dependence. However, this hypothesis requires further confirmation with functional studies 
in order to prove a direct regulation of DNMT3A and DNMT3B by E2F1.
The presence of dense CpG islands in DNMTs and UHRF1 promoters led us to examine the 
hypothesis of a possible negative feedback loop through DNA methylation. However, no 
methylation was found within these promoters in any of the lung tumours, or adjacent normal 
tissue examined, thus excluding this possibility. Interestingly we found that overexpression of 
DNMT3B correlates with worse survival in NSCLC patients. This is in accordance with a 
previous study demonstrating prognostic significance of DNMT3B expression but only in 
younger patients <65 years [Xing, 2008]. Although in our present study survival data are 
available only for a small subset (n=52), the potential clinical exploitation of this observation 
should be further investigated.
8.2 Expression of DNMTs and UHRF1 in relation to hypermethylation
During the past years many studies have examined the aberrant expression patterns of 
DNMTs in comparison to regional hypermethylation in primary tumours. In some cases the 
expression of DNMTs could not be associated with promoter hypermethylation [Ehrlich,
140
2006], [Sato, 2002], [Park, 2006], while other studies demonstrated correlations between the
expression of particular DNMTs and hypermethylation status of certain promoters such as 
RASSF1 or CDKN2A [Wang, 2007], [Kim, 2006], [Lin, 2007]. Here we investigated the potential 
relationship between DNMTs or UHRF1 overexpression with regional hypermethylation of 
tumour suppressor genes in NSCLCs. We examined the methylation status of RASSF1 and 
CDKN2A TSGs as they are two of the most frequently hypermethylated genes in lung cancers 
[Virmani, 2000], [Zochbauer-Muller, 2001]. Statistical analysis in primary tumours 
demonstrated a correlation between DNMT1 overexpression and a hypermethylated CDKN2A 
promoter, being in agreement with two previous studies [Lin, 2007] [Kim, 2006]. We also 
found that DNMT3B overexpression correlates with RASSF1 promoter hypermethylation. It 
has been reported that a specific DNMT3B subfamily, ADNMT3B, correlates with RASSF1 
hypermethylation but not CDKN2A hypermethylation in NSCLC suggesting that ADNMT3B can 
regulate methylation in a promoter specific manner [Wang, 2007]. The primer set we used to 
amplify the DNMT3B transcript, amplifies all different DNMT3B transcripts and since 
ADNMT3B is the predominant form of DNMT3B in NSCLCs [Wang, 2006] we believe that our 
result reflects the observed correlation between ADNMT3B and RASSF1. Our data together 
with previous reports [Wang, 2007], [Lin, 2007], [Kim, 2006] suggest that DNMT1 and 
DNMT3B can regulate DNA methylation in a promoter-specific manner, in concordance to this 
suggestion is the classification of common and distinct promoter groups identified following 
RNAi-mediated suppression of DNMT1 and DNMT3B [Foltz, 2009],
UHRF1 plays a critical function in DNA methylation maintenance [Bostick, 2007], however, its 
involvement in TSG promoter hypermethylation in cancer is not yet clear. Here we 
investigated in NSCLCs the relationship of UHRF1 expression with the hypermethylation status
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of CDKN2A and RASSF1 promoters. UHRF1 overexpression correlated with increased DNA 
methylation of both CDKN2A and RASSF1 promoters. Moreover, a much stronger association 
was observed when analyzing UHRF1 expression against a combined CDKN2A/RASSF1 
methylation epigenotype. Thus, these data suggest that UHRF1 activity is important in 
maintaining the hypermethylation of certain TSGs. This is also supported by findings in breast 
tumours, where UHRF1 overexpression correlated to BRCA1 promoter hypermethylation [Jin, 
2009].
The importance of both DNMT1 and DNMT3B expression in the maintenance of aberrant CpG 
island methylation of TSGs has been adequately demonstrated in mammalian cell models 
[Robert, 2003], [Suzuki, 2004], [Rhee, 2002], [Wang, 2007]. However, this is not the case for 
UHRF1, which was only recently found to play a role in methylation maintenance [Bostick, 
2007]. There is only one study up to date connecting the overexpression of UHRF1 in a breast 
cancer cell line with hypermethylation of BRCA1 promoter in sporadic breast cancers [Jin, 
2009]. We therefore choose to provide additional evidence to our ex vivo observations 
regarding UHRF1 and TSG hypermethylation. In order to do that we knocked down the 
expression of UHRF1 in the A549 lung adenocarcinoma cell line. Both UHRF1 knockdown 
derived clones demonstrated reduced methylation of RASSF1, CYGB and CDH13 promoters, 
which are hypermethylated in A549 cells. Since CDKN2A promoter was completely 
unmethylated in this cell line we could not assess the effect of UHRF1 downregulation on the 
hypermethylation of this promoter. The UHRF1 knockdown clones presented with reduced 
proliferation rates and migration efficiency in comparison to those characteristics of the 
parental and mock cell lines. This is in acquiescence with UHRFTs reported association with 
proliferation [Fujimori, 1998] and tumour cell growth [Jenkins, 2005]. E2F1 levels did not
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change upon UHRF1 knockdown indicating a lack of a feedback loop. Both our ex vivo and in 
vitro data suggest that UHRFl-mediated cell cycle control is mainly facilitated by the 
epigenetic silencing of key cell cycle regulators, such as RASSF1 and CDKN2A or other tumour 
suppressor genes such as CDH13 or CYGB.
Interestingly, while the expression levels of DNMT1 and DNMT3A remained unchanged in the 
UHRF1 knockdown clones, there was a significant increase of DNMT3B expression in the 
absence of any methylation change of its promoter. The reasons behind the increase of 
DNMT3B expression upon UHRF1 knockdown are not currently clear, it is not known whether 
this is a directly UFiRFl-related effect or whether unprompted high-DNMT3B expression 
provides a selective advantage which eventually takes over the cell population in the culture 
environment. Nevertheless, the incomplete RASSF1, CYGB and CDH13 promoter 
hypomethylation observed in the UHRF1 knockdown clones suggests that DNMTs can 
maintain a degree of methylation in the presence of low abundance of UHRF1 protein.
It is worth noting that UHRF1 was recently found to bind strongly to DNMT3A and DNMT3B 
proteins [Meilinger, 2009]. This, in combination with the proven ability of DNMT1 to act as a 
de novo methyltransferase as well, could therefore imply a potential role of UHRF1 in de novo 
methylation apart from its role on methylation maintenance. In support of this, is a recent 
study which demonstrates that UHRF1 overexpression can lead to methylation of the BRCA1 
promoter in sporadic breast cancers [Jin, 2009].
This study provides compelling new evidence to suggest that the overexpression of UHRF1 in 
NSCLC is critical, alongside the overexpression of DNMTs, for the maintenance of 
hypermethylated TSG promoters. UHRF1 is thus emerging as key epigenetic switch for ceil 
cycle control and can be utilized as a new target for epigenetic therapies.
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8.3 Expression of DNMTs and UHRF1 in relation to hypomethylation
We have also examined the role of DNMTs and UHRF1 expression in the global 
hypomethylation observed in lung cancers. In order to do this we have examined the 
methyiation status of LINE-1 which can serve as a global DNA methylation surrogate 
[Weisenberger, 2005]. Interestingly, when examining the expression status of DNMTs and 
UHRF1 in relation to LINE-1 methylation we found an inverse correlation. This result appears 
to be a great paradox since one would expect that high expression of DNMTs and/or UHRF1 
would lead to higher global methylation or at least would be enough to maintain the 
methylation patterns of repeated sequences. Indeed, double knockdowns of DNMT1 and 
DNMT3B in a cancer cell line have been shown to reduce the genome methylation up to 95% 
affecting repeated sequences including Alu [Rhee, 2002] and LiNE-1 [Weisenberger, 2005]. 
Knockout of UHRF1 in mouse embryonic stem cells has lead to global hypomethylation in 
mouse IAP and LINE-1 elements [Bostick, 2007]. In the same direction we observed here that 
downregulation of UHRF1 in the A549 cell line has lead to global hypomethylation as 
measured by LINE-1.
Nevertheless, it must be noted that an association between two parameters does not indicate 
which of the two affects the other. Moreover, it is also possible that the two phenomena are 
associated because they are affected by a third unknown parameter. Based on previous 
reports and our observations that loss of DNMTs or UHRF1 leads to global hypomethylation 
we suggest that LINE-1 hypomethylation observed in our lung set cannot be the cause of 
DNMTs and /or UFIRF1 overexpression. The opposite effect is more likely. Global 
hypomethylation is thought to be an early event in human carcinogenesis [Fraga, 2004], 
[Suter, 2004]. It is possible that early induced global hypomethylation is sensed by the cell 
which in response induces the overexpression of DNMTs and/or UHRF1 proteins in order to
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balance this effect. However this is only one possible explanation lacking any functional data
and needs to be further investigated.
Previous studies investigating the expression of DNTMT1 in relation to proliferation measuring 
the levels of PCNA reported that although DNMT1 is overexpressed in cancers, when 
compared to a housekeeping gene, it is underexpressed when normalised to a proliferation 
marker such as PCNA. They suggest that, although DNMT1 is overexpressed, the proliferation 
rates of cancer cells are quite high and the enzyme is not able to maintain the methylation 
patterns during replications and thus global hypomethylation occurs passively through 
subsequent cell cycles. However they failed to prove a relationship between LINE-1 
hypomethylation and DNMT1/PCNA expression [Kimura, 2003], This concept could explain the 
observed inverse correlation in our sample set between LINE-1 hypomethylation and E2F1 
expression. Since E2F1 is a measure of cell proliferation it is possible that tissues with higher 
proliferation fail to maintain methylation patterns demonstrating greater hypomethylation of 
the genome. This suggestion also explains the relationships between LINE-1 hypomethylation 
and DNMT1, DNMT3B and UHRF1 expression since they are E2F1 targets and demonstrate 
similar expression patterns. This suggestion needs to be further investigated exploring the 
expression status of DNMTs and UHRF1 normalised to proliferation markers in comparison to 
global hypomethylation. Nevertheless, if this suggestion is true the paradox remains since the 
inability of DNMT1 or UHRF1 to maintain DNA methylation is in contrast to the observed 
hypermethylated genes and the role of these proteins in their maintenance.
It is also worth noting that we have observed an inverse relationship between global 
hypomethylation and regional hypermethylation of RASSF1 promoter. The same relationship 
was not significant for CDKN2A hypermethylation as well, however, when combining the two
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promoters the relationship was apparent. This implies that the two phenomena, global 
hypomethylation and regional hypermethylation are inverse correlated in lung cancers. A 
similar association between LINE-1 hypomethylation and CpG island methylator phenotype 
was observed in colorectal cancers [Ogino, 2008], [Nosho, 2008].
Cancer-associated global hypomethylation is a very important event which has been linked 
with tumour formation [Gaudet, 2003], [Eden, 2003]. Many studies have demonstrated 
several causes of passive hypomethylation in cell models most of them including the 
knockdown of DNMTs or UHRF1. In addition a number of studies have searched for a 
demethylase enzyme that could actively promote hypomethylation [Ooi, 2008]. However, an 
enzyme with a demethylase activity is not yet proven to exist while DNMTs irregular activity is 
not yet associated with global hypomethylation in primary tumours. Although in this study we 
demonstrate that UHRF1 downregulation leads to global demethylation of a lung cancer cell 
line, we fail to provide any evidence regarding the expression status of UHRF1 and/or DNMTs 
that would explain the observed hypomethylation in primary lung tumours.
8.4 Hypomethylation of retrotransposable elements and genomic instability in NSCLC
The second aim of this study was to examine the link between global hypomethylation and 
tumour formation in NSCLC [Gaudet, 2003], [Eden, 2003]. As we already described in the 
introduction global hypomethylation in cancer cells mainly affect repeated sequences. The 
vast majority of these sequences are comprised of retrotransposable elements. The LINE-1 
and Alu elements are non-LTR containing retrotransposons which comprise a long stretch of 
the human repeat DNA sequences [Cordaux, 2009]. Although only a small number of these 
elements are considered to be retrotranspositionaliy active in the human genome, 
spontaneous retrotransposition events are associated with insertional mutagenesis and can
146
lead to genetic disorders [Babushok, 2007], [Kazazian, 2004], [Sassaman,1997], [Cordaux, 
2009], [Lin, 1988]. LINE-1 and Alu elements are methylated in normal somatic cells and are 
frequently demethylated in cancer following global genome hypomethylation [Ehrlich, 2002]. 
Indeed, because of their abundance in the genome they have been shown to be a good 
measure of such global hypomethylation in cancer [Weisenberger, 2005]. However, the 
possible involvement of hypomethylation-mediated activation of LINE-1 and Alu in the 
genome stability and cancer development has not been widely studied, although there is 
recent evidence to fuel such investigations [Schulz, 2006], [Gilbert, 2002], [Kazazian, 2002], 
[Belgnaoui, 2006], [Roman-Gomez, 2005], As demethylating agents are increasingly used in 
cancer treatment, it is imperative to understand how cancer-related and/or drug-induced 
hypomethylation may initiate retrotransposition and subsequent genomic alterations, thus 
drawing valuable conclusions for implications in cancer therapy.
Here, we quantitatively determined in NSCLC the methylation status of LINE and Alu elements 
utilizing the sequences of LINE-1.2 and Alu-PV species respectively. These particular LINE and 
SINE species were selected based on their activity in the human genome [Sassaman, 1999], 
[Mighell, 1997], [Wallace, 1991]. Of course, due to the high degeneracy of these sequences 
the final amplified products most probably contain copies of different families [Schulz, 2006]. 
We demonstrated a significant reduction of the methylation levels of both LINE-1.2 and Alu- 
PV elements in primary NSCLC. These findings suggest a potentially important role for LINEs 
and SINEs in lung cancer development, adding to the limited information for retro-element 
methylation in this cancer type [Chalitchagorn, 2004], [Rauch, 2007], [Rauch, 2008].
There are profound differences on the detected methylation levels of LINE-1.2 and Alu-PV in 
normal and tumour specimens. More precisely, the observed average change in LINE is 13.2%
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while in Alu is only 3.1%. The small decrease of Alu-PV element methylation was expected 
since we have used as a template the Alu-PV element which comprises an evolutionary young 
Alu family. It has been demonstrated that hypomethylation of Alu elements is greater in older 
retrotranspositionally inactive families, while at younger transpositionally active families, as 
in the Alu-PV family, hypomethylation occurs in a much lesser extent [Rodriguez, 2007]. This 
data suggest that younger Alu families in which the most active elements exist and are closer 
to genes are under a stronger silencing pressure [Rodriguez, 2007].
From the clinicopathological point of view, it is notable that the observed hypomethylation 
was widespread among tumours of variable stage, nodal metastasis and differentiation status, 
most probably suggesting an early onset of this molecular abnormality in the course of lung 
cancer development [Morey Kinney, 2008]. When examining LINE-1 hypomethylation further 
in a second set of NSCLC tissues we verified the observed trend of greater LINE-1 
hypomethylation in squamous cell carcinomas compared to adenocarcinomas.
Our study confirms that NSCLC follows a similar global hypomethylation pattern as other 
human tumours [Ehrlich, 2002], [Weisenberger, 2005]. Of particular note here is the finding 
that the methylation status of LINE-1.2 is highly correlated to that of Alu-PV (p=0.004). This 
suggests a common mechanism of methylation maintenance of these elements in cancer and 
receives further supporting evidence from data in prostate cancer [Cho, 2007] and the 
reported correlation of both elements methylation with global genome methylation as 
measured by HPLC [Weisenberger, 2005].
In order to assess the potential implication of LINE-1 and Alu elements demethylation in 
genome stability maintenance in NSCLCs, we have examined LOH at loci which are hotspots 
for lung cancer [Liloglou, 2001] and used fractional allele loss (FAL) as a measure of the overall
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genomic instability. We demonstrated that hypomethylation of both transposable elements 
correlates with high FAL values indicating a strong link between genome stability and 
transposable element methylation. A similar observation has been reported in colorectal 
carcinomas where LINE-1 hypomethylation correlated with microsatellite instability [Estecio, 
2007], [Ogino, 2008], although the mechanisms responsible for chromosomal instability 
(expressed by FAL) and microsatellite instability (MSI) are different. Genomic 
hypomethylation has been shown to induce chromosomal instability and tumourigenesis in 
mice models [Gaudet, 2003], [Eden, 2003]. Genomic hypomethylation may promote genomic 
instability and tumourigenesis by unmasking transposable elements and therefore allowing 
retrotransposition events to take place. It is well established that LINE-1 retrotransposition in 
model systems induces genomic instability and deletions promoting carcinogenesis [Gilbert, 
2002], [Symer, 2002], [Kazazian, 2002],
8.5 Re-Expression of LINE-1 and Alu elements due to demethylation in lung cancer
A triangular relationship between global hypomethylation - transposable elements -genomic 
instability has been suggested for many types of human tumours [Schulz, 2006], [Kazazian, 
2002] and the correlation between genomic instability and hypomethylation in our study is in 
agreement to this. This hypothesis suggests that hypomethylation of retrotransposable 
elements leads to their re-expression and subsequent retrotransposition in cancer. The 
information on LINE-1 expression in human tumours is very limited but suggests a degree of 
transcriptional activation in leukaemias [Roman-Gomez, 2005], breast [Bratthauer, 1994], 
urothelial and renal carcinomas [Florl, 1999].
However, identification of LINE-1 or Alu-PV elements expression levels at the RNA levels poses 
significant limitations. These elements are intronless and thus primers designed to amplify the
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LINE-1 or Alu RNAs will inevitably amplify gDNA copies of these elements as well. Bearing in 
mind the great number of copies of these elements in the human genome one understands 
that even minimum amounts of gDNA contamination of RNA samples will lead to false results. 
In order to circumvent this problem one needs to treat RNA samples with DNAse extensively. 
However this leads to the loss of the greater percentage of the starting RNA material and can 
also lead to RNA degradation due to long incubation times. The problem becomes greater 
when comparing RNA samples from tumour and adjacent normal tissues. Tumour cells are 
characterised by genomic instability (chromosome amplifications, loss of chromosome arms) 
compared to their normal adjacent tissues which have a normal human genome, therefore 
providing different starting backgrounds.
To overcome these problems we chose to study the potential epigenetic re-expression of 
LINE-1 and Alu elements by utilizing decitabine and TSA (common inhibitors of methyiation 
and histone deacetylation, respectively) on two lung cancer cell lines and a non-tumourigenic 
bronchial epithelial cell line to verify hypomethylation-mediated activation of transcription. 
The study of expression of these elements in a cell line can be more accurate providing more 
trustful results than when working with RNA from primary tumours. Firstly, cell lines can 
provide endless amount of RNA and therefore we were able to treat our RNAs with DNase at 
three different steps without compromising RNA integrity or quantity. We performed on 
column DNase digestion during RNA extraction, we treated our RNAs with turbo DNAse and 
finally we have included a gDNA elimination step during cDNA preparation. Secondly, 
comparing the effect of hypomethylating and de-acetylating agents in a cell line provide us 
with the ability to compare the differences of LINE-1 and Alu expression on an almost identical 
genomic background. Finally, we have undertaken PCR reactions amplifying p21 promoter in
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order to check for any possible gDNA contamination on our final cDNA samples. Only 'clean7 
cDNAs were used for our experiments.
We have identified the optimal dose of decitabine in order to achieve maximum 
hypomethylation of LINE-1 and Alu-PV elements and found that decitabine shows greater 
activity in low concentrations. This is in agreement with another study demonstrating similar 
results [Qin, 2008]. in higher doses decitabine gradually lost any effect which probably is 
caused by the induction of cell cycle arrest [Qin, 2008]. In all three cell lines, the use of 
decitabine, which led to experimentally confirmed hypomethylation of LINE-1.2 and Alu-PV 
elements, resulted in increased transcription of both elements. Notably, simultaneous use of 
TSA further increased transcription level. It has to be noted at this point that the observed 
increased expression of LINE-1.2 and Alu-PV could be partly due to incomplete elements 
encompassed in genes that are overexpressed in the presence of decitabine.
While we are clearly demonstrating that expression of LINE-1.2 and Alu-PV elements is under 
epigenetic control in a lung cancer environment, it has to be noted that retrotransposition 
could be impaired by methylation-independent mechanisms. siRNAs produced by the LINE-1 
5'antisense promoter have been shown to inhibit its retrotransposition [Yang, 2006], [Soifer, 
2006]. In addition, LINE and Aiu retrotransposition is controlled by APOBEC3 proteins 
[Muckenfuss, 2006], [Esnault, 2005] and sequestration into stress granules [Goodier, 2007]. 
Last, it must be also noted that hypomethylation of LINE and Alu is not necessarily uniform 
[Schulz, 2006], [Rodriguez, 2008] thus it is not totally clear to which extent our data can be 
extrapolated.
We have found an association between hypomethylation of retrotransposable elements and 
genomic instability in primary NSCLCs. In addition, we ascertained that demethylation of these
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elements can lead to their re-expression in lung cancer cell lines. Together these data imply a
possible re-activation of LINE-1 and Alu elements in NSLCs which could lead after successful or 
unsuccessful retrotransposition cycles to genomic instability therefore promoting tumour 
progression. In support of this notion is a recent study demonstrating the activation and 
retrotransposition of endogenous retroviral elements in hypomethylation induced tumours in 
mice [Howard, 2008]. An alternative suggestion is that chromatin relaxation at such 
retroelement sites may promote illegitimate recombination leading to genomic instability 
[Schulz, 2006], [Kolomietz, 2002], [Jurka, 2004]. In fact it is possible that both phenomena 
could take place during lung cancer progression.
Taking into account that global hypomethylation is an early event in tumour formation it is 
apparent that the retrotransposable element may have a great role towards lung 
carcinogenesis and progression [Fraga, 2004], [Suter, 2004]. This suggestion is reflected by the 
findings of a study in a large number of colorectal cancer cases (n=643) where UNE-1 
hypomethylation correlated with shorter survival of cancer patients [Ogino, 2008]. We were 
not able to establish a similar association between UNE-1 hypomethylation and survival in our 
data set, however, this was probably due to the small number of cases (n=52) for which we 
had survival information.
Although we provide evidence towards a more active role of UNE-1 and Alu elements in lung 
tumourigenesis there are certain limitations due to technical difficulties arising from the 
massive sequence homology among LINE and SINE species members. We have utilised the 
LINE-1.2 and Alu-PV elements to design our primers for methylation detection which are 
retrotranspositionally active elements. However, it is most likely that we have amplified the 
promoter region of thousands of family members in the genome. These could be other highly
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homologous LINE-l/Alu sequences or even L1.2/Alu-PV truncated smaller sequences 
incapable of retrotransposition. The same problem exists regarding the expression data. It is 
particularly difficult to ascertain that the observed overexpression of LINE-1.2 and Alu-PV 
reflects exclusively retrotranspositionally active elements. In other words, as the detection of 
endogenous retro-elements re-insertion events is practically not feasible with current 
technology, the detected activation of transcription does not guarantee increased re­
insertion.
8.6 Activity of a full LINE-1 element in lung cancer environment 
In order to bypass these limitations and investigate further the hypomethylation induced 
reactivation of LINE-1 in the lung cancer environment we have created a cell culture model 
utilising the KS-101 construct which was a generous gift from Dr John V. Moran. The KS-101 
construct carries a full LINE-1 element tagged with a retrotransposition cassette. The full LINE- 
1 element in this construct (LRE3) is located to chromosome 2q24.1 on the human genome 
and is one of the most actively retrotransposing LINE-1 elements [Brouha, 2002]. Similar 
constructs carrying different LINE-1 retrotransposition competent elements have been used in 
cell lines demonstrating variable retrotransposition efficiencies [Moran, 1996], [Morrish, 
2002], [Wei, 2000], [Garcia-Perez, 2007]. In most of these studies the LINE-1 element in these 
constructs was under the regulation of a CMV promoter and therefore under extreme 
modelling conditions that do not resemble human cells where LINE-1 elements are regulated 
by their own 5' end promoter. The KS-101 construct we used has the advantage that its LINE-1 
element is only regulated by its own promoter [Garcia-Perez, 2007]. Using this construct we 
have proved that LINE-1 element is active in a CRL5802 lung cancer cell line with a low LINE-1 
methylation status, while it remained inactive in other 5 cell lines with high LINE-1
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methylation. These data suggest that LINE-1 element may preferentially retrotranspose in cell 
lines with low global methylation status. However, the use of decitabine in all cell lines which 
leads to global demethylation has not led to an increase in the number of retrotransposition 
events in the CRL5802 or in any retrotransposition events in the other cell lines.
It must be noted that the methylation status of the specific LRE3 promoter could not be 
examined before retrotransposition using the KS-101 plasmid. In order to investigate further 
the effect of decitabine-induced hypomethylation we have constructed the KS101B plasmid, 
incorporating a blasticidin resistance gene, which enables stable transfection. Using this 
construct in the CRL5802 cell line we have seen that all the obtained colonies had a very low 
methylated LRE3 promoter. Treating these colonies with decitabine did not lead to an 
increase in the number of retrotransposition events. Since the LINE-1 promoter was by itself 
unmethylated any change would be due to global hypomethylation changes. This data confirm 
the hypothesis that the retrotransposition machinery of LINE-1 element has a strong cis 
preference for its own RNA transcript [Wei, 2001]. Since the LINE-1 promoter in the obtained 
colonies remained unmethylated we could not test the effect of decitabine on this specific 
promoter in the case that it would have become methylated. In order to bypass this problem, 
in vitro methylation of the KS101B plasmid before transfection should be included in future 
experiments. Although there are some reports demonstrating successful in vitro methylation 
of plasmids and subsequent transfection in mammalian cells [Qu, 1999], it remains to be 
discovered whether the cells will maintain the methylation status of the inserted vector long 
enough for the needs of the study.
Epigenetic mechanisms appear to have a key role in cancer development and thus are 
considered as critical targets in anticancer therapies. DNMT inhibitors are increasingly used in
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clinical trials [Lyko, 2005], [Issa, 2007]. Recent studies provide very promising results
[Appleton, 2007], [Oki, 2008] as epigenetic modulation of drug resistance may be critical for 
improving cancer drug efficiency overall [Glasspool, 2006]. It is, however, important to 
understand in detail the epigenetic reprogramming of cancer cells. In this direction, further to 
identifying the most commonly hypermethylated genes, it is crucial to understand the impact 
of transposable element hypomethylation in cancer biology. In addition, we need to 
understand how and to what extent DNA hypomethylation may be a critical adverse effect of 
epigenetic therapies [Ehrlich, 2006].
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8.7 Conclusions
Our findings in this study demonstrate for the first time in primary human lung tumours the 
relationship between retro-element hypomethylation and genomic instability. In addition, we 
provide evidence that hypomethylation of LINE-1 and Alu elements in human lung cancer cell 
lines leads to enhanced transcription, which in combination with previous reports on 
retrotransposition-induced genomic instability and the observed ability of a full LINE-1 
element to retrotranspose under the regulation of its own promoter in a lung cancer cell line, 
points towards a more active role of the reactivation of such retroelements in the 
pathogenesis of human tumours. Furthermore we demonstrate that UHRF1 is a key epigenetic 
switch that is overexpressed in NSCLC and can promote cancer development mediating the 
silencing of tumour-suppressor genes. Therefore UHRF1 might serve as a biomarker in 
diagnostics or therapeutic stratification of patients with lung cancer.
As mentioned above although current epigenetic therapies present some interesting data, the 
promotion of hypomethylation and potential re-activation of retrotransposable elements is 
one of their main adverse effects. Therefore new epigenetic targets, apart from DNMTs 
blocking, that will enable the re-expression of TSGs without affecting the methylation status 
of retrotransposable elements are needed. It is of great importance that in the present study 
we have identified an epigenetic regulator which acts towards this direction. UHRF1 
downregulation has led to a profound hypomethylation on the promoter region of TSGs while 
at the same time it has led only to a modest hypomethylation of LINE-1 and Alu elements. 
These data suggest that UHRF1 protein is emerging as a new more promising target towards 
epigenetic therapies since it shows more specificity for TSGs than transposable elements.
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8.8 Future directions
UHRF1 appears to be a key factor of epigenetic deregulation in lung cancers acting mainly 
through the silencing of TSGs. Although the present study provided important data regarding 
the role of UHRF1 in lung tumourigenesis there are a number of issues which could be further 
investigated.
UHRF1 protein expression should be studied in a large cohort in order to verify the data we 
provide regarding the expression of UHRF1 at the RNA level.
In addition the observed important effect of UHRF1 downregulation on the methylation status 
of TSGs should be further investigated. Towards this direction rescue experiments should be 
undertaken in the UHRF1 knockdown clones. The re-expression of UHRF1 would further 
establish the relationship between this protein and TSG hypermethylation. Furthermore this 
rescue experiment would demonstrate whether the indication that UHRF1 underexpression 
leads to DNMT3B overexpression is true or not.
We have already pointed out that UHRF1 downregulation has lead to various degrees of 
hypomethylation in certain TSGs while the retrotransposable elements were affected in a 
lesser extend. As this implies that there is a preference of UHRF1 protein for different DNA 
regions, methylation array experiments could be undertaken in order to identify potential 
groups of gene promoters that are affected in a greater extend. In addition nuclear extracts 
could be used in order to prove in vitro whether UHRF1 enzymatic activity preferentially 
methylates TSG promoters in comparison to repetitive sequences.
We also provide evidence towards a potential reactivation of retrotransposable elements due 
to hypomethylation in lung cancer. Whole genome sequencing in a cohort of lung cancer
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tissues would reveal the potential re-activation and retrotransposition of these elements as
well as their relationship to genomic instability and tumour progression.
Future work in this blooming field of cancer epigenetics will assist to fully elucidate the 
molecular mechanisms involved and provide the basis for the better clinical utilization of 
demethylating agents for the treatment of human cancer.
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Appendices
Appendix 1. Expression of DNMTs, UHRF1 and E2F1 in 50 paired NSCLC tissues.
Sample DNMT1 DNMT3A DNMT3B UHRF1 E2F1
T N T N I N T N I N
1 7.55 4.77 20.36 13.41 16.87 14.86 0.55 0.33 3.00 1.87
2 12.96 4.17 31.56 13.07 44.70 6.88 3.90 0.16 21.61 4.57
3 11.87 5.25 16.20 15.97 36.45 11.70 3.01 0.13 12.83 2.90
4 15.36 3.88 41.98 12.67 114.16 6.35 3.89 0.33 40.38 2.98
5 3.20 2.52 15.89 12.86 6.88 8.20 2.68 0.19 7.12 2.52
6 11.86 4.80 69.70 15.33 120.41 15.70 2.60 0.14 33.28 8.94
7 6.14 8.02 7.82 60.80 110.89 60.55 1.94 1.11 8.72 13.64
8 1.75 3.20 6.96 7.78 15.80 6.64 0.56 0.15 2.10 3.18
9 9.24 4.72 30.04 19.85 77.26 11.19 5.56 0.31 18.01 4.31
10 10.21 4.56 35.39 12.87 29.91 13.44 6.67 0.15 19.85 4.28
11 13.42 5.73 26.40 56.04 40.07 40.34 5.42 0.26 45.96 18.44
12 7.10 4.12 19.79 20.79 59.42 15.91 2.45 0,30 17.10 5.61
13 20.94 11.31 61.19 33.94 99.26 26.83 6.53 0.86 31.75 7.72
14 5.29 3.39 16.55 15.53 36.97 9.50 0.79 0.12 6.31 3.78
15 10.16 3.74 59.18 46.68 119.17 50.49 2.85 0.20 37.02 14.83
16 7.78 4.67 252.93 17.68 506.79 17.08 4.06 0.32 123.37 5.08
17 13.54 3.69 24.00 18.93 38.16 14.43 2.47 0.39 16.27 6.12
18 17.24 4.60 25.38 17.44 14.58 10.28 2.99 0.42 47.00 4.32
19 10.17 6,83 53.39 52.69 75.77 38.99 3.50 0.78 14.67 12.16
20 15.19 8.68 39.45 52.20 74.76 69.66 10.01 0.56 38.70 24.24
21 10.07 5.87 75.43 69.36 45.12 94.61 5.94 0.45 16.37 20.23
22 8.95 3.85 22.21 25.46 34.46 12.06 1,84 0.17 14.28 4.99
23 3.23 5.25 9.70 20.10 22.07 10.26 1.70 0.53 6.89 5.19
24 5.77 13.10 40.63 66.44 32.16 122.80 2.00 1.58 7.89 24.58
25 10.43 3.79 31.37 17.55 26.04 9.00 1.95 0,19 6.59 3.83
26 5.96 3.66 16.73 21.77 17.63 19.71 0.61 0.26 6.37 3.54
27 17.72 3.09 25.87 8.30 57.33 5.22 7.73 0.15 23.73 2.71
28 14.07 15.89 36.33 132.62 63.00 202.41 5.54 1.27 13.76 43.47
29 5.33 7.51 44.21 30.05 70.23 42.68 2.41 0.45 16.23 5.67
30 16.03 3.39 58.86 15.71 115.61 9.74 3.27 0.16 22.61 4.56
31 5.13 1.94 20.71 8.79 10.08 7.97 2.35 0.13 14.54 3.17
32 4.80 9.27 136.37 92.58 543.70 111.79 8.27 ND 92.95 15.71
33 21.83 8.12 63.73 51.69 108.97 40.44 4.34 0.33 37.54 15.11
34 3.65 4.03 18.11 15.53 42.89 13.27 3.89 0.04 12.29 3.87
35 14.41 7.63 222.35 32.00 410.91 14.05 7.22 0.43 120.83 7.42
36 2.93 5.19 20.51 22.58 135.05 10.39 0.99 0,08 15,10 3.74
37 4.06 10.29 28.30 ND 37.16 ND 0.97 ND 6.55 ND
38 16.44 6.15 40.26 10.49 ND 19.51 9.08 3.38 9.09 19.41
39 4.64 7.38 14.55 41.08 19.18 31.07 1.44 0.59 5.75 13.17
40 8.17 7.95 32.31 30.03 67.59 18.54 6.56 0.30 27.57 5.08
41 3.87 4.05 21.17 14.85 18.04 8.36 3.76 0.05 11.92 3.95
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42 7.06 5.09 17.96 12.76 11.12 4.10 1.15 0.11 3.69 2.33
43 3.60 3.03 20.66 10.84 30.11 8.12 3.82 0.15 8.59 3.83
44 13.86 5.24 60.41 20.84 221.17 15.10 2.92 0.27 29.27 2.97
45 10.49 8.64 16.33 15.23 25.09 8.95 5.63 0.21 16.27 3.23
46 2.15 3.68 21.00 23.35 61.48 14.22 1.99 0.27 7.98 4.82
on 28.96 11.72 178.98 169.42 226.66 135.82 13.30 1.58 68.58 57.98
48 4.92 4.53 16.99 29.88 26.74 32.93 4.85 2.10 20.41 9.12
49 8.85 4.49 93.43 34.54 56.93 22.44 4.18 0.74 20.51 4.40
50 13.25 4.84 116.58 53.21 136.46 49.44 5.35 0.30 36.97 14.04
Values represent the mean RQ values. The expression of IMR-90 cells was used as a calibrator.
Appendix 2. Expression of DNMTs, UHRF1 and E2F1 in 54 NSCLC tumours and survival information
Sample DNMT1 DNMT3A UHRF1 E2F-1 DNMT3B Fate1 FU2
1 11.44 40.81 12.44 72.99 268.72 0 87.8
2 9.33 52.72 1.44 17.35 73.72 0 46.6
3 4.86 9.86 5.68 5.62 11.03 1 93.5
4 11.87 16.20 3.01 12.83 36.45 0 36.1
5 10.21 35.39 6.67 19.85 29.91 0 30.8
6 15.19 39.45 10.01 38.70 74.76 0 15.3
7 8.95 22.21 1.84 14.28 34.46 0 37.4
8 3.23 9.70 1.70 6.89 22.07 0 6.5
9 5.13 20.71 2.35 14.54 10.08 1 79.6
10 7.06 17.96 1.15 3.69 11.12 1 78.2
11 2.15 21.00 1.99 7.98 61.48 0 14.2
12 4.92 16.99 4.85 20.41 26.74 0 5.8
13 40.53 87.09 20.64 57.55 211.37 0 35.2
14 2.90 3.60 1.20 17.38 167.14 0 14.2
15 2.80 8.21 0.25 1.36 6.41 1 37.5
16 2.32 6.51 0.78 6.01 3.87 0 18.3
17 7.54 24.02 2.40 5.29 29.64 0 10.9
18 23.47 4.85 4.83 10.49 16.58 1 26.6
19 5.26 7.32 1.15 3.38 7.34 1 25.4
20 5.49 6.90 2.02 8.96 14.36 1 25.3
21 7.11 9.16 2.54 6.98 56.48 1 18.3
22 4.27 10.29 1.11 3.64 9.02 1 17.5
23 7.24 73.34 4.69 44.94 46.25 1 22.5
24 2.22 7.70 0.74 4.36 12.50 1 16.5
25 3.99 23.20 2.86 17.58 28.68 1 21.7
26 5.77 22.50 3.04 32.23 77.75 0 12.9
27 7.53 24.84 6.13 29.45 26.57 1 15.1
28 2.47 10.84 3.01 7.12 37.27 0 6.5
29 5.49 33.69 1.10 25.01 78.23 0 2.1
30 3.43 19.90 0.65 7.85 40.82 0 24.9
31 2.89 10.11 0.71 7.40 14.09 1 14.4
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32 5.51 24.41 3.30 33.99 54.94 1 11.7
33 2,07 7.86 0.81 3.36 8.71 1 11.7
34 1.36 6.36 2.10 4.80 2.88 1 10.5
35 4.42 16.59 2.08 14.66 44.61 1 26.2
36 2.06 9.44 1.93 5.52 33.09 1 12.0
37 5.23 29.00 3.44 31.81 171.15 1 7.5
38 1.77 7.51 1.83 7.40 15.22 1 7.4
39 1.82 7.49 2.14 7.73 9.61 1 6.3
40 1.74 7.25 0.92 4.14 6.52 1 6.5
41 2.20 19.17 3.80 19.21 49.45 1 5.9
42 1.27 5.98 0.78 2.37 8.84 0 19.9
43 1,55 7.55 0.23 2.14 8.23 1 5.3
44 3.15 15.25 0.48 10.56 26.84 1 5.2
45 2.65 6.45 1.09 7.74 63.58 1 3.1
46 2.80 8.53 3.04 10.73 15.98 1 2.5
47 1.97 10.48 0.73 4.39 7.21 1 3.5
48 2.04 8.13 0.68 5.53 8.46 1 3.5
49 3.42 19.21 3.36 23.92 22.92 1 2.3
50 2.73 13.51 0.21 8.21 23.73 1 2.7
51 2.52 7.46 1.70 6.94 38.33 1 2.6
52 4.14 12.40 1.12 10.58 24.35 0 1.7
53 2.17 16.26 2.98 11.50 30.32 0 8.9
54 2.42 13.64 1.90 9.80 20,67 1 4.8
Values represent the mean RQ values. The expression of iMR-90 cells was used as a calibrator 
^Fate 1: diseased, 0: alive
2FU: Time in months post surgery with available follow up information
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Appendix 3. Expression of UHRF1, DNMTs, and DNA methylation of CDKN2A and RASSF1 promoters in NSCLC.
mRNA expression (mean RQ value}1 DNA methylation status2
Sample Gender Histology UHRF1 DNMT1 DNMT3A DNMT3B E2F1 CDKN2A RASSF1
1 M SqCCL 12.44 11.44 40.81 268.72 72.99 0 1
2 M SqCCL 1.44 9.33 52.72 73.72 17.35 0 0
3 M SqCCL 5.68 4.86 9.86 11.03 5.62 1 0
4 M SqCCL 0.55 7.55 20.36 16.87 3.00 0 0
5 M SqCCL 3.90 12.96 31.56 44.70 21.61 0 1
6 M SqCCL 3.01 11.87 16.20 36.45 12.83 ND 1
7 M AdenoCa 3.89 15.36 41.98 114.16 40.38 1 0
8 F AdenoCa 2.68 3.20 15.89 6.88 7.12 0 0
g F AdenoCa 2.60 11.86 69.70 120.41 33.28 1 1
10 M AdenoCa 1.94 6.14 7.82 110.89 8.72 1 1
ii M SqCCL 0.56 1.75 6.96 15.80 2.10 0 0
12 M AdenoCa 5.56 9.24 30.04 77.26 18.01 1 1
13 M SqCCL 6.67 10.21 35.39 29.91 19.85 0 0
14 M SqCCL 5.42 13.42 26.40 40.07 45.96 0 1
15 F AdenoCa 2.45 7.10 19.79 59.42 17.10 0 0
16 F SqCCL 6.53 20.94 61.19 99.26 31.75 1 0
17 F AdenoCa 0.79 5.29 16.55 36.97 6.31 0 0
18 F AdenoCa 2.85 10.16 59.18 119.17 37.02 0 0
19 M SqCCL 4.06 7.78 252,93 506.79 123.37 1 0
20 M SqCCL 2.47 13.54 24.00 38.16 16.27 1 1
21 M SqCCL 2.99 17.24 25.38 14.58 47.00 0 0
22 M AdenoCa 3.50 10.17 53.39 75.77 14.67 0 0
23 M SqCCL 10.01 15.19 39.45 74.76 38.70 0 0
24 F AdenoCa 5.94 10.07 75.43 45.12 16.37 1 1
25 M AdenoCa 1.84 8.95 22.21 34.46 14.28 0 0
26 M SqCCL 1.70 3.23 9.70 22.07 6.89 0 0
27 F AdenoCa 2.00 5.77 40.63 32.16 7.89 0 0
28 M SqCCL 1.95 10.43 31.37 26.04 6.59 1 0
29 F AdenoCa 0.61 5.96 16.73 17.63 6.37 0 1
30 M SqCCL 7.73 17.72 25.87 57.33 23.73 0 0
31 F SqCCL 5.54 14.07 36.33 63.00 13.76 0 1
32 F AdenoCa 2.41 5.33 44.21 70.23 16.23 0 1
33 M AdenoCa 3.27 16.03 58.86 115.61 22.61 1 1
34 M SqCCL 2.35 5.13 20.71 10.08 14.54 0 1
35 F AdenoCa 8.27 4.80 136.37 543.70 92.95 0 1
36 F SqCCL 4.34 21.83 63.73 108.97 37.54 0 0
37 M SqCCL 3.89 3.65 18.11 42,89 12.29 0 1
38 M AdenoCa 7.22 14.41 222.35 410.91 120.83 ND 0
39 F AdenoCa 0.99 2.93 20.51 135.05 15.10 0 1
40 F AdenoCa 0.97 4.06 28.30 37.16 6.55 0 0
41 F AdenoCa 9.08 16.44 40.26 9.09 1 1
42 M AdenoCa 1.44 4.64 14.55 19.18 5.75 0 0
43 M SqCCL 6.56 8.17 32.31 67,59 27.57 1 0
44 M SqCCL 3.76 3.87 21.17 18.04 11.92 0 0
45 M AdenoCa 1.15 7.06 17.96 11.12 3,69 0 0
46 F AdenoCa 3.82 3.60 20.66 30.11 8.59 1 0
47 F AdenoCa 2.92 13.86 60.41 221.17 29.27 0 0
48 M SqCCL 5.63 10.49 16.33 25.09 16.27 1 1
49 F SqCCL 1.99 2.15 21.00 61.48 7.98 0 0
50 M SqCCL 13.30 28.96 178.98 226.66 68.58 0 0
51 F AdenoCa 4.85 4.92 16.99 26.74 20.41 0 0
52 M SqCCL 4.18 8.85 93.43 56.93 20.51 ND 0
162
53 F SqCCL 5.35 13.25 116.58 136.46 36.97 ND 0
54 F AdenoCa 20.64 40.53 87.09 211.37 57.55 0 1
55 M AdenoCa 1.20 2.90 3.60 167.14 17.38 1 1
56 F SqCCL 0.25 2.80 8.21 6.41 1.36 0 0
57 F AdenoCa 0.78 2.32 6.51 3.87 6.01 0 0
58 M AdenoCa 2.40 7.54 24.02 29.64 5.29 1 0
59 M AdenoCa 4.83 23.47 4.85 16.58 10.49 1 0
60 M SqCCL 1.15 5.26 7.32 7.34 3.38 0 0
61 F SqCCL 2.02 5.49 6,90 14.36 8.96 1 1
62 F SqCCL 2.54 7.11 9.16 56.48 6.98 0 0
63 F AdenoCa 1.11 4.27 10.29 9.02 3.64 0 0
64 M AdenoCa 4.69 7.24 73.34 46.25 44.94 0 1
65 M AdenoCa 1.08 4.29 20.28 48.36 7.34 0 0
66 M AdenoCa 0.74 2.22 7.70 12.50 4.36 1 0
67 F AdenoCa 2.86 3.99 23.20 28.68 17.58 0 0
68 F AdenoCa 3.04 5.77 22.50 77.75 32.23 0 1
69 F SqCCL 6.13 7.53 24.84 26.57 29.45 0 1
70 M AdenoCa 3.01 2.47 10.84 37.27 7.12 0 0
71 M AdenoCa 1.10 5.49 33.69 78.23 25.01 0 0
72 M AdenoCa 0.65 3.43 19.90 40.82 7.85 0 0
73 F SqCCL 2.84 6.78 35.17 57.50 20.49 1 0
74 F SqCCL 0.71 2.89 10.11 14.09 7.40 0 0
75 M SqCCL 3.30 5.51 24.41 54.94 33.99 0 0
76 F AdenoCa 0.81 2.07 7.86 8.71 3.36 0 0
77 M AdenoCa 2.10 1.36 6.36 2.88 4.80 0 1
78 M SqCCL 2.08 4.42 16.59 44.61 14.66 0 0
79 M AdenoCa 1.93 2.06 9.44 349.04 5.52 0 1
80 F AdenoCa 0.24 2.31 23.70 14.27 6.07 0 1
81 F SqCCL 0.30 3.57 18.17 33.09 5.22 0 0
82 F SqCCL 3.44 5.23 29.00 171.15 31.81 0 1
83 M AdenoCa 1.83 1.77 7.51 15.22 7.40 0 0
84 F SqCCL 2.14 1.82 7.49 9.61 7.73 1 0
85 F SqCCL 0.92 1.74 7.25 6.52 4.14 0 0
86 M SqCCL 3.80 2.20 19.17 49,45 19.21 1 1
87 M AdenoCa 0.78 1.27 5.98 8.84 2.37 0 0
88 M AdenoCa 0.23 1.55 7.55 8.23 2.14 0 0
89 F AdenoCa 0.48 3.15 15.25 26.84 10.56 0 0
90 M SqCCL 1.09 2.65 6.45 63.58 7.74 0 0
91 M SqCCL 3.04 2.80 8.53 15.98 10.73 1 0
92 M AdenoCa 0.73 1.97 10.48 7.21 4.39 0 1
93 F AdenoCa 0.68 2.04 8.13 8.46 5.53 0 0
94 F AdenoCa 3.36 3.42 19.21 22.92 23.92 0 0
95 M SqCCL 0.21 2.73 13.51 23.73 8.21 0 0
96 F AdenoCa 1.70 2.52 7.46 38.33 6.94 1 0
97 F AdenoCa 0.17 1.45 6.69 6.03 3.38 0 0
98 M SqCCL 1.12 4.14 12.40 24.35 10.58 0 0
99 F AdenoCa 2.98 2.17 16.26 30.32 11.50 0 0
100 F SqCCL 3.21 1.73 5.33 15.42 8.25 0 1
101 M AdenoCa 3.98 3.64 20.36 60.57 19.83 0 0
102 F SqCCL 1.90 2.42 13.64 20.67 9.80 1 1
103 F AdenoCa 1.55 1.77 4.77 18.22 4.81 ND 1
104 F SqCCL 7.73 5.31 18.89 28.86 22.54 1 0
105 M SqCCL 4.96 4.26 16.74 43.33 18.62 0 0
1 RQ=Relative quantification value= Z-™01. The expression of IMR90 lung fibroblasts has been used as calibrator in all
genes. The mean value was deduced by triplicate experiments.
2 Methylation status: 1= methylated (methylation index >5%), 0=unmethyiated (methylation index <5%)
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Appendix 4 Loss of heterozygosity data on 48 NSCLC tissues.
Sample FAL D13S153 D13S171 D13S263 D17S938 D3S1263 D3S1289 D3S1300 D3S1566 D5S644 D9S157 D9S161
1 0.455 HET LOH HET HET LOH HET LOH LOH LOH HET HET
2 0.857 LOH LOH LOH LOH HET LOH LOH
3 0.857 HET LOH LOH LOH LOH LOH LOH
4 0.375 HET HET LOH HET HET HET LOH LOH
5 0.400 HET HET HET HET HET LOH HET LOH LOH LOH
6 0.625 HET HET LOH LOH LOH LOH LOH HET
7 0.500 LOH LOH LOH HET HET HET HET HET LOH LOH
8 0.778 LOH LOH HET LOH LOH LOH HET LOH LOH
9 0.000 HET HET HET HET HET HET HET HET HET HET
10 1.000 LOH LOH LOH LOH LOH LOH LOH
11 0.909 LOH LOH LOH LOH HET LOH LOH LOH LOH LOH LOH
12 1.000 LOH LOH LOH LOH LOH LOH LOH LOH LOH
13 0.900 LOH LOH LOH LOH LOH LOH LOH LOH LOH HET
14 0.889 HET LOH LOH LOH LOH LOH LOH LOH LOH
15 0.000 HET HET HET HET HET HET HET HET HET HET
16 0.600 HET HET HET LOH LOH LOH LOH LOH LOH HET
17 0.143 HET HET LOH HET HET HET HET
18 1.000 LOH LOH LOH LOH LOH LOH LOH LOH
19 0.889 LOH LOH LOH LOH LOH LOH LOH HET LOH
20 0.818 HET LOH LOH LOH LOH LOH HET LOH LOH LOH LOH
21 1,000 LOH LOH LOH LOH LOH LOH LOH LOH LOH
22 0.556 LOH LOH LOH LOH HET HET HET LOH HET
23 0.500 HET HET HET HET LOH LOH LOH LOH
24 0.250 LOH HET HET HET HET LOH HET HET
25 0.833 LOH HET LOH LOH LOH LOH
26 0.000 HET HET HET HET HET HET HET
27 0.556 HET HET HET LOH HET LOH LOH LOH LOH
28 0.375 HET HET HET LOH LOH HET LOH HET
29 0.333 HET LOH LOH HET HET HET LOH HET HET
30 0.556 HET HET HET LOH LOH HET LOH LOH LOH
31 0.636 HET HET HET LOH LOH LOH LOH LOH HET LOH LOH
32 1.000 LOH LOH LOH LOH LOH LOH LOH LOH LOH LOH
33 0.900 LOH LOH LOH LOH LOH HET LOH LOH LOH LOH
34 0.900 LOH LOH LOH LOH LOH LOH LOH HET LOH LOH
35 1.000 LOH LOH LOH LOH LOH LOH LOH LOH
36 1.000 LOH LOH LOH LOH LOH LOH LOH LOH LOH LOH
37 1.000 LOH LOH LOH LOH LOH LOH LOH LOH LOH
38 0.714 HET LOH LOH HET LOH LOH LOH
39 0.182 HET HET HET HET HET HET HET HET HET LOH LOH
40 0.300 HET HET LOH HET HET HET LOH HET HET LOH
41 0.667 LOH LOH LOH HET HET HET LOH LOH LOH
42 0.700 LOH HET HET LOH LOH LOH LOH HET LOH LOH
43 0.636 LOH HET HET LOH LOH LOH LOH LOH LOH HET HET
44 0.100 HET HET HET HET HET HET HET HET HET LOH
45 0.182 HET LOH HET HET HET HET HET HET HET LOH HET
46 0.714 LOH LOH HET LOH HET LOH LOH
47 0.778 HET LOH HET LOH LOH LOH LOH LOH LOH
48 0.667 HET HET LOH LOH LOH LOH LOH HET LOH
LOH: loss of heterozygosity, HET: heterozygous, blank cells: homozygous (non-informative). FAL: fractional allele 
loss.
164
List of Reagents
ANTIBIOTICS
Name Company Cat. number
Ampicilin Sigma Aldrich A9518
Blasticidin Invitrogen R21001
G41S Promega V7983
Kanamycin Sigma Aldrich K4000
ANTIBODIES
Name Company Cat. number
Anti-tubulin a goat Ab P-16 Santa Cruz SC-31779
HRP-rabbit anti-mouse secondary antibody Abeam AB6728
Rabbit polyclonal anti-goat Ab HRP coupled Abeam AB6741
UHRF1 mouse antibody Abeam ab57083
CHEMICAL REAGENTS
Name Company Cat. number
5-Aza-2'-deoxycytidine Sigma Aldrich A3 65 6
Acetic Acid Fisher Chemicals BP2401
Agar Gibco BRL 30391-023
Agarose Fisher Bioreagents BPE-1356-50
Annealing Buffer Biotage 40-0036
Betaine Sigma Aldrich B0300
Binding Buffer Biotage 40-0033
Boric Acid (H2BO3) Fluka 15663
Bovine serum Albumine (BSA) Sigma Aldrich A7906
Chloroform BDH 100776B
Deoxycholate sodium Sigma Aldrich D6750
Dextran blue Sigma Aldrich D5751
Doxycycline hyclate Sigma Aldrich 44577-1G
EDTA BDH 100935V
Ethanol
Department of Chemistry, 
UoL UN1170
Glycerol
Sigma Aldrich G6279
Hi-Di™ Formamide Applied Biosystems 4311320
Hydrogen chloride (HC1) BDH 101254H
Isopropanol Fisher Scientific P17490/17
Leupeptin Sigma Aldrich L2884
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Low-melting point agarose Sigma Aldrich A9414
Methanol BDH 10158BG
Nonidet P-40 BDH 56009
NuPAGE® Antioxidant Invitrogen NP0005
NuPAGE® LDS Sample Preparation Buffer Invitrogen MP0007
NuPAGE® MES SDS Running Buffer Invitrogen NP0002
NuPage® Sample Reducing Agent Invitrogen NP0009
NuPAGE® Tris-Acetate SDS Running Buffer Invitrogen LA0041
Phenol: chloroform : isoamyl alcohol (50:49:1) Fisher Bioreagents BPE-1752p-400
Phenylmethanesulfonyl (PMSF) Sigma Aldrich P7626
Phosphate Buffered Saline (PBS) Invitrogen 18912-014
SafeView solution NBS Biologicals NBS-SV1
Simple Blue™ SafeStain Invitrogen LC6060
Sodium chloride (NaCI) Sigma Aldrich S9625
Sodium dodecyl sulphate (SDS) BDH 444464T
Sodium flouride (NaF) Fluka 71519
Sodium hydroxide (NaOH) Fluka 7169
Sodium orthovanadate (NaaVCXj) Sigma Aldrich S6508
Streptavidin Coated Dynabeads Invitrogen 112-05D
Thiazolyl Blue Tetrazolium Bromide (MTT) Sigma Aldrich M5655
Trichostatin A Sigma Aldrich T8552
Trizma® Acetate Fluka 93337
Trizma® base Sigma Aldrich T1503
Trypton BIO101 3066-022
Tween 20 Sigma Aldrich P7949
Yeast extract Gibco BRL 30393-029
Yeast tRNA Invitrogen 15401-011
ENZYMES AND BUFFERS
Name Company Cat. number
Alkaline phosphatase NEB M0290S
Apa 1 NEB R0114S
Bglll NEB R0144S
EcoR 1 NEB R0101S
Hind III NEB R0104S
NEB buffer 2 NEB B7002S
NEB buffer 3 NEB B7003S
NEB buffer 4 NEB B7004S
PCR buffer Roche 11 699 105 001
Proteinase K Qiagen 19133
RNase A Qiagen 19101
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Sal 1 NEB R0138S
T4 DNA Ligase NEB M0202S
T4 ligase reaction buffer NEB B0202S
Xhol NEB R0146S
KITS AND ASSAYS
Name Company Cat. number
Agilent RNA 6000 Nano Kit Agilent 5067-1511
DC Biorad Assay Biorad 500-0119
DNeasy Blood and Tissue kit (96-well protocol) Qiagen 69581
DNeasy Blood and Tissue kit (Spin column 
protocol)
Qiagen 69504
ECL Western Blotting Detection Reagents GE Healthcare RPN2109
EZ DNA Methylation-Gold™ kit Zymo Research D5005
EZ-96 DNA Methylation-Gold™ Kit Zymo Research D5007
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368813
HotStarTaq Plus DNA Polymerase Master Mix 
Kit
Qiagen 203645
Mini RNA Isolation II Kit™ Zymo Research R1030
Multiplex PCR Master Mix Qiagen 206143
ProtoBlock Solution National Diagnostics CL-252
Pyro Gold™ SQA Reagents Qiagen 40-0045
QIAquick Gel Extraction Kit Qiagen 28704
QIAquick Nucleotide Removal Kit Qiagen 28304
Quantitect reverse transcription kit Qiagen 205311
R.E.A.L® Prep 96 Kit Qiagen 26171
RNeasy Mini Kit Qiagen 74104
TaqMan® Gene Expression Master Mix Applied Biosystems 4369542
BigDye® Terminator v3.1 Cycle Sequencing Kit Applied Biosystems 4337456
TURBO DNAse Free kit Ambion AM 1907
Venor®GeM-qEP Mycoplasma PCR Detection
Kit
Minerva Biolabs 11-4025
Zyppy Plasmid Miniprep kit Zymo Research D4036
Zyppy™ Plasmid Maxiprep Kit Zymo Research D4028
MOLECULAR MASS LADDERS
Name Company Cat. number
Full Range Amersham™ Rainbow™ Marker GE Healthcare RPN800E
HyperLadder 1 Bioline BIO-33025
HyperLadder IV Bioline BIO-33029
A DNA-Hindlll Digest NEB N3012L
ROX400 size standard Applied Biosystems 402985
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PLASMIDS AND BACTERIA
Name Company Cat. number
One Shot” TOPIO Chemically Competent E. coli
bacteria Invitrogen C4040-10
pCMV/Bsd vector Invitrogen V51020
PRIMERS
Name Company Cat. number
Actin-P (ACTS) Applied Biosystems 4326315E
DNMT1 Applied Biosystems Hs00945898 gl
DNMT3A Applied Biosystems Hs01027167 gl
DNMT3B Applied Biosystems Hs01003404 gl
E2F1 Applied Biosystems HS01566605„gl
UHRF1 Applied Biosystems Hs00273589_ml
TISSUE CULTURE MEDIA AND 
REAGENTS
Name Company Cat. number
Attractene Transfection Reagent Qiagen 301007
Cell Freezing Medium Serum-free Sigma Aldrich C2639
D-MEM/F-12, liquid 1:1 with Glutamax™-L invitrogen 31331-093
Dulbecco Phosphate Buffered Saline (DPBS) Invitrogen 14040-174
Foetal bovine serum Biosera S1810
Keratinocyte-SFM medium Invitrogen 17005-59
Supplements for K-SFM medium Invitrogen 37005-059
7ro/7slT®-2020 Transfection Reagent Mirus MIR 5404
Tryple Express Gibco Invitrogen 12605-036
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UHRFl-Mediated Tumor Suppressor Gene 
Inactivation in Nonsmall Cell Lung Cancer
Alexandros Daskalos, BSc1; Urszula Oleksiewicz, MSc’; Anastasia Filia, BSc1; George Nikolaidis, MSc1; 
George Xinarianos, PhD1; John R. Gosney, MD, PhD2; Angeliki Mailiri, PhD3;
John K. Field, BDS, PhD1; and Triantafillos Liloglou, PhD1
BACKGROUND: The UHRF1 gene possesses an essential role in DNA methylation maintenance, but its contribution to 
tumor suppressor gene hypermethylation in primary human cancers currently remains unclear. METHODS: mRNA 
expression levels of UHRFI, DNMT1, DNMT3A, DNMT3B, and E2F1 were evaluated in 105 primary nonsmall cell lung 
carcinomas by quantitative polymerase chain reaction. The methylation status of CDKN2A and RASSF1 promoters 
was examined by pyrosequencing. UHRFI was knocked down by short hairpin RNA in A549 lung adenocarcinoma 
cells. RESULTS: All 4 genes were overexpressed in a coordinated manner in the lung tumor tissues, and their expres­
sion correlated with that of E2F1. Higher UHRFI expression in tumor tissues correlated with the hypermethylation of 
CDKN2A (P = .005) and RASSF1 promoters (P = .034), and the relationship with a combined epigenotype was even 
stronger (P = 2.3 x 10~4), When UHRFI was knocked down in A549 lung adenocarcinoma cells, lower methylation 
levels of RASSF1, CYGB, and CDH13 promoters were observed. Also, UHRFI knockdown clones demonstrated reduced 
proliferation and decreased cell migration properties. CONCLUSIONS: Our data demonstrate that UHRFI is a key epi­
genetic switch, which controls cell cycle in nonsmall cell lung carcinoma through its ability to sustain the transcrip­
tional silencing of tumor suppressor genes by maintaining their promoters in a hypermethylated status. Thus, UHRFI 
should be considered, along with DNMTs, among the potential targets for cancer treatment and/or therapeutic strati­
fication. Cancer 2010;000:000-000. © 2010 American Cancer Society.
KEYWORDS: UHRFI, DNMT, DNA methylation, tumor suppressor genes.
Epigenetic silencing of tumor suppressor genes (TSGs) is a hallmark in human cancers affecting multiple cellular 
pathways, such as cell signaling, adhesion and invasion, cell cycle, angiogenesis, DNA repair and apoptosis.1'2 Nonsmall 
cell lung carcinomas (NSCLCs) are no exception to this, with a plethora of TSG promoters affected, including RASSFL* 
CDKN2A,4 CYGB?, EDNRB? RARbeta7'*MGMT? and CDH13?
DNMTs (DNA methyltransferases) are the key enzymes responsible for the establishment and maintenance of 
DNA methylation profiles.'111- Until recendy, DNMTl was considered to be the maintenance enzyme after DNA repli­
cation, whereas DNMT3A and DNMT3B were characterized as de novo methyltransferases.13 The revised model suggests 
that DNMTl carries out the bulk of the DNA methylation maintenance, whereas DNMT3A and DNMT3B, being 
compartmentalized to particular chromosome regions, can complete the methylation process and correct errors.11 In addi­
tion, there is increasing evidence suggesting the involvement of histone modifications and nucleosome positioning in both 
de novo and maintenance methylation processes.''i’,<’ Numerous studies have demonstrated frequent overexpression 
of the DNMTs in many cancer types,1 1 ’ which in some cases correlated with the hypermethylation of particular 
TSGs.20 " However, other reports suggest that DNMT overexpression does not by itself seem to sufficiently account for 
the hypermethylation of TSG promoters.19’21'23'24
UHRFI (also known as ICBP90) has recendy been shown to play an important role in methylation maintenance. ^ 
It has the ability to bind hemimethylated DNA through its SET- and RING-associated domain,26 2 triggering the 
recruitment of DNMTl-5'2s and histone deacetylace-1.21 UHRFI-knockout mouse embryonic stem cells exhibit signifi­
cant loss of genomic methylation.2^ The UHRFI gene is a target for the transcriptional activator E2F1,29 and its
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expression is associated with increased cell prolifera­
tion.30,31 Accumulating evidence suggests that UHRF1 
has a putative oncogene function.32 Despite die impor­
tance of UHRF1 function in DNA mechylation, the cur­
rent data regarding its contribution to die epigenetic 
silencing of TSGs in primary human tumors are limited 
to a single report associating UHRFl overexpression widi 
BRCA1 promoter mechylation in sporadic breast 
cancer.33
In this study, we examined the mRNA expression 
profile of UHRFl as well as DNMT1, DNMT3A, and 
DNMT3B in NSCLC and examined their relationship to 
the methylation status of CDKN2A and RASSFl gene 
promoters. In addition, we further investigated the role of 
UHRFl in regional hypermethylation by knocking its 
expression down in a lung cancer cell line.
MATERIALS AND METHODS 
Human Tissues and Cell Lines
Frozen tissue from 105 NSCLCs (55 adenocarcinomas 
and 50 squamous cell carcinomas), as well as 50 adja­
cent normal lung tissues were obtained from Liverpool 
Heart and Chest Hospital (Liverpool, UK). Fifty-seven 
patients were male, and 48 were female. Specimens 
comprised the following pathological stages (pT): 10 
Tl, 81 T2, 10 T3, and 4 T4. Ethical approval was 
obtained from the Liverpool Ethics Committee for 
this study, and informed consent was obtained from 
each individual. The A549 adenocarcinoma cell line 
and its transfectant derivatives used in this study were 
grown in Dulbecco modified Eagle medium:F12 with 
L-glutamine and 10% fetal bovine serum, at 37°C 
supplemented with 5% C02.
DNA, RNA, and cDNA Synthesis
DNA and RNA extraction from tissues used 20 x 
40 pm frozen sections from each patient sample. 
The first and last sections underwent pathological 
review to ensure >80% tumor cell content. DNA 
and RNA extraction from tissues and cell lines were 
performed using the DNeasy and RNeasy kits (Qia- 
gen, Crawley, UK), respectively, after the manufac­
turer’s protocol. Five hundred nanograms total RNA 
was reverse transcribed in a 20 pL reaction using the 
Quantitect kit (Qiagen) following the supplier’s 
protocol.
Quantitative Polymerase Chain Reaction 
Expression Assays
TaqMan Gene Expression Assays for DNMTl 
(Hs00945898_gl), DNMT3A (Hs01027167_gl), 
DNMT3B (Hs01003404„gl), UHRFl (Hs00273589_ 
ml), and E2F1 (HS01566605_gl) (FAM-labeled) as well 
asACTB (4326315E) as endogenous control (VIC-labeled) 
were purchased from Applied Biosystems, Warrington, 
UK. Assays were performed in 15 pL containing 7.5 pL 
Taqman expression master mix (Applied Biosystems), 0.75 
pL of the target primer/probe mix, 0.75 pL endogenous 
control, and 2 pL of cDNA per die universal conditions (2 
minutes at 50C'C, 95°C for 10 minutes, 50 cycles of 94°C 
for 30 seconds, 60°C for 45 seconds) on an Applied Biosys­
tems 7500 real-time polymerase chain reaction (PCR) 
machine, mRNA levels were expressed as relative quantifi­
cation values, which were calculated as relative quantifica­
tion = 2(~AACl), where the mRNA expression of IMR-90 
cells was used as a calibrator in each run. All assays were run 
in triplicate, and die mean value was used for the analysis.
DNA Methylation Analysis
Pyrosequencing assays (Qiagen) were developed to mea­
sure the DNA mediylation levels of CDKN2A, RASSFl, 
CYGB, CDH13, DNMTl, DNMT3A, DNMT3B, and 
UHRFl promoters. The locations of the interrogated CG 
dinucleotides (CpGs) and relevant primers in each pro­
moter are shown in Figure 1. The primer sequences used 
are the following:
(CDKN2A) F: 5,-AGGGGTTGGTTGGTTAT- 
TAG-3', R: 5'-biotin-CTACCTACTCTCCCCCTCT 
C-3', S: 5'-GGTTGGTTATTAGAGGGT-3'; (RASSFl) 
F: 5'-AGTATAGTAAAGTTGGTTTTTAGAAA-3,> R: 
y-biotin-CCCTTCCTTCCCTCCTT-S', S: T-AAGTT 
GGTTTTTAGAAATA-3'; (CDH13) F: 5'-biotin-TTA 
GGGAAAATATGTTTAGTGTAGT-3', R: 5'-ACCCC 
TCTTCCCTACCTA-3', S: ^-ACCCCTCTTCCCTA 
CCT-3'; (CYGB) F: S'-biotm-GGGAATTGATTTAA 
AGTTTA-3', R: 5'-AAAAAACCCAACTAAATCCAC- 
3', S: 5'-ACCCAACTAAATCCAC-3'; (UHRFl) F: 5'- 
GGTTAATTAGGAGGTAGG-37, R: S'-biotin-ACTC 
CACATTTAAAAATTAC-3', S: 5/-GGTTAATTAGGA 
GGTAG-T; (DNMTl) F: 5'-GATATTTTGTGTA 
GAAGGATGGAA-3', R: 5'-biotin-ACCCACCTCC 
CAACAAAC-3', S: 5'-ATTTTGTGTAGAAGGATG- 
3'; (DNMT3A) F: S'-GATTTTGGTTTTGTAGAG 
TAGAG-3', R: 5'-biotin-TCTACCTACCTCAACAC 
TAAAACT-3', S: 5'-ATTCACCTCCCAACAAAC-3'; 
(DNMT3B) F: 5'-GAGTTAGGTTTATTTGGGTT
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Figure 1. Diagrammatic map of the promoter regions exam­
ined is shown. CG dinucleotides are represented by vertical 
lines and primers as arrows. Numbering refers to the tran­
scriptions start site depicted by the gamma-shaped arrow.
AT-3\ R: 5/-biotin-CTTCCTCCCAACAACTACT-3', 
S: 5'-n’ATTrGGGTTATTTAA-3'.
One microgram of genomic DNA was treated with 
sodium bisulphite (EZ DNA methylation Kit, Zymo 
Research, Orange, CaliO following the manufacturer's 
protocol. All primers were designed using Pyromark Assay 
Design 2.0 software (Qiagen) and supplied by Eurofins 
MWG Operon (Ebersberg, Germany). PCR amplifica­
tions were performed in a final volume of 23 pL using 
Qiagen HotStarTaq Master Mix, 200 nM biotinylated 
primer, 400 nM nonbiotinylated primer, and approxi­
mately 60 ng of bisulfite-treated genomic DNA. The ther­
mal profile was: 95CC for 5 minutes followed by 40 cycles 
consisting of 94°C for 30 seconds, 51 to 57CC for 30 sec­
onds, 72°C for 30 seconds. The annealing temperature 
for each gene was: CDKN2A, 55°C; RASSF1, 50°C; 
CYGB, 50CC; CDH13, 523C; UHRFl, 51°C; DNMTl, 
57 C; DNMT3A, 54 C; DNMT3B, 573C. For pyrose- 
quencing analysis, the PyroMark Gold Q96 SQA 
Reagents and the PyroMark Q96 ID instrument (Qiagen) 
were used following the supplier’s protocol. The methyla­
tion index for each promoter was calculated as the mean 
value of mC/(mC + C), where C is unmethylated cyto­
sine and mC is 5' methyl-cytosine, for all examined CpGs 
in the target sequence.v*
Construction of a Short Hairpin RNA UHRFl 
Knockdown Stable Ceil Line
The short hairpin RNA (shRNA) oligonucleotides 
used were (bold characters indicate the target 
sequence): UHRFl-sense, 5'GATCCC GGACGGCG 
CGGGAACTCTATT CAAGAGATAGAGTTCCCGCG 
CCGTCCTTTTTGGAAA 3'; UHRFl-antisense, 5,AGC 
TTTT CC AAAAAGGACGGCGCGGGAACTCTAT CT 
CTTGAATAGAGTTCCCGCGCCGTCCGG 3'; saambled- 
sense, 5'GATCCCATGAAGTCG CATGGTGCAGTT 
CAAGAGACTGCACCATGCGACTTCATTTTTTGG 
AAA 3'; scrambled-antisense, S'AGCTTTTCCAAAAA 
ATGAAGTCGCATGGTGCAGTCTCTTGAACTGCA 
CCATGCGACTTCATGG 3'.
Oligonucleotides were annealed and ligated into the 
pGEM-T-easy shuttle vector (Promega, Madison, Wis) 
containing the HI promoter. Constructs were verified by 
sequencing analysis on a 3130 capillary sequencer using 
the BigDye 1.1 kit (Applied Biosystems). The shRNA 
module was then excised and ligated into the vector 
backbone of the pNlpPactin-rtTA2S-M2-IRESEGFP 
plasmid ’ containing the tetracycline repressor and a neo­
mycin resistance gene. The final pNlpPactin-rtTA2S- 
M2-IRESEGFP-UHRF1 and pN 1 ppactin-rtTA2S-M2- 
IRESEGFP-scrambled constructs were transfected into 
the A549 cell line using the Attractene reagent (Invitro- 
gen, Carlsbad, Calif) - Stable cell lines were selected after 2 
weeks using 600 ng/pL G418 antibiotics. Twenty differ­
ent clones were checked for UHRFl down-regulation at 
both RNA (quantitative PCR) and protein (Western blot) 
level in the presence/absence of 1 pg/mL doxycycline. The 
clones demonstrating inducible knockdown of UHRFl 
did not produce >45% reduction of the UHRFl mRNA. 
In contrast, 2 clones (named clone 1 and 2 thereafter) 
demonstrated constitutive, noninducible >80% knock­
down of UHRFl mRNA. Thus, it was decided to proceed 
to the subsequent experiments with these 2 clones.
MTT Proliferation Assay
The viability of A549 parental and UHRFl knockdown 
clones was measured using the MTT proliferation assay; 5 
x 103 of A549 parental, mock, A549 PAXUHRF1 clone 
1 and clone 2 cells were seeded in 12-well plates. The next 
day, cells were washed with phosphate-buffered saline 
(PBS) and incubated with fresh medium containing 0.5
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mg/mL of MTT (3-[4,5-dimethyl thiazol-2-yl]-2,5- 
diphenyltetrazolium bromide) (Sigma-Aldrich, St Louis, 
Mo) for 2.5 hours at 37°C supplemented with 5% C02. 
The medium was subsequently removed, and cells were 
washed with PBS. The converted formazan was solubi­
lized by adding 1 mL of isopropyl alcohol-0,04 M HC1. 
After 5 minutes, viability of die cells was determined by 
measuring the difference in absorbance at 570 nm widi 
reference at 630 nm. Time point measurements were per­
formed every 24 hours for 5 days in total. The average 
proliferation rate was deduced from 3 biological 
replicates.
Western Blot
A549 cells were lysed at 80% confluence using RIPA 
buffer supplemented with protease inhibitors (1 mM 
phenylmethylsulfonyl fluoride [Sigma Aldrich], 10 pg/ 
mLleupeptin [Sigma Aldrich], 10 mM NaF [Fluka, Neu- 
Ulm, Germany], 1 mM Na3VO^ [Sigma Aldrich]). Total 
protein concentration was measured with the DC Biorad 
Assay [Biorad, Hercules, Calif]. Twenty micrograms of 
total protein were denatured, separated on a 3%-8% 
NuPAGE Novex Tris-Acetate Mini gel (Invitrogen), and 
blotted onto a polyvinylidene difluoride membrane using 
an iBLOT platform (Invitrogen). Membranes were 
blocked in 5% Protoblock Reagent A (National Diagnos­
tics) for 1 hour, incubated overnight with 2 pg/mL of die 
primary anti-UHRFl mouse antibody (ab57083, Abeam, 
Cambridge, UK) at 4°C, and probed with horseradish 
peroxidase-rabbit antimouse secondary antibody 
(ab674l, Abeam). Antitubulin primary antibody 
(SC31779, Santa Cruz Biotechnology, Santa Cruz, Calif) 
was used as an internal control of total protein concentra­
tion. The bands were observed with the ECL western blot­
ting detection kit (Amersham, Piscataway, NJ).
Wound Healing Assay
Wound-healing capacity of die A549 parental, mock, and 
A549 UHRFl knockdown colonies was measured using 
scratch assays. Approximately 3 to 5 x 103 of A549 paren­
tal, mock, A549 PAXUHRF1 clone 1 and clone 2 cells 
were seeded in 24-well plates. The next day, when cells 
had reached confluence, monolayers were scratched using 
a dp. Time-lapsed images were digitally captured with a 
charge-coupled device camera over a period of 24 hours. 
The area that was covered by the migrating cells was calcu­
lated using TScratch software.36
Table 1. mRNA Expression of Examined Genes in Lung Tumor 
and Paired Normal Lung Tissue (n=50)
Gene mRNA Expression P (Wilcoxon
(RQ Values, Mean±SE) Test)
Tumor Normal Lung
UHRF1 3.9 ± 0.4 0.5 ± 0.1 1.7 X 10"9
DNMTl 9.8 ± 0.8 5.8 ± 0.4 2.0 x 10 5
DNMT3A 47.9 ± 7.4 32.9 ± 4.5 3.9 x 10 4
DNMT3B 89.0 ± 16.7 31.8 ± 5.8 4.4 x 10“6
E2F1 25.3 ± 3.8 9.5 ± 1.5 1.9 x 10"6
RQ indicates relative quantification value = SE, standard error.
The expression of IMR90 lung fibroblasts has been used as calibrator in all 
genes. The mean value was deduced by 2 repeats.
Statistical Analysis
The fitness of continuous data into a normal distribution 
was tested by die one-sample Kolmogorov-Smirnov test. 
As none of the variable data fitted into normal distribu­
tion, nonparametric tests such as Mann-Whitney and 
Wilcoxon were used to analyze expression values among 
different groups. Spearman correlation was used to assess 
die relationship between continuous values. All statistical 
tests were performed by SPSS version 16.0 (SPSS Inc. 
Chicago, Ill).
RESULTS
UHRFl, DNMT1, DNMTSA, and DNMT3B Are 
Overexpressed in Primary NSCLCs
We measured by quantitative PCR die mRNA expression 
levels of UHRFl, DNMTl, DNMT3A, DNMT3B, and 
E2F1 in 105 primary NSCLC tumors, 50 of which had 
available paired adjacent nontumor tissue. Analysis of 
normal/tumor paired tissue sets demonstrated higher 
mRNA levels for all these genes in the tumors (Table 1). 
Bivariate analysis of the expression of the above genes in 
the set of 105 tumors demonstrated significant correla­
tions between all of them (Table 2). In addition, expres­
sion of UHRFl, DNMTs, and E2F1 was comparatively 
analyzed widi die clinicopathological data. UHRFl was 
found to be expressed at higher levels in squamous carci­
nomas (mean relative quantification, 3.8 ± 0.4) than 
adenocarcinomas (mean relative quantification, 2.8 ± 
0.4, Mann-Whitney, P = .019). No further associations 
were observed between other clinical parameters (age, sex, 
T stage, nodal metastasis and differentiation) and any of 
the examined genes with the exception of the correlation 
between DNMT3B mRNA overexpression and poor 
prognosis. In particular, patients with lower dian median 
DNMT3B expression (relative quantification <24.4) had 
a mean estimated survival of 70.2 ± 10.4 months,
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Table 2. Coordinated Expression of UHRF1, DNMTs, and E2F1 in Nonsmall Cell Lung Carcinoma 
(N=105)
Gene DNMT1 DNMT3A DNMT3B E2F1
UHRFl
Spearman correlation coefficient
P
0.633
4.5 x lO '3
0.583
6.6 x 10 11
0.514
2.4 x 10 8
0.754
1.5 X 10
DNMT1
Spearman correlation coefficient
P
0.737
3.2 x 10-'9
0.558
7.3 x 10'10
0.659
2.3 x 10
DNMT3A
Spearman correlation coefficient
P
0.688
6.9 x 10 16
0.744
1.1 x 10
DNMT3B
Spearman correlation coefficient
P
0.732
1.1 x 10
LowDNMIBB
> 0 6-
FU (month*)
Figure 2. Kaplan-Meier survival analysis of nonsmall cell lung 
carcinoma patients in relation to DNMT3B mRNA expression 
is shown. X axis represents follow-up (FU) time; cumulative 
(Cum) survival is represented on the Y axis. Tumors with 
DNMT3B relative quantification value >24.4 (median) demon­
strate a lower survival rate than those with lower than the 
median DNMT3B expression. It must be noted that none of 
the patients received postoperative chemo- or radiotherapy.
whereas the corresponding figure for those with higher 
DNMT3B expression was 29.3 ± 5.7 months (log-rank 
test, 7>= .013, Fig. 2).
The presence of CpG islands in the promoters of 
UHRF1 and all DNMTs led us to examine their DNA 
methylation status in this NSCLC set. All 4 promoters 
were found to be unmethylated in both normal and tumor 
tissues examined.
UHRF1 and DNMT Overexpression Correlates 
With Hypermethylation of TSGs
The methylation levels of CDKN2A and RASSF1 pro­
moters were measured by pyrosequencing in this set of 
105 NSCLC tissues. Representative pyrograms are given 
in Figure 3. The threshold for scoring hypermethylated 
samples was conservatively set to 10%, which is higher 
than previously established thresholds,3 38 to increase the 
prospect of the detected methylation for biologically rele­
vance. DNA hypermethylation was observed in 32.4% of 
the tumors for RASSF1 and 26% of the tumors for 
CDKN2A. The expression of the UHRFl and DNMTs 
genes was analyzed in relation to the hypermethylation 
status of the TSGs (Table 3). Tumors with hypermethy­
lated CDKN2A demonstrated higher levels of DNMT1 
(Mann-Whitney, P = .018) and UHRFl (P = .005) 
expression compared with the CDA7V2/l-unmethylated 
tumors. Also, tumors with hypermethylated RASSFl 
demonstrated higher levels of DNMT3B (Mann- 
Whitney, P = .043) and UFfRFl {P = .034) expression. 
DNMT3A expression did not demonstrate a correlation 
with any of the 2 examined promoters. Interesdngly, 
when combining the methylation status of both CDKN2A 
and RASSFl (positive = at least 1 methylated), the corre­
lation between UHRFl expression and hypermethylation 
becomes more significant (P = 2.3 x 10-4, Table 3).
UHRFl Down-Regulation Leads to 
Hypomethylation of TSGs in A549 Cells
After the observations regarding the relationship between 
UHRFl expression and TSG hypermethylation in pri­
mary NSCLCs, we further investigated the role of 
UHRFl in a cell line model by knocking down UHRFl
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Figure 3. Representative pyrograms from the DNA methyla- 
tion analysis are shown. X axis shows the dispensation order; 
the examined sequence is shown at the top of each pyro- 
gram. Gray lanes are indicative of individual CG dinucleotides; 
yellow lanes indicate the bisulfite conversion controls.
in A549 lung adenocarcinoma cell line and acquiring sta­
ble transfectants. Both derived clones demonstrated 80% 
knockdown at the RNA level (Fig. 4A), whereas the 
protein was almost undetectable in Western blotting
(Fig. 4B). The mRNA expression levels of DNMT1 and 
DNMT3A demonstrated no significant changes between 
A459, the mock, and the UFIR.F1 knockdown clones. In 
contrast, DNAfT3B was consistently up-regulated in both 
UHRFl knockdown clones (Table 4). UHRF1 and 
DNMT promoters were unmethylated in the A549 cells, 
and no change was observed in the UHRFl knockdown 
clones (Table 4). To examine the UHRFl knockdown 
effect on regional hypermethylation, we examined by 
pyrosequencing the promoters of RASSF1, CYGB, and 
CDH13, which were known from previous unpublished 
work to be methylated in the A549 parental line 
{CDKN2A promoter was found to be unmethylated in 
A549 cells). Although no difference was observed in the 
mock cell line, the methylation status of all 3 promoters 
was consistendy, aldiough variably, reduced in both 
UHRFl knockdown clones (Fig. 5).
Phenotypic Effects of UHRFl 
Down-Regulation
The phenotypic characteristics of the UHRFl knock­
down clones were significandy different from those of 
A549 and mock cell lines. Both UHRFl knockdown 
clones had reduced proliferation rates (Fig. 6). In addi­
tion, scratch assays (Fig. 7) demonstrated lower migration 
efficiency of the UHRFl knockdown clones. In particu­
lar, TScratch software analysis demonstrated that after 24 
hours, the open wound area was 10.5% ± 1.3% in the 
parental A549, 14.1% ± 1.1% in mock cells, 71.9% ± 
1.8% in UHRFl clone 1, and 56.1% ± 1.8% in clone 
2 (Fig. 8).
DISCUSSION
Inactivation of TSGs by promoter hypermethylation is 
among the most frequent abnormalities in human can­
cers.1 Our understanding of epigenedc deregulation is 
advancing as the list of genes and mechanisms mediating 
the DNA methylation process grows/ ’ 4"
UHRFl performs a critical function in DNA meth­
ylation maintenance"^; however, its involvement in TSG 
promoter hypermethylation in cancer is not yet clear. In 
the present study, we investigated in NSCLCs the rela­
tionship of UHRFl expression with the hypermethylation 
status of CDKN2A and RASSF1 promoters, which are 
among the most frequently hypermethylated genes in this 
tumor type. UHRFl mRNA was overexpressed in 
NSCLC tumor tissues in comparison to their normal 
adjacent tissue, confirming in a large sample set a
6 Cancer Month oo, 2010
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Table 3. mRNA Expression Levels of UHRF1, DNMTI, DNMT3A, and DNMT3B in Groups of NSCLCs With Different Methylation 
Status of CDKN2A and RASSF1
Gene CDKN2A P RASSF1 P CDKN2A and/or P
Methylation Methylation RASSF1
— + — + — +
UHRFl 2.9 ± 0.4 3.9 ± 0.4 .0053 2.8 ± 0.3 4.1 ± 0.7 ,034J 2.4 ± 0.3 4.1 ± 0.5 2.3 x 10
DNMTI 6.5 ± 0.8 8.8 ± 1.2 .018* 6.8 ± 0.7 8.1 ± 1.3 .301 6.0 ± 0.7 8.2 ± 1.0 .058
DNMT3A 26.4 ± 3.2 35.3 ± 9.6 .604 31.7 ±5.3 31.4 ±4.9 .314 23.7 ± 3.6 33.3 ± 5.9 .151
DNMT3B 59.5 ± 10.0 73.1 ± 20.0 .200 54.8 ± 9.7 90.8 ± 19.8 .043J 41.9 ± 6.1 84.6 ± 16.8 .037"
Values are presented as mean relative quantification-standard error. P values originate from Mann-Whitney tests. 
a Statistically significant.
B
A549 mock donel done 2
UHRF1 
lUwfln
Figure 4. (A) Quantitative polymerase chain reaction and (B) 
Western blotting demonstrate UHRF1 mRNA and protein 
expression, respectively, of the A549-derived UHRF1 knock­
down clones. A >80% reduction of mRNA levels is observed 
in both clones; UHRF1 protein is hardly detectable in the 
Western blot in comparison to the strong UHRF1 expression 
in A549 and mock cells. RQ indicates relative quantification.
preliminary observation.11 UHRF1 overexpression was 
more profound in squamous carcinomas than adenocarci­
nomas, further underlying the differences in the molecular 
evolution of these tumor types. Further research is 
required to provide evidence on whether this difference 
could be used in the clinical management of these 2 histo­
logical types. Although UHRFl promoter bears a CpG 
island, no DNA methylation was found in normal or tu­
mor tissue, excluding the possibility of an epigenetic 
expression feedback loop. As UHRFl is a known E2F1 
target,29'1^ we also examined E2F1 mRNA expression lev­
els in this sample set. Indeed, a strong relationship was 
observed between the expression levels of the 2 genes, sup­
porting the concept that UHRFl regulation is under the 
control of the pRb/E2Fl pathway.4*'
It is of note that UHRFl overexpression in the 
NSCLC tissue set was correlated with increased DNA 
methylation of both CDKN2A and RASSFl promoters, 
and moreover that a much stronger association was 
observed when analyzing UHRFl expression against a 
combined CDKN2AIRASSF1 methylation epigenotype. 
Thus, UHRFl activity is important in mainuining 
the hypermethylation of certain TSGs. This is also 
supported by findings in breast tumors, where UHRFl 
overexpression was correlated with BRCA1 promoter 
hypermethylation. '
To provide additional support to our ex vivo obser­
vations, we knocked down the expression of UHRFl in 
A549 lung adenocarcinoma cell line. Both UHRFl 
knockdown derived clones demonstrated reduced methyl­
ation of RASSFl, CYGB, and CDH13 promoters, which 
are hypermethylated in A549. The UHRFl knockdown 
clones presented with reduced proliferation rates and 
migration efficiency in comparison to those of the parent 
and the mock cell lines. This is consistent with the 
reported association between UHRFl, proliferation,30 
and tumor cell growth." E2F1 levels did not change upon 
UHRFl knockdown, indicating a lack of a feedback loop. 
Both our ex vivo and in vitro data suggest that UHRFl 
can influence the cell cycle control mainly through the epi­
genetic silencing of relevant tumor suppressors.
To gain a wider view of the DNA methylation 
machinery status, we also measured the mRNA expression 
of DNMTI, DNMT3A, and DNMT3B. All these 
genes were overexpressed in NSCLC tissues, in concord­
ance with previous reports in other human cancer 
types.17'19,21,4 ,48 A strong correlation between the
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Tabl* 4. mRNA Expression and DNA Methylation of DNMTs in UHRF1 Knockdown Clones
Cells mRNA Expression (Mean RQ±SE) Promoter Methylation Index
DNMT1 DNMT3A DNMT3B UHRFI DNMT1 DNMT3A DNMT3B
A549 1.00 ± 0.21 1.02 ± 0.08 1.02 ± 0.08 2% 1% 0% 1%
Mock 1.07 ±0.19 0.96 ± 0.04 1.2 ± 0.13 3% 2% 1% 0%
Clone 1 0.78 ± 0.15 1.16 ± 0.06 6.03 ± 0.39 2% 0% 2% 1%
Clone 2 0.94 ± 0.18 1.27 ± 0.06 4.16 ± 0.19 2% 1% 1% 1%
RQ indicates relative quantification; SE, standard error.
Means and SE have been calculated from 6 replicates (2 biological x 3 technical). The average value of the A549 cells was used as calibrator for calculating 
RQ.
tarn mmk riMNS AM* MW* rfwwl •InnX AM* am* ctowrl «Im«Z
RASSn OOB GOMU
Figure 5. Effect of UHRF1 expression knockdown on the DNA methylation levels of RASSF1, CYGB, and CHD13 is shown. A con­
sistent reduction of the DNA methylation of all 3 promoters is observed across biological replicates in both UHRFI knockdown 
clones. The Y axis represents the mean methylation index detected by triplicate pyrosequencing experiments. Error bars repre­
sent standard error of the mean.
expression levels of all the DNMTs was observed, in ac­
cordance with a reported coordinated expression of 
DNMTs.11 ' Furthermore, the expression levels of all 
DNMTs examined in this set was correlated with the 
expression of E2F1. Although the E2F1 dependence of 
DNMT1 transcription is well established,1 ’ our data sug­
gest that DNMT3A and DNMT3B may also be regulated 
by E2F1. Recent evidence of the participation of 
DNMT3A and DNMT3B in DNA methylation mainte­
nance after DNA replication14^0 provides a biological 
reason behind the E2F1 dependence. Flowever, this 
requires further confirmation with functional studies. The 
overexpression of DNMT3B correlated with poor survival 
in our NSCLC set, and this is in agreement with a previ­
ous study demonstrating prognostic significance of 
DNMT3B expression but only in younger patients aged 
<65 years.1 The potential clinical implementation of 
these observations should be further investigated.
Statistical analysis in primary tumors demonstrated 
that DNMT1 overexpression was correlated with hyper- 
methylation of CDKN2A promoter, in accordance with 
previous reports.'In addition, DNMT3B overexpres­
sion was correlated with hypermethylation of RASSF1 
but not CDKN2A promoter. Interestingly, the same find-
Figure 6. Proliferation rates over 5 days, measured by MTT 
experiments, are shown. Proliferation is significantly reduced 
in both UHRFI knockdown clones in comparison to A549 
cells and mock (scrambled short hairpin RNA) cell lines.
ing was reported for ADNMT3B in NSCLC. 11 The 
amplicon detected in our study includes all different 
DNMT3B transcripts, and because ADNMT3B is the 
predominant form of DNMT3B in NSCLCs,^2 it is likely 
that our results reflect the observed correlation between
8 Cancer Month oo. 2010
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Figure 7. Scratch assays demonstrate the reduced migration 
efficiency of UHRF1 knockdown clones in comparison to 
A549 cells and mock (scrambled short hairpin RNA) cell 
lines. Photographs of t = 0 and t = 24 hours are presented.
ADNMT3B and RASSF1. The importance of both 
DNMTl and DNMT3B expression in the maintenance 
of aberrant CpG island methylation of TSGs in mamma­
lian cell models20'53 ^ has been demonstrated. Our data 
together with previous reports-0 ~~ suggest that DNMTl 
and DNMT3B can regulate DNA methylation in a pro­
moter-specific manner. In concordance with this sugges­
tion is the classification of common and distinct promoter 
groups identified after RNA interference-mediated sup­
pression of DNMTl and DNMT3B. 0
Interestingly, whereas the expression levels of 
DNMTl and DNMT3A remained unchanged in the 
UHRFl knockdown clones, there was a significant 
increase of DNMT3B expression in the absence of any 
methylation change of its promoter. The reasons behind 
the increase of DNMT3B expression upon UHRFl 
knockdown are not currently clear. It is not known
5g 4000-
Time (hours)
Figure 8. Diagrammatic representation shows the migration 
rates of parental, mock, and UHRFl knockdown clones in 
scratch assays. The open wound area (OWA) was quantified 
using TScratch software. The increased OWAs of the UHRFl 
clones indicate their reduced migration capability.
whether this is a direedy UHRFl-related effect or whether 
unprompted high-DNMT3B expression provides a selec­
tive advantage that eventually takes over the cell popula­
tion in the culture environment. Nevertheless, the 
incomplete RASSFl, CYGB, and CDH13 promoter 
hypomethylation observed in the UHRFl knockdown 
clones suggests that DNMTs can maintain a degree of 
methylation in the presence of low abundance of UHRFl 
protein.
This study provides compelling new evidence to 
suggest that the overexpression of UHRFl in NSCLC is 
critical, alongside the overexpression of DNMTs, for 
the maintenance of hypermethylated TSG promoters. 
UHRFl is thus emerging as key epigenetic switch for cell 
cycle control and can be used as a new target for epigenetic 
therapies.
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p73 possesses an extrinsic PI promoter and an intrinsic P2 promoter controlling the 
expression of the pro-apoptotic TAp73 isoforms and the anti-apoptotic ANp73 isoforms 
respectively. In this study, we investigated the DNA methylation status of both promoters 
as a means of epigenetic transcriptional control of their corresponding isoforms in 102 pri­
mary non-small cell lung carcinomas (NSCLCs). We demonstrated that while PI hyperme- 
thylation-associated reduction of TAp73 mRNA levels is relatively infrequent, the P2 
hypomethylation-associated over-expression of ANp73 mRNA is a frequent event, partic­
ularly among squamous cell carcinomas. P2 hypomethylation strongly correlated with 
LINE-1 element hypomethylation, indicating that ANp73 over-expression may be a passive 
consequence of global DNA hypomethylation.
© 2010 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
p73 is a p53-family member which, despite its high 
homology with p53, is not a typical Knudson-type gene. It 
encodes a number of protein isoforms with a suggested dual 
role in cancer. In detail, the full-length TAp73 isoforms 
induce cell cycle arrest and apoptosis by transactivating a 
number of p53 target genes, whereas the N-terminal trun­
cated ANp73 isoforms hamper apoptosis either by directly 
inhibiting TAp73 and p53 or through indirect inhibition of 
p53-mediated transcription, therefore exerting ongogenic 
activities in the cells (1-4). The synthesis of isoforms with 
opposing properties by only one gene is mainly achieved 
by the alternative usage of two different promoters in p73 
gene, the extrinsic promoter (PI) located upstream to 
exon 1, which gives rise to the transactivation domain
* Corresponding author. Tel.: +44 0151 7948958.
E-mail address: liloglout@roycastle.liv.ac.uk (T. Liloglou).
0304-3835/S - see front matter © 2010 Elsevier Ireland Ltd. All rights reserved, 
doi: 10.1016/j.canlet.2010.09.009
(TA)-containing (TAp73) isoforms and the intrinsic pro­
moter (P2) located in intron 3, which controls the transcrip­
tion ofTA-deprived (ANp73) isoforms. Isoforms lacking the 
TA domain (p73Aex2, p73Aex2/3 and AN'-p73) can also be 
produced through alternative splicing of transcripts driven 
by the extrinsic promoter [5,6].
DNA methylation is a dynamic, reversible mode of epige­
netic regulation which can modify functionality of numer­
ous genes within the cell. Alterations of the pattern of 
DNA methylation are common in cancer cells. On the one 
hand, hypermethylation of CpG islands within certain gene 
promoter regions inhibits transcription, thus contributing 
in the silencing of crucial tumour suppressor genes, such 
as p 16INK4*, Rb, E-cadherin and BRCA J [ 7 ]. On the other hand, 
hypomethylation of specific loci reactivates expression of 
genes with an oncogenic potential. For example, hypome- 
thylation-linked activation has been reported in some 
cancers for genes such as H-Ras, c-myc [7], PAX2 [8], Cros 
[9] and NGALR [10]. DNA demethylation occurs through
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two distinct processes, referred as passive demethylation, 
which results from improper preservation of methylation 
marks during DNA replication due to the lack of methyla­
tion maintenance activities; and active demethylation, 
which involves a demethylase that erases methylation 
marks from DNA in a replication-independent manner 
[11]. Global hypomethylation of the genome occurs simul­
taneously with hypermethylation of CpG islands in cancer 
cells, involving genes implicated in cell cycle regulation, 
DNA repair and apoptosis [7], These changes are usually 
tumour-type specific [12].
Methylation of p73 has been reported in certain types of 
cancer, such as leukemias/lymphomas and neuroblastomas. 
Specifically, p73 hypermethylation poses as a common 
event in acute lymphoblastic leukemia, responsible for inhi­
bition of transcription of the corresponding gene product 
[13], whereas it is very rare and has no effect on pathogen­
esis in acute myeloblastic leukemia [14]. In non-Hodgkins 
lymphomas, PI p73 promoter has been found methylated 
in B-cell lymphomas, accompanied by absence or low levels 
of TAp73, but unmethylated inT-cell lymphomas [15]. The 
highest p73 methylation frequency up to 94% has been re­
ported in natural killer cell lymphomas, while p73 transcript 
was not detectable in these malignancies [16]. Other studies 
indicate that extrinsic and intrinsic p73 promoters are dif­
ferentially affected by methylation. In detail, PI promoter 
is unmethylated independently from TAp73 transcription 
in neuroblastomas [17], In contrast, P2 promoter is partially 
methylated in ANp73-expressing primary neuroblastomas 
and fully methylated in ANp73-non-expressing primary 
neuroblastomas, suggesting that expression of ANp73, but 
not TAp73, is at least in part, controlled by epigenetic events 
[18].
Recently, p73 promoter methylation was investigated in 
the context of lung cancer. Using qualitative methods, Di 
Vinci et al. showed that both ANp73 and TAp73 proteins 
are overexpressed in NSCLCs and that PI promoter was 
unmethylated in most cases examined (39/41), whereas P2 
was partially unmethylated in 24/41 cases examined. Both 
TAp73 and ANp73 protein levels were variably elevated in 
these tumours in comparison with normal adjacent tissues, 
however no correlation was established between PI and P2 
methylation status and the expression of the corresponding 
protein products in tumours [19]. Following this work and 
expanding the analysis to a larger number of patients, we 
used sensitive quantitative assays to thoroughly determine 
the methylation levels of PI and P2 promoters and to further 
investigate their correlation with TAp73 and ANp73 mRNA 
levels, as well as with LINE-1 promoter methylation, the 
surrogate marker of global hypomethylation [20,21 ], in lung 
cancer. We also evaluated the association of PI and P2 
promoter methylation with their corresponding products 
in the context of distinct histological NSCLC types, mainly 
adenocarcinomas and squamous cell carcinomas.
2. Materials and methods
2.1. Patients and tissues
Frozen tumour samples for 102 NSCLC patients were 
obtained from Liverpool Heart and Chest Hospital. Corre­
sponding normal lung tissues were available for 38 of these 
patients. The patients comprised 56 males and 46 females 
and ranged in age between 49 and 81 years (mean, 
64 years). Fifty-three of the NSCLCs were adenocarcino­
mas, whereas the remaining 49 were squamous cell carci­
nomas. Tissues were dissected by the pathologist within 
30 min from surgical resection and were immediately 
stored to a -80 °C freezer. The study protocol was ap­
proved by the Liverpool Ethics Committee and all patients 
provided written, informed consent in accordance with the 
Declaration of Helsinki,
2.2. DNA extraction and methylation analysis
For the DNA extraction 20 pm-thick sections were cut 
from frozen tissue. Tumour sections were stained with 
H&E and microscopically reviewed to ensure a >80% tu­
mour cell content. Genomic DNA was extracted from the 
samples using the DNeasy kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol. Quality and 
quantity of the DNA was assessed by spectrophotometry 
at 260/280 nm. For the methylation analysis, CpG rich re­
gions of both p73 gene promoters were identified by CpG 
island searcher (http://cpgislands.usc.edu/). For PI a target 
region upstream to exon 1 containing eight CpGs was cho­
sen, whereas for P2 a target region containing six CpGs up­
stream to the alternative 3' exon was chosen. The following 
primers were designed for pyrosequencing methylation 
analysis of PI using the Assay Design Software (Biotage, 
Uppsala, Sweden); FWD: 5'-GGTTATATTTTTTGTTTTTTG- 
GA-3', REV (biotinylated): 5'-ACCCATCnTCCTAACACC-3', 
SEQ: 5'-GTTTTTTGGATTTTAAG-3'. For the P2 promoter, 
the primers were: FWD: 5'-AGGAGTTTTGGTGGGTTTAAT- 
TAT-3', REV (biotinylated): 5'-CCCACCCCmATTCCTC-3\ 
SEQ: 5'-GGTGGGTTTAATTATGG-3'. One pg of genomic 
DNA was treated with sodium bisulfite, using the EZ DNA 
methylation Kit™ (ZymoResearch, CA, USA). Fifty nano- 
grams of bisulfite-treated genomic DNA, 5 pM of each pri­
mer and GoTaq mix (Promega, Madison, WI) were used in a 
25 pl-PCR reaction. The thermal profile was: 95 °C for 
2 min, [-94 °C for 30 s, 51 °C for 45 s at, 72 °C for 45 s] 
40 cycles, 72 °C for 10 min. Pyrosequencing was performed 
as previously described [22]. The methylation index (Mtl) 
for each promoter was calculated as the average methyla- 
tion% of the examined CpGs.
2.3. RNA extraction, cDNA synthesis and mRNA expression 
analysis by qPCR
RNA extraction was performed using the RNeasy kit 
(Qiagen, Hilden, Germany) following the manufacturer’s 
protocol and the quality and the quantity of the RNA was 
assessed by capillary electrophoresis on an Agilent 2100 
Bioanalyser (Agilent Technologies, CA, USA). For cDNA syn­
thesis, the Quantitect kit (Qiagen, Hilden, Germany) was 
used. Primers/probe designed to specifically amplify the 
TAp73 transcript were: FWD: 5' GGTTATAli 1111 - 
GTTTTTTGGA 3', REV: 5' Biotin-ACCCATCTTTCCTAACACC 
3', sequencing: 5' GM111 iGGAi 11 iAAG 3'. Primers/probe 
for ANp73 transcript were: FWD: 5'-GCCCGCATGTTCCC- 
CAG-3', REV: 5'-TTGAACTGGGCCGTGGC~3' and Probe:
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5 -FAM-TCACCGACGTACAGCATGGTAGGCG-TAMRA-3'. Each 
amplification reaction was performed using 1 pi of the 
reverse transcription reaction, 900 nM of each primer, 
250 nM probe, 1 pi of the endogenous control ACTB-V1C 
(Applied Biosystems, CA, USA) and Taqman expression 
master mix (Applied Biosystems, CA, USA) under universal 
conditions (50 °C for 2 min, 95 °C for 10 min, [94 °C for 
30 s, 60 °C for 45 s] 50 cycles, on a 7500 real time PCR sys­
tem (Applied Biosystems, CA, USA). Relative quantification 
(RQ) values were calculated using the expression of A549 
cells as a calibrator. All qPCR experiments were performed 
in triplicate from a single RNA preparation from each tu­
mour specimen.
2.4. Cell lines and in vitro experiments
CRL5802 and A549 lung cancer cell lines, obtained from 
American Type Culture Collection (Rockville, MD, USA), 
were grown in DMEM: FI2 with i-glutamine and 10% FBS. 
Cell lines were treated with 100 nM 5-aza-2'-deoxycytidine 
(Sigma-Aldrich, St. Louis, MO) alone or combined with 
100 nM Trichostatin-A (TSA) (Sigma-Aldrich, St. Louis, 
MO) for 24 h as previously described [22] and ANp73 mRNA 
expression was measured by qPCR. All qPCR experiments 
were performed in triplicate from two biological replicates 
for each condition (overall six measurements taken).
2.5. Statistical analysis
The SPSS Statistics 17.0 (SPSS Inc.) was used for statistical 
analysis. Non-parametric tests were selected, since 
Kolmogorov Smirnov test revealed that the distribution of 
each study parameter was not normal both in squamous cell 
cancer patients and in adenocarcinoma patients. The Mann- 
Whitney test was employed to examine the differences in
PI Promoter
mRNA expression levels of TAp73 RQ and the ANp73 RQ 
between the sample groups with hypermethylated and 
hypomethylated promoters, as well as between sample 
groups with different histologies. The P2 Mtl was correlated 
with LINE-1 promoter Mtl also using the Spearman correla­
tion test. The statistical significance was defined by p < 0.05.
3. Results
3.1. Methylation status of PI and P2 p73 promoters in NSCLCs
We used pyrosequencing to quantitatively determine the methylation 
levels of PI and P2 p73 promoters in NSCLC tissues, as well as in the avail­
able adjacent normal tissues. Representative pyrograms of the pyrose­
quencing assays for both promoters are given in Fig. 1 while detailed 
methylation index values for all examined specimens are provided in 
Table 1. Hypermethylation in tumours was designated at the 10% level 
as has been previously used (22]. Similarly, we set a threshold of 10% 
reduction to classify tumours as hypomethylated (22). Very low methyl­
ation levels of PI promoter were observed in normal adjacent tissues. 
Only seven tumour samples (6.8%) exceeded the 10% hypermethylation 
threshold (Table 1). The P2 promoter was heavily methylated in normal 
tissues (mean Mtl: 91 ±0.2%) while a variable degree of demethylation 
was observed in the tumour tissues. Fifty-seven (55.9%) of the examined 
tumours demonstrated P2 hypomethylation (Table 1). Simultaneous PI 
hypermethylation and P2 hypomethylation was observed in 5/102 
(4.91%) tumour samples, whereas 2/102 (0.02%) tumour samples pre­
sented only PI hypermethylation and 50/102 (49.1%) tumour samples 
presented only P2 hypomethylation.
We have also assessed global DNA methylation by examining the 
methylation levels of the LINE-1 retrotransposable element A variable 
degree of LINE-1 hypomethylation was observed in tumour tissue (mean 
Mtl 58.5% ± 0.9) as compared to the normal adjacent lung tissue (mean 
Mtl 69.5% ± 0.1. Mann-Whitney test p < 0.05). Notably, a significant asso­
ciation was observed between the DNA methylation levels of P2 and 
LINE-1 promoters (Spearman’s R - 0.340, p - 0.001).
No significant associations were observed between the methylation 
status of any of the p73 promoters or LINE-1 element and clinicopatholog- 
ical parameters, such as age, gender, T status, nodal metastasis and 
differentiation.
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Fig. 1. Representative pyrograms from the DNA methylation analysis of the PI and P2 promoters. X-axis shows the dispensation order and V-axis the 
fluorescence level. The percentage of methylation is calculated as the C/(C + T) peak ratio per CpG. The C dispensation at position 35 controls for the full 
bisulfite conversion of DNA. Normal adjacent tissue (top) demonstrates high levels of DNA methylation while lung cancer tissue (bottom) has lower levels 
of methylation.
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Table 1
mRNA expression of p73 isoforms and DNA tnethylation levels of their promoters in NSCLC specimens, in comparison to their clinicopathological parameters. 
M = male, F = female, Sq = squamous carcinoma, Ad = adenocarcinoma, ND = not determined.
Sample Clinicopathological parameters Methylation index (%) mRNA expression (RCL value)
Gender Histology Differentiation T
status
N
status
PI
tumour
P2
tumour
P2
normal
LINE-1
tumour
TAp73 RQ 
tumour
ANp73 RQ 
tumour
1 M Sq Moderate 2 0 4.23 58.43 91.2 45.5 1.12 0.46
2 M Sq Good 2 1 5.00 93.79 ND 70.5 0.18 0.00
3 M Sq Moderate 2 1 2.85 63.83 90.7 64.8 0.42 0.45
4 M Sq Moderate 2 0 7.34 88.04 91.3 66.5 0.22 0.28
5 M Sq Poor 2 1 4.24 47.13 ND 53.0 0.62 0.04
6 M Sq Moderate 3 1 6.04 68.41 89.7 51.2 0.46 0.07
7 M Ad Poor 2 0 3.29 92.06 92.8 58.3 1.08 0.16
8 F Ad Moderate 2 1 2.72 90.74 ND 64.1 0.15 0.00
9 F Ad Moderate 2 0 46.89 56.02 ND 58.4 0.06 0.00
10 M Ad Poor 2 1 15.85 48,24 ND 40.6 0.03 0.00
11 M Sq Moderate 2 1 0.47 69.51 92.6 60.0 0.07 0.19
12 M Ad Poor 2 2 5.18 93.30 92.1 67.7 0.98 0.07
13 M Sq Moderate 2 1 6.82 92.93 91.4 43.1 ND ND
14 M Sq Poor 2 1 3.39 47.39 ND 50.1 0.41 2.30
15 F Ad Poor 2 2 5.65 60.56 92.7 49.8 0.41 0.08
16 F Sq Poor 2 1 10.12 60.78 92.3 58.8 0.12 0.04
17 F Ad Moderate 2 0 6.15 60.19 92.4 ND 0.30 0,99
18 F Ad Moderate 2 0 3.83 94.12 91,9 64.2 0.33 0.03
19 M Sq Moderate 2 0 4.07 80.68 90.1 50.2 0.26 0.00
20 M Sq Moderate 2 0 3.41 59.79 91 55.0 3.18 15.89
21 M Sq Moderate 2 1 2.66 54.28 92.5 45.9 0.75 0.22
22 M Ad Moderate 3 0 6.11 75.18 ND 69.2 0.24 0.06
23 M Sq Poor 3 1 3.98 90.91 ND 58.2 0.10 0.00
24 F Ad Moderate 2 0 1.83 84.06 ND 66.9 0.77 0.26
25 F Ad Moderate 2 0 4.03 91.88 ND 41.5 ND ND
26 M Ad Poor 2 0 2.46 45.98 ND 64.3 0.12 0.47
27 M Sq Poor 2 1 3.48 86.93 91 58.9 0.91 0.39
28 M Sq Good 3 1 3.03 62.32 ND 53.7 0.55 0.13
29 F Ad Moderate 1 0 3.18 61.49 ND 69.1 0.26 0.29
30 M Sq Moderate 2 1 5.95 94.37 ND 22.9 0.28 0.04
31 F Sq Moderate 2 1 0.30 12.77 ND 63.9 0,42 9.99
32 F Ad Moderate 2 0 2.68 54.50 92.2 52.7 0.48 0.07
33 M Ad Poor 2 1 2.66 93.08 ND 62.0 0.11 0.00
34 M Sq Moderate 2 0 0.59 72.05 ND 50.4 1.44 0.23
35 F Ad Poor 2 2 7.65 54.47 90.2 57.4 0.25 0.10
36 M Sq Moderate 2 2 3.32 94.75 90.9 44.1 1.67 0.00
37 M Ad Poor 2 0 4.78 52.23 ND 50.5 0.29 0.08
38 F Ad Poor 3 0 5.05 61.82 ND 33.1 0.93 0.88
39 F Ad Poor 2 2 4.14 36.43 91.3 67.0 0.06 0.00
40 M Ad Poor 2 1 3.43 94.46 93.3 60.8 0.11 0.00
41 M Sq Moderate 4 2 5.13 92.77 ND 43.1 0.15 0.00
42 M Sq Moderate 2 1 2.83 50.72 ND 43.4 1.00 0.65
43 M Ad Poor 2 0 2.50 52.29 90.3 68.0 0.32 0.32
44 F Ad Poor 2 2 2.45 93.00 93.3 64.6 0.25 0.07
45 F Ad Poor 2 0 2,56 92.48 91.4 63.1 0.42 0.00
46 M Sq Moderate 2 1 6.53 71.60 ND 44.6 0.23 ND
47 F Sq Moderate 2 1 7.19 29.01 ND ND 0.18 0.00
48 M Sq Moderate 2 0 3.05 62.68 91 51.2 0.28 0.41
49 F Ad Moderate 2 1 3.29 62.20 85.8 64.2 3.03 9.71
50 M Sq Poor 3 1 2.81 90.59 92.2 68.9 1.00 0.02
51 F Sq Poor 2 0 3.86 75.91 ND 58.9 2.97 0.77
52 M Ad Poor 2 1 3.04 65.23 93.5 56.8 1.35 1.04
53 F Sq Nd 2 0 4.73 72.00 ND 67.0 0.02 0.00
54 F Ad Poor 2 2 4.86 93.75 ND 66.1 0.09 0.00
55 M Ad Moderate 2 2 3.24 71.38 90.6 64.0 0.90 0.45
56 M Ad Poor 1 0 28.04 67.58 ND 47.1 0.09 0.00
57 M Sq Moderate 2 0 6.59 89.25 92.2 60.3 0.13 0.02
58 F Sq Moderate 2 0 3.05 49.05 91.6 52.3 0.42 0.29
59 F Sq Moderate 1 0 3.99 71.49 ND 58.5 0.31 0.04
60 F Ad Poor 2 1 3.96 75.82 90.3 ND 0.08 0.54
61 M Ad Poor 1 0 3.25 52.69 90 47.4 1.16 2,10
62 M Ad Good 2 0 5.49 92.53 91.2 ND 0.19 0.00
63 M Ad Poor 2 0 4.69 80.36 ND 67.9 0.33 0.44
64 F Ad Poor 1 0 5,10 91.42 ND 55.9 0.47 0,00
65 F Ad Moderate 2 2 4.18 88.41 ND 66.3 0.55 0.30
66 F Sq Moderate 2 0 3.42 59.23 90.9 64.1 0.96 0.01
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Table 1 (continued)
Sample Clinicopathological parameters Methylation index (%) mRNA expression (RQ value)
Gender Histology Differentiation T
status
N
status
PI
tumour
P2
tumour
P2
normal
LINE-1
tumour
TAp73 RQ 
tumour
ANp73 RQ 
tumour
67 M Ad Moderate 2 0 2.97 94.42 91.3 69.1 0.29 0.00
68 M Ad Moderate 2 1 4.77 93.29 ND ND 0.07 0.00
69 M Ad Moderate 2 1 5.13 91.35 ND 63.8 0.31 0.39
70 F Sq Moderate 2 0 3.36 81.21 92.5 60.1 2.48 1.10
71 F Sq Moderate 2 2 3.45 88.46 91.7 64.6 0.10 0.00
72 M Sq Poor 2 0 5.53 93.60 ND 63.0 0.10 0.00
73 F Ad Poor 2 1 4.98 91.71 ND 64.9 0.38 0.58
74 M Ad Moderate 2 0 5.51 93.93 ND 68.0 0.15 0.00
75 M Sq Moderate 3 0 4.22 92.25 ND 64.7 0.15 0.13
76 M Ad Poor 2 0 32.06 84.48 ND 45.2 0.05 0.00
77 F Ad Good 1 0 5.81 94.16 ND 61.1 0.02 0.00
78 F Sq Moderate 2 0 4.93 94.14 ND 71.0 0.07 0.00
79 F Sq Moderate 2 0 4.64 79.34 ND 65.8 0.88 1.46
80 M Ad Moderate 2 1 7.81 91.28 ND 67.3 0.04 0.00
81 F Sq Moderate 2 1 3.74 72.74 ND 67.0 0.14 0.04
82 F Sq Poor 1 2 5.71 93.93 ND 66.4 0.28 0.01
83 M Sq Poor 2 0 6.89 47.57 ND 60.2 0.48 0.05
84 M Ad Poor 4 1 6.99 91.45 ND 66.1 0.04 0.00
85 M Ad Moderate 4 0 3.79 91.49 ND 67.7 0.06 0.11
86 F Ad Moderate 1 1 4.38 89.66 ND 68.6 0.55 0.41
87 M Sq Moderate 2 0 5.31 75.11 ND 58.8 0.24 0.06
88 M Sq Moderate 2 2 3.37 66.26 ND 45.5 0.22 0.13
89 M Ad Moderate 4 0 4.66 92.56 ND 65.4 0.07 0.00
90 F Ad Moderate 1 0 14.12 91.57 ND 67.4 0.09 0.00
91 F Ad Poor 1 0 2.72 53.84 ND 51.9 0.73 1.69
92 M Sq Poor 2 1 3.46 92.96 ND 68.4 0.06 0.00
93 F Ad Moderate 2 0 2.97 72.49 ND 65.9 0.43 0.14
94 F Ad Moderate 3 2 3.95 92.46 ND 60.9 0.02 0.02
95 M Sq Poor 2 2 10.77 89.74 ND 59.2 0.10 0.00
96 F Ad Moderate 2 0 5.29 92.22 ND 66.7 0.09 0.00
97 F Sq Moderate 3 2 3.17 65.56 ND 50.0 0.41 0.10
98 M Ad Poor 2 0 5.05 81.15 ND 67.9 1.06 0.04
99 F Sq Poor 2 1 7.76 92.51 ND 61.9 0.18 0.00
100 F Ad Moderate 2 2 8.73 93.31 ND 57.9 0.05 0.01
101 F Sq Moderate 2 0 3.34 60.62 ND 44.4 0.27 0.08
102 M Sq Poor 3 1 4.09 64.67 ND 55.6 0.25 0.04
PI promoter P2 promoter
Fig. 2. (A) Box plot representation of the distribution of TAp73 RQ values in lung cancer tissues bearing an unmethylated PI promoter versus lung cancer 
tissues bearing a hypermethylated PI promoter. (B) Box plot representation of the distribution of ANp73 RQ values in lung cancer tissues bearing a 
methylated P2 promoter versus lung cancer tissues bearing a hypomethylated P2 promoter. Stars and circles in the plot indicate outliers.
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Fig. 3. ANp73 expression analysis in lung cancer cell lines treated with 
5'-aza-2'-deoxycytidine (AZA) and trichostatin (TSA). The addition of 
compounds separately triggers the over-expression of ANp73 in both cell 
lines while an additive effect is profound in CRL5802 cells. ANp73 mRNA 
expression (V-axis) is given as relative quantification (RQ) values in 
logarithmic scale. For each cell line, the untreated control was used as 
calibrator, thus the control expression is set to 1.
3.2. TAp73 and ANp73 mRNA levels correlated to the methylation status of 
their corresponding promoters
The TAp73 and ANp73 mRNA levels were measured in primary 
NSCLCs by qPCR. Particular attention was given experimentally to ensure 
the use of primers that amplify only the ANp73 transcripts and none of 
PI-derived p73Aex2, p73Aex2/3 and AN'-p73 transcripts. We subse­
quently analyzed the TAp73 expression comparatively to the DNA meth­
ylation levels of PI promoter in the panel of tumour samples. The mRNA 
expression in the seven samples bearing a hypermethylated PI promoter 
was significantly lower to that of the sample group with an unmethylated 
PI promoter (Fig. 2). However, the correlation between the ANp73 mRNA 
expression and the methylation levels of the P2 promoter was more pro­
found (Mann-Whitney test, p-1.1 x 10-7), with ANp73 mRNA levels 
being significantly higher in the tumours with a hypomethylated P2 pro­
moter (Fig. 2). No other association was observed between TAp73 or 
ANp73 mRNA expression and any of the clinicopathological parameters 
of the examined specimens.
In order to further validate the impact of P2 hypomethylation on ANp73 
expression, we monitored the effect of epigenetic modifiers on ANp73 
mRNA levels in vitro by treating one adenocarcinoma lung cancer cell line 
(A549) and one squamous cell carcinoma lung cancer cell line (CRL5802) 
with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (AZA) 
and the histone deacetylase inhibitor trichostatin-A (TSA). Both cell lines 
bear a methylated P2 promoter, whereas methylation levels of PI promoter 
are very low (data not shown). ANp73 mRNA expression was increased 
upon treatment, while an additive effect of the two compounds was ob­
served in both cell lines. Strikingly, treatment with 5-aza-2'-deoxycytidine 
alone increased ANp73 levels as much as 100-fold in A549 cell line (Fig. 3).
3.3. Hypomethylation-induced ANp73 over-expression is more profound in 
squamous cell carcinomas than in adenocarcinomas
As shown in Fig. 4, P2 methylation levels were markedly lower in 
squamous cell carcinomas (mean Mtl: 68* ± 2.5) in comparison with ade­
nocarcinomas (mean Mtl: 83% ±3.0, Mann-Whitney test U - 655.50,
p < 0.05). Consistently, ANp73 mRNA expression was higher in squamous 
carcinomas (mean RQ= 0.98 ±0.41) than in adenocarcinomas (mean 
RQ-0.19 ±0.05, Mann-Whitney test, p-0.006). The methylation levels 
were significantly correlated to ANp73 mRNA levels both in adenocarci­
nomas (Spearman's R - -0.373, p = 0.008) and in squamous cell carcino­
mas (Spearman's R - -0.425, p - 0.002). Importantly, this correlation 
was more intense in squamous cell carcinomas compared to adenocarci­
nomas. Thus, higher P2 methylation levels in adenocarcinomas result to 
lower ANp73 mRNA levels whereas lower P2 methylation levels in squa­
mous cell carcinomas correspond to higher ANp73 mRNA levels (Fig. 4). 
In contrast, no differences were observed in PI methylation levels be­
tween squamous cell carcinomas and adenocarcinomas (Mann-Whitney 
test U-1112.00, p-0.212) although a borderline difference of TAp73 
mRNA levels was observed between squamous cell carcinomas (mean 
RQ= 0.57 ±0.1) and adenocarcinomas (mean RQ-0.4±0.07) (Mann- 
Whitney test U - 957.50, p - 0.044). Therefore, inter-histological differ­
ences exist for both ANp73 and TAp73 mRNA levels, but only ANp73 
mRNA levels are consistent with corresponding differences in the P2 
methylation levels.
4. Discussion
In this study we demonstrated that PI promoter of the 
p73 gene is rarely hypermethylated (6.8%) in NSCLCs 
whereas the P2 promoter is often hypomethylated 
(55.9%). This epigenetic deregulation is, linked with de­
creased TAp73 mRNA levels and increased ANp73 mRNA 
levels, respectively. Treatment of lung cancer cell lines 
with epigenetic modifiers confirmed the epigenetic induc­
tion of ANp73 transcription in vitro. Notably, P2 hypome­
thylation was associated with LINE-1 hypomethylation, 
an indicator of global methylation. We also demonstrated 
a tissue type specific difference in the hypomethylation- 
linked induction of ANp73 mRNA levels. TAp73 mRNA lev­
els are also more increased in squamous cell carcinomas, 
however independently from inter-histological differences 
in the PI methylation levels.
In agreement with Di Vinci et al., PI promoter is essen­
tially unmethylated in normal tissues and its methylation 
levels remain invariably low in the majority of the tumour 
samples. Only a few tumour samples bear a hypermethy­
lated PI promoter in conjunction with lower TAp73 
expression when compared to the TAp73 expression of 
the unmethylated tumour samples ([19] and this study). 
Since PI promoter remains unmethylated in the majority 
of tumour tissues, TAp73 expression cannot be prevented, 
provided that specific transcription factors are present 
within the nucleus. Indeed, recently it has been shown that 
TAp73 isoforms are overexpressed in response to over­
expression of Spl transcription factor, which directly acti­
vates PI promoter in lung cancer [23], Therefore, changes 
in the levels of transcription factors seem to mainly dereg­
ulate PI promoter control, whereas the infrequent methyl­
ation of PI promoter does not pose as a major determinant 
of TAp73 deregulation in lung cancer.
The P2 promoter which was generally heavily methyl­
ated in normal lung tissues was found partially demethylat- 
ed in the tumour samples in a percentage slightly lower 
than the one previously determined by methylation- 
specific PCR [19]. It is of note that although methylation 
levels were significantly correlated to the ANp73 mRNA 
expression, a clear association between the methylation 
status of P2 promoter and the ANp73 protein levels could 
not be established in NSCLC tissues examined previously
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Fig. 4. Hypomethylation of P2 promoter is more profound in squamous cell carcinomas than adenocarcinomas (A). This is directly reflected in the ANp73 
transcript levels which are higher in squamous carcinomas than adenocarcinomas (B). Histograms represent mean values and error bars are indicative of 
the standard error of the mean.
[191. This discrepancy could possibly be attributed to 
the fact that commercially available ANp73-specific anti­
bodies inevitably detect not only the translational product 
of the P2-derived AN transcript, but also the translational 
product of the Pl-derived AN' transcript, which is identical 
to the ANp73 protein [6]. Indeed, Pl-derived AN' tran­
scripts have been reported to be expressed in lung cancer 
tumours used in the abovementioned study [19]. In con­
trast, quantitative RT-PCR assays detect products arising 
exclusively from P2 promoter and, therefore, they provide 
a more accurate means of estimating sheer P2 transcrip­
tional activity, unbiased by PI transcriptional activity. An­
other reason of inconsistent results between studies based 
on qualitative (methylation-specific PCR) versus quantita­
tive methylation methods (pyrosequencing) could be 
mis-priming of methylation-specific PCR, which subse­
quently yields false positive results in up to 10% frequency, 
in assays combining small amounts of DNA input and high 
numbers of PCR cycles. Methylation enrichment pyrose­
quencing used herein overcomes these technical limita­
tions and provides a higher degree of sensitivity in 
estimating methylation status, whenever clinical samples 
with low DNA concentrations are used [24].
Both TAp73 and ANp73 mRNA levels demonstrated sig­
nificant inter-histological differences, but only ANp73 
mRNA levels were dependent on the methylation levels 
of the corresponding promoter. Importantly, ANp73 
expression has been previously shown to predict poor 
prognosis in lung cancer, with squamous cell carcinoma 
patients presenting lower 5-year survival rates in compar­
ison with adenocarcinoma patients [25,26]. Thus, elevated 
ANp73 mRNA levels, consistent with lower P2 methylation 
levels in squamous cell lung cancer patients, may contrib­
ute, among other discrete molecular changes, to the poorer 
prognosis of this histological group in comparison to lung 
adenocarcinoma patients. In addition, the correlation of 
P2 promoter hypomethylation with LINE-1 hypomethyla­
tion, an accepted measure of global DNA methylation sta­
tus [21,22], suggests that this reduction of P2 
methylation levels is a passive consequence of global
hypomethylation, which is more frequent in squamous cell 
carcinomas comparatively to adenocarcinomas [22,27]. In 
contrast, differences in TAp73 mRNA expression between 
distinct histological lung cancer types might be attributed 
to tissue type-related differences in the levels of specific 
transcription factors that activate PI promoter.
Collectively, the above data suggest that epigenetic 
events might be crucial for the deregulation of P2 activity, 
whereas transcriptional events seem to be mainly impli­
cated to deregulation of PI activity in lung cancer [23]. 
ANp73 mRNA expression appears to be restrained by strict 
epigenetic control of P2 promoter in the normal lung cell. 
Once deregulated, specific transcription factor(s) have the 
opportunity to approach P2 promoter, therefore enhancing 
transcription of the anti-apoptotic ANp73 isoforms and 
possibly favoring oncogenic activities within the cell. In 
contrast, epigenetic control is looser in the case of PI pro­
moter and the synthesis of its corresponding products 
seems to be deregulated only upon presence of excess 
amounts of specific transcription factors.
In addition, the fact that P2 hypomethylation is mark­
edly more frequent than PI hypermethylation in lung can­
cer samples suggests that the resulting over-expression of 
the anti-apoptotic ANp73 contributes in a much greater 
extent to oncogenesis as compared to the under-expres­
sion of the apoptotic TAp73. Considering the strict epige­
netic inhibition of ANp73 transcription in the normal 
lung cell, the question if increase of ANp73 rather than 
alterations of TAp73 may determine the ultimate effect of 
p73 in lung carcinogenesis should be addressed in future 
studies. As demethylating agents are now entering lung 
cancer trials, it is imperative to gain a greater insight into 
the potential reactivation of oncogenic ANp73 in order to 
evaluate the risk of the usage of these agents in anti-cancer 
treatment and to advance for the clinical utilization of epi- 
genetics in cancer therapy.
Our study also provides hints of a differential rather 
than opposing mode of regulation of p73 promoters in lung 
tissues. In case that the modes of regulation of PI and P2 
promoters do present a non-yin-yang relationship, they
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could offer a certain degree of freedom in the synthesis of 
their corresponding products in specific tissues, thus 
allowing their participation in distinct functions. This no­
tion is further supported by the fact that TAp73 and 
ANp73 isoforms present not only strictly counteracting 
functions, i.e. TAp73 apoptotic activities versus ANp73 
anti-apoptotic activities [3], but also unique, independent 
functions especially in developmental processes, in which 
p73 gene is primarily implicated. For instance, ANp73 is 
essential for normal ventricular size and cortical thickness 
during neurogenesis in ANp73-/~ mice, whereas lack of 
TAp73 does not influence these parameters in TAp73-/- 
mice [28]. The investigation of this hypothesis in the future 
would set more light on the range of functions and the 
interplay of the p73 isoforms.
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Hypomethylation of retrotransposable elements correlates with genomic instability 
in non-small cell lung cancer
Alexandres Daskalos1, Georgios Nikolaidis1, George Xinarianos1, Paraskevi Savvari2, Adrian Cassidy1, Roubini Zakopoulou1’2, 
Athanasios Kotsinas2, Yassilis Gorgoulis2, John K. Field1 and Triantafilios Liloglou’* 
iRoy Castle Lung Cancer Research Programme, The University of Liverpool, School of Cancer Studies, Liverpool, United Kingdom 
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LINE-1 and Ain elements are non-LTR retrotransposons, consti­
tuting together over 30% of the human genome and they are fre­
quently hypomethylated in human tumors. A relationship between 
global hypomethylation and genomic instability has been shown, 
however, there is iittic evidence to suggest active role for hypomc- 
thylation-mediated reactivation of retroetements in human cancer. 
In our study, we examined by Pyrosequencing the methylation lev­
els of LINE-1 and Ain sequences in 48 primary nonsmall cell car­
cinomas and their paired adjacent tissues. We demonstrate a sig­
nificant reduction of the methylation levels of both elements (p = 
7.7 x 10 14 and 9.6 x 10-7, respectively). The methylation indices 
of the 2 elements correlated (p = 0.006), suggesting a possible 
common mechanism for their methylation maintenance. Genomic 
instability was measured utilizing 11 fluorescent microsatcliitc 
markers located on lung cancer hot-spot regions such as 3p, 5q 9p, 
13q and 17p. Hypomethylation of both transposable elements was 
associated with increased genomic instability (LINE, p ~ 7,1 X 
10-5; Alu, p = 0.008). The reduction of the methylation index of 
LINE-1 and Alu following treatment of 3 lung cell lines with 5- 
aza-2'-deoxycitidine, consistently resulted in Increased expression 
of both elements. Our study demonstrates the strong link between 
hypomethylation of transposable elements with genomic instabil­
ity in non-small cell lung cancer and provides early evidence for a 
potential active role of these elements in lung neoplasia. As deme- 
thylating agents are now entering lung cancer trials, it is impera­
tive to gain a greater insight into the potential reactivation of 
silent retrotransposons in order to advance for the clinical utiliza­
tion of epigenetics in cancer therapy,
© 2008 Wiley-Liss, Inc.
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LINE-1 elements are autonomous non-LTR retrotransposons 
comprising almost 21% of the human genome.1 Although most of 
these elements are inactive, mostly due to 5' truncations, there are 
a number of 80-100 intact LINE-1 elements that remain capable 
of rctrotransposition.2’3 The full length human LINE-1 retrotrans- 
poson is about 6 kb consisting of a 5' UTR, two open reading 
frames (ORF 1 and ORF2), and a 3' UTR with a functional poly- 
adenylation signal and a variable length poly-A tail.1 The bicis- 
tronic mRNA of LINE-1 is generated by an internal promoter at 
the 5' UTR region. ORFi encodes for p40, a 40 kDa RNA-binding 
protein with cis preference for LINE-1 RNA, while ORF2 encodes 
for a 150 kDa protein with 3 conserved domains.4 LINE-1 retro- 
transposition is undertaken with the help of both ORFI and ORF2 
proteins through a target-primed reverse transcription mechanism 
(TPRT).2
In nonnal human cells, transcription and rctrotransposition of 
LINE-1 is suppressed by a variety of control mechanisms includ­
ing methylation, siRNAs and transcription regulators.4"6 As a 
result, cells manage to protect themselves from a number of 
adverse effects exerted by LINE-1 activity. LINE-1 retrotransposi- 
tion events elicit enhanced illegitimate and homologous recombi­
nation,2,7 genomic deletions,8 chromosome breaks and transloca­
tions9 leading to enhanced genomic instability of the cell.10 In 
addition, successful rctrotransposition events may change the ac­
tivity of genes at the insertion sites, either by inducing or reducing 
their transcription, or by generating alternative transcripts.7
Tire Alu element, the most prevalent human SINE, is another 
retrotransposon which, like LINE-1, can retrotranspose promoting
chromosomal rearrangements, inserdons/deletions and unequal 
recombination.4 A typical Alu element stretches over about 
300 bp and has an internal promoter. It is not known to encode a 
protein product, thus it is in need of other retrotransposons’ 
machinery to undertake transposition. It is mainly suggested that 
LINE-1 facilitates Alu element rctrotransposition.4. As with 
LINE-1, Alu’s activity in the nonnal cells is inhibited mostly 
through methylation of its sequence.10,12
Two phenomenically contradicting epigenetic events coexist in 
cancer, namely global hypomethylation of DNA, mainly associ­
ated with repeated DNA and hypennethylation in nonrepeat DNA 
stretches, frequently associated with gene promoter sequences.7,13 
Indeed, LINE-1 sequences are found to be hypomethylated in a 
large number of human cancers including colorectal, prostate, 
lung, bladder, teratocarcinoma, renal and gastric cancer suggesting 
potential activation in these cancers.7,13-17 Although less 
studied, Alu element hypomethylation in cancer has been also 
reported.16,18-20 Of note is the fact that in ovarian tumors this 
global DNA hypomethylation cannot be attributed to differential 
mRNA expression of any particular DNMT gene or isoform.20
Taking the above observations under consideration, one could 
hypothesize that reactivation of LINE-1 and Alu elements in nor­
mal cells through hypomethylation could potentially induce 
genomic instability, thus introducing cells into a precancerous 
state. Animal studies demonstrate that genome wide hypomethyla­
tion induces genomic instability and tumors.21,22 However, these 
findings have not been directly connected to retrotransposition. In 
addition, LINE-1 retrotransposition was shown to induce DNA 
damage and apoptosis in a breast cancer cell line.23
Lung cancer is a major cause of cancer-related death. Numerous 
molecular abnormalities have associated with the development of 
the disease including extensive epigenetic deregulation events.24 
So far, a large number of hypermethylated and hypomethylated 
genes have been reported in primary lung cancers,23--8
To date, there is evidence linking global hypomethylation in 
human cancer with genomic instability. However, it remains ques­
tionable whether LINE and Alu elements are actively mediating 
this process. In our study we examine the methylation status of the 
LINE-1.2 and Alu-PV elements in a set of nonsmall cell lung car­
cinomas (NSCLCs) comparatively to genomic instability. In addi­
tion, we assess the epigenetic control potential on the expression 
levels of both elements in lung cell lines by treating these with a 
demethylating agent and a histone deacetylase inhibitor.
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LINE, long interspersed nucleotide elements; LOH, loss of heterozygosity; 
LTR, long temiinal repeat; NSCLC, nonsmall cell lung cancer, ORF, open 
reading frame; SINE, short interspersed nucleotide elements; TSA, trichos- 
tatin A.
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Figure 1 - Representative pyrograms of the LINE-1 and Alu sequences examined in our study, (a) LINE-1; adjacent normal, (b) LINE-1; 
lung tumor, (c) Alu; adjacent normal, (d) Alu; lung tumor. The percentages in boxes indicate the individual CpGs methylation values. The meth- 
ylation index (Mtl) is calculated as the average values of the examined CpGs.
Material and methods
Human tissues and cell lines
Forty-eight NSCLCs (24 adenocarcinomas and 24 squamous 
carcinomas) and adjacent normal tissues were collected from 
patients undergoing surgery at Broadgreen Cardiothoracic Centre 
(Liverpool, UK). Twenty-six (54%) patients were male. Age 
ranged between 46 and 80 years (mean = 64). All specimens were 
of advanced stage (43 T2. 4 T3 and 1 T4). The study protocol was 
approved by the Liverpool Ethics Committee and all patients pro­
vided written, informed consent in accordance with the Declara­
tion of Helsinki. Nine cell lines of lung cancer origin were studied 
in parallel: CRL5802, SKMES (squamous), A549. SKLU1, 
CALU 3, CRL 5935 (adenocarcinoma). DMS 53 (small cell) 
CORL 23 (large cell), CALU 6 (anaplastic carcinoma). Cells were 
grown in DMEM: F12 with L-glutamine and 10% FBS. In addition 
one immortalized, nontumorigenic lung epithelial cell line 
(HBEC3KT—kindly donated by A. Gazdar) and a commercially 
available normal epithelial cell line (NHBE, Lonza, Basel, Swit­
zerland) were analyzed. These cell lines were grown in Keratino- 
cyte serum-free medium (Invitrogen) supplemented with EGF and 
pituitary extract (Invitrogen). All cells were grown at 37°C supple­
mented with 5% COi.
For the DNA methylation/histone acetylation inhibition experi­
ments, we treated cell lines with 100 nM 5-aza-2'-deoxycytidine 
(Decitabine; Sigma-Aldrich, cat nol 1390) or 100 nM Trichostatin 
A (TSA, Sigma-Aldrich, Dorset, UK) cat no T8552) and a combi­
nation of both compounds. Cells were treated with decitabine for 
2 cell duplications, with medium and fresh decitabine being 
replenished daily. TSA was added and were applicable for the last 
16 hr before harvesting cells. All observations were confirmed by 
duplicate experiments at both the technical and biological level.
DNA, RNA extraction and cDNA synthesis
For the DNA extraction 20 pm X 40 pm sections were cut from 
frozen tissue. The first and last sections underwent pathological
review to ensure at least 80% tumor cell content. DNA extraction 
of the samples and cell lines was performed using the DNeasy kit 
(Qiagen, West Sussex, UK) following the manufacturer’s proto­
col. Quality and quantity of the DNA was assessed by spectropho­
tometry at 260/280 nm. RNA from cell lines was extracted using 
the RNeasy kit (DNAse digest protocol, Qiagen, West Sussex, 
UK) following the manufacturer’s protocol. Quality and quantity 
of the RNA was assessed by capillary electrophoresis on an Agi­
lent 2100 Bioanalyser (Agilent Technologies). cDNA was pre­
pared from 1 pg RNA using the Quantitect kit (Qiagen, West Sus­
sex, UK), which includes an initial genomic DNA elimination step 
eliminating thus the possibility of genomic DNA carry over into 
the cDNA preparation.
DNA methylation analysis
For the methylation analysis of the LINE-1.2 (Genebank acces­
sion no M80343) and the Alu-PV (Genebank accession no 
Z49816) elements, 1 pg of genomic DNA was treated with sodium 
bisulfite, using the EZ DNA methylation KitINI (ZymoResearch) 
following the manufacturer’s protocol. For the LINE-1.2 element 
a target region inside the CpG-rich region of the 5' internal pro­
moter including 6 CpGs was chosen, whereas for the Alu PV ele­
ment we selected a target CpG-rich region near its 3' end encom­
passing 4 CpG sites. All primers were designed using the Assay 
Design Software (Biotage, Uppsala, Sweden) and synthesized by 
MWG (Germany): LINE-1 fwd: 5'-BIO-TAG GGA GTG TTA 
GAT ACT GG-3', LINE-1 rev: 5'-AAC TCC CTA ACC CCT 
TAC-3\ LINE-1 seq 5'-CAA ATA AAA CAA TAC CTC-3'. Alu 
fwd: 5'-GAG GTT GAG GTA GGA GAA-3', Alu rev: 5'-BIO- 
CCC AAA CTA AAA TAC AAT AAC-3\ Alu seq: 5'-GTT GAG 
GTA GGA GAA-3'. PCR amplifications were performed using 
Qiagen HotStarTaq Master Mix Kit, (5 pM biotinylated primer. 
10 pM nonbiotinylated primer and 3 pi (~60 ng) bisulfite-treated 
DNA. Thermal profiles were as follows: 95°C for 5 min followed 
by 40 cycles of 94°C for 30 sec, 58°C (LINE-1) or 49°C (Alu) for
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TABLE I - CLINICAL SAMPLES OF THE UTILIZED COHORT AND RESULTS FOR LINE-1 AND Am METHYLATION AND GENOMIC INSTABILITY (FAL)
Sample Gender Age Diagnosis
Methylation index (%) FAL
LINE-t normal LINE-1 tumor Alu normal Alu tumor
1 F 74 AdenoCa 70.3 61.3 53.3 52.7 0.455
2 M 68 AdenoCa 69.7 58.0 55.0 53.2 0.857
3 F 50 AdenoCa 69.1 56.3 50.6 53.9 0.857
4 M 52 AdenoCa 69.6 65.6 57.4 54.1 0.375
5 F 68 AdenoCa 69.7 64.7 56.6 60.0 0.400
6 F 74 AdenoCa 69.4 47.0 56.6 55.0 0.625
7 F 67 AdenoCa 69.3 67.8 53.5 54.0 0.500
8 F 53 AdenoCa 70.0 60,8 58.2 52.8 0.778
9 F 73 AdenoCa 70.6 67.6 56,7 55.7 0.000
10 F 58 AdenoCa 70.2 54.0 58.4 55.2 1.000
11 M 74 AdenoCa 69.8 48.4 60.3 51.8 0,909
12 F 69 AdenoCa 69.6 34.8 59.0 56.5 1.000
13 M 63 AdenoCa 69.3 47.2 56.7 51.6 0.900
14 F 64 AdenoCa 69.8 51.3 56.2 50.7 0.889
15 F 66 AdenoCa 70.0 68.8 56.6 56.6 0.000
16 F 61 AdenoCa 68.3 57.4 58.8 55.7 0.600
17 M 67 AdenoCa 70.2 69.4 55.9 60.5 0.143
18 M 65 AdenoCa 69.3 62.4 58.8 52.2 1.000
19 F 68 AdenoCa 68.4 59.2 56.0 52.8 0.889
20 F 69 AdenoCa 69.5 52.2 ND ND 0.818
21 F 77 AdenoCa 69.7 54.5 55.7 54.3 1.000
22 F 53 AdenoCa 69.1 59.3 54.8 53.1 0.556
23 F 67 AdenoCa 68.1 52.1 56.9 48.6 0.500
24 F 45 SqCCL 69.4 66.8 55.3 53.4 0.250
25 M 62 SqCCL 69,7 30.9 56.4 46.3 0.833
26 M 68 SqCCL 69.9 70.3 58.7 54,5 0.000
27 M 78 SqCCL 67.1 48.2 58.7 59.9 0.556
28 M 68 SqCCL 70.8 41.5 58.8 54.1 0.375
29 M 60 SqCCL 70.2 62.7 53.4 52.4 0.333
30 M 62 SqCCL 69.5 40.8 59.9 51.7 0.556
31 M 60 SqCCL 70.3 43.9 58.2 52.2 0.636
32 M 70 SqCCL 69.6 63.1 56.5 54.4 1.000
33 F 70 SqCCL 69.6 40.0 55.4 51.2 0.900
34 M 83 SqCCL 69.6 49.8 56.4 53.8 0.900
35 M 83 SqCCL 70.5 56.8 56.5 48.8 1.000
36 M 66 SqCCL 68.3 41.0 60.6 47.6 1.000
37 M 65 SqCCL 70.4 50.5 53.0 55.9 1.000
38 M 58 SqCCL 69.0 48.2 55.6 51.8 0.714
39 M 66 SqCCL 70.1 60.3 57.2 53.4 0.182
40 M 72 SqCCL 69.8 61.9 62.5 54.9 0.300
41 F 66 SqCCL 68.8 57.1 53.9 50.9 0.667
42 M 47 SqCCL 69.4 38.6 55.7 53.4 0.700
43 M 69 SqCCL 70.3 66.4 57.2 54.1 0.636
44 M 68 SqCCL 73.5 67.7 55.2 55.1 0.100
45 F 48 SqCCL ND ND 56.6 57.5 0.182
46 M 63 SqCCL 65.4 34.6 55.6 52.6 0.714
47 F 71 SqCCL 69.1 41.6 54.4 53.7 0.778
48 F 69 SqCCL 70.1 52.1 ND ND 0.667
45 sec and 72°C for 45 sec and a final extension step at 72°C for 
10 rain. The quality and quantity of the PCR product was con­
firmed by agarose gel (2%) electrophoresis before the clean up 
and Pyrosequencing analysis. For the latter, the SQA kit was used 
following the suppliers protocol {Biotage, Uppsala, Sweden) and 
the reaction was performed on a 96MA Pyrosequencer (Biotage, 
Uppsala, Sweden). The raethylation index for the LINE-1 and Alu 
elements was calculated as the mean value of raC/(mC + C) for 
all examined CpGs in the elements.
qPCR expression assay
To investigate the expression status of the LINE-1 and Alu-PV 
elements in our cell lines, qPCR (real time) assays were designed 
using the Primer Express software (Applied Biosysteras, Warring­
ton, UK): LINE-1 fwd 5'-GAG AGG ATG CGG AGA AAT AGG 
A-3', LINE-1 rev 5'-GGA TGG CTG GGT CAA ATG GT-3' and 
LINE-1 probe 5'-FAM-CAA CCA TTG TGG AAG TCA GTG 
TGG CG-TAMRA-3'; Alu-PV fwd 5'-GAG GCG GGC GGA 
TCA C-3', Alu-PV rev 5'-GTT TCA CCG TTT TAG CCA GGA 
T-3' and Alu-PV probe 5'-FAM-AGG TCA GGA GAT CGA G- 
TAMR A-3'. Assays were performed in a final reaction volume of
20 pi containing 10 pi Taqman expression master mix, 900 nM of 
each primer and 250 nM probe, 1 pi of the endogenous control 
ACTB-VIC (Applied Biosystems, Warrington, UK) and 2 pi of 
cDNA following the universal conditions (2 min at 50DC, 95°C for 
10 min, 50 cycles of 94°C for 30 sec, 60°C for 45 sec) on an 
Applied Biosystems 7500 real time PCR machine. All qPCR 
assays were run in triplicates.
Microsatellite analysis
The microsatellite marker panel reaction was carried out in a 
multiplex fashion using the Qiagen Multiplex PCR Master Mix 
(Qiagen, UK). Primers were selected from the LMS HD5 set 
(Applied Biosystems, Warrington, UK) and were custom synthe­
sized with 5' biotinylated reverse primers. The reaction volume 
was 20 pi and the loci included were D3S1300, D3S1263, 
D3S1566, D3S1289, D5S644, D9S157, D9S161, D13S153, 
D13S171, D13S263 and D17S938. The thennal profile consisted 
of 95°C for 15 min followed by 30 cycles consisting of 94°C for 
30 sec, 56°C for 90 sec and 72°C for 60 sec and a final 30-min 
step extension at 72°C. PCR products were cleaned using Strcpta- 
vidin coated Dynabeads (Invitrogen, Paisley, UK). Immobilized
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TABLE II - METHYLATION LEVELS OF THE LINE-1.2 
AND Ali-PV ELEMENTS IN LUNG CELL LINES
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Figure 2 - Box plot representation of LINE-1 and Alu methylation 
values observed in the studied cohort. There is a profound hypomethy- 
lation of both elements in the lung cancer tissue (T) compared to adja­
cent normal (N). p values above each pair are produced by 2-tailed 
paired Mest.
PCR products were washed with 200 pi 70% ethanol and dis­
solved in 4 pi loading buffer containing formamide:dextran blue:- 
ROX400 size standard (Applied Biosystems. Warrington, UK) in 
a 10:2:1.5 ratio. The mixture was denatured at 95°C for 5 min, 
cooled on ice and loaded on a 4.2% denaturing polyacrylamide gel 
on a 377 ABI PRISM automated sequencer. Peak area analysis was 
undertaken using the GeneScan and Genotyper software (Applied 
Biosystems, Warrington, UK). The allelic imbalance index (All) 
was calculated for each sample as follows: AH = (A1/A2)T/(A1/ 
A2)N. The loss of heterozygosity (LOH) threshold was calculated 
based on the 99% reference range (= mean ± 3 X SD) created by 
values produced by multiple repetition of normal blood DNA sam- 
ples/ ' The fractional allele loss (FAL) value was used as an 
expression of overall genomic instability in each sample and was 
calculated as: FAL = [number of loci with loss]/[number of 
informative loci].
Statistical analysis
Q-Q plots and the one-sample Kolmogorov-Smimof test were 
used to evaluate fitness to normal distribution of continuous pa­
rameters. Paired Mest was used to determine if there was a statisti­
cally significant change in the methylation status of LINE-1 and 
AluPV in primary NSCLC tumors. Based on the fitness of parame­
ters to normal distribution, the Pearson’s (parametric) test was 
used to analyze correlations between LINE-1 and AluPV methyla­
tion and genomic instability. All analyses were performed 
using the SPSS 13.0 package, p < 0.05 is considered statistically 
significant.
Results
Methylation status ofUNE-1 and AluPV 
in primary NSCLC tumors
We have examined the methylation levels of the 5' promoter 
CpG island of LINE-1 and the 3'-end CpG island of the Alu ele­
ment, utilizing Pyrosequencing assays that we developed and vali­
dated. Representative pyrograms of such assays are given in Fig­
ure 1 and the results are summarized in Table I. LINE-1 promoter 
was highly methylated with minimal variability in normal lung tis­
Cell line Origin Methylation index (%)
UNE-1 Alu
NHBE Primary normal bronchial 56 52
HBEC3KT Bronchial immortalized 56 45
A549 Adenocarcinoma 51 42
CALU3 Adenocarcinoma 64 46
CRL 5935 Adenocarcinoma 64 44
SKLU-1 Adenocarcinoma 62 46
CALU6 Anaplastic carcinoma 50 45
CORL 23 Large cell carcinoma 63 48
DMS 53 Small cell carcinoma 40 43
CRL 5802 Squamous carcinoma 33 37
SKMES Squamous carcinoma 59 46
sues (Methylation index = 69.8% ± 0.14%). The corresponding 
tumor samples demonstrated a significant drop in the methylation 
index values (56.4% ± 1.4%, paired f-test, p = 7.7 X 10“u. 
Fig. 2). A highly significant difference between normal (56.6% ± 
0.3%) and tumor (53.5% ± 0.4%) tissue methylation indexes were 
found for Alu (paired f-test, p = 9.6 X 10-7, Fig. 2). Notably, 
LINE-1 and Alu methylation indices in primary tumors strongly 
correlated with each other (Pearson’s correlation = 0.401, p = 
0.006). Clinicopathological parameters such as age, gender, T sta­
tus, differentiation and nodal metastasis did not correlate with 
LINE-1 and Alu methylation (data not shown). LINE-1 hypome- 
thylation was more frequent in squamous carcinomas than adeno­
carcinomas, however only at borderline significance (p = 0.052). 
As only 4 never smokers were present in this patient cohort, no 
valid conclusions regarding the impact of smoking can be drawn.
Correlation ofUNE-I and Alu elements with genomic instability
We determined genomic instability in this tumor set utilizing 11 
microsatellite markers, which have been previously shown to be 
hot spots for LOH in lung tumors.29 ,0 Detailed results from indi­
vidual microsatellites are given in supplementary data. Genomic 
instability for each sample is expressed as the FAL value (Table I). 
The bivariate correlation analysis between methylation index and 
FAL demonstrated that genomic instability is associated with hypo- 
methylation of LINE-1 (Pearson’s correlation = —0.547,p = 7.1 X 
10-5) and Alu (Pearson’s correlation = —0.392,p = 0.008).
Epigenetic regulation ofUNE-1 and Alu elements 
in lung cell lines
We measured the methylation levels of the LINE-1 and Alu ele­
ments in 9 lung cancer cell lines, 1 immortalized, nontumorigenic 
bronchial epithelial cell line (HBEC3KT) and a commercially 
available normal bronchial epithelial line (NHBE). Cancer cell 
lines demonstrated a variable degree of methylation in these ele­
ments, whereas the normal and immortalized cell lines methyla­
tion status was somewhat lower than the average index of surgical 
normal adjacent tissue (Table II). We examined the possible epi­
genetic control of LINE-1 and Alu expression by using the deme- 
thylating agent 5-aza-2-deoxycytidine (Decitabine) and a histone 
deacetylase inhibitor such as trichostatin (TSA). We selected the 
A549, CRL5802 and HBEC3KT lines (1 adenocarcinoma, 1 squa­
mous and 1 nontumorigenic, respectively). Treatment with decita­
bine resulted in hypomethylation while addition of TSA did not 
affect, as expected, the methylation status. Decitabin and TSA 
increased the expression of both elements, with the exception of 
LINE expression in HBEC3KT where TSA had no effect. As 
expected the combined use of both substances resulted in 
enhanced transcription compared to single substance use (Fig. 3).
Discussion
The LINE-1 and Alu elements are non-LTR containing retro- 
transposons which comprise a long stretch of the human repeat
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Figure 3 - Bar charts demonstrating the methylation (top panels) and expression (bottom panels) levels of LINE-1 and Alu transcripts fol­
lowing treatment of lung cell lines with 5-aza-2'-deoxycitidne (Aza) and trichostatin (TSA). The addition of azacytidine reduces methylation 
and increases expression of both Alu and LINE. The addition of TSA does not affect methylation, but has a significant effect in expression of 
both elements with the exception of LINE in HBEC3KT cells. Simultaneous use of both compounds has a profound synergistic effect in expres­
sion of Alu and LINE. Expression is given in relative quantification (RQ) values which are calculated as RQ = 2( ACu value using the 
untreated control cell population as the calibrator.
DNA sequences. Although only a small number of these elements 
are considered to be actively retrotransposing in the human ge­
nome, these are associated with insertional mutagenesis.1 1 LINE- 
1 and Alu elements are methylated in normal somatic cells and are 
frequently demethylated in cancer following global genome hypo- 
methylation.’ ' Indeed, because of their abundance in the genome 
they have been shown to be a good measure of such global hypo- 
methylation in cancer.18 However, the possible involvement of 
hypomethylation-mediated activation of LINE-1 and Alu in ge­
nome stability and cancer development has not been widely stud­
ied, although there is recent evidence to fuel such investiga­
tions.7 810 2 As demethylating agents are increasingly used in 
cancer treatment, it is imperative to understand how cancer-related 
and/or drug-induced hypomethylation may initiate retrotransposi- 
tion and subsequent genomic alterations, thus drawing valuable 
conclusions for implications in cancer therapy.
In our study, we quantitatively determined in NSCLC the meth­
ylation status LINE and Alu elements utilizing the sequences of 
LINE-1.2 and Alu-PV species. These particular LINE and SINE 
species were selected based on their activity in the human ge­
nome.212':,2 We demonstrated a significant reduction of the meth­
ylation levels of both LINE and Alu elements in primary NSCLC. 
These findings suggest a potentially important role for LINEs and 
SINEs in lung cancer development, adding to the limited informa­
tion for retroelement methylation in this type of cancer.I5 ?, ;u
There are profound differences on the detected methylation levels 
of LINE and Alu in normal and tumor specimens. More precisely, 
the observed average change in LINE is 13.2%, whereas in Alu it 
is only 3.1%. This most probably reflects the species/subfamilies 
covered by the particular primers used considering the known 
degeneracy of the targeted sequences.
From the clinicopathological point of view, it is notable that the 
observed hypomethylation was widespread among tumors of vari­
able stage, nodal metastasis and differentiation status, most prob­
ably suggesting an early onset of this molecular abnormality in the 
course of lung cancer development. Our study confirms that 
NSCLC follows a similar global hypomethylation pattern as other 
human tumors.13 18 Of particular note here is the finding that the 
methylation status of LINE is highly correlated with that of Alu 
(p = 0.004). This suggests a common mechanism of methylation 
maintenance of these elements in cancer and receives further sup­
porting evidence from data in prostate cancer1'1 and the reported 
correlation of both elements methylation with global genome 
methylation as measured by HPLC.1,
To assess the potential implication of LINE and SINE demethy- 
lation in genome stability maintenance in NSCLCs, we have 
examined LOH at loci which are hotspots for lung cancer30 and 
used FAL as a measure of the overall genomic instability. We 
demonstrated that hypomethylation of both transposable elements 
correlates with high FAL values indicating a strong link between
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genome stability and transposable element methylation, A similar 
observation has been reported in colorectal carcinomas where 
LINE-1 hypomethylation correlated with microsatellite instabil­
ity,35 although the mechanisms responsible for chromosomal 
instability (expressed by FAL) and MSI are different. Genomic 
hypomethylation has been shown to induce chromosomal instabil­
ity and tumorigenesis.21'22 A triangular relationship between 
global hypomethylation-transposable elements-genomic instability 
has been suggested for many types of human tumors7,10 and the 
correlation between genomic instability and hypomethylation in 
our study is in agreement with this. Currently, we have no func­
tional evidence to prove a cause-effect relationship between hypo­
methylation of transposable elements and genomic instability, and 
further studies are required toward this direction. Alternatively, it 
may be suggested that hypomethylation of transposable elements 
and genomic instability could be consequences of the overall 
genetic and epigenetic reprogramming in human tumors. LINE-1 
overexpression in model systems has been shown to induce 
genomic instability and deletions.8-10 Other models have demon­
strated successful retrotransposition events of such elements.3,36-38 
The information on LINE-1 expression in human tumors is veiy 
limited but suggests a degree of transcriptional activation in leuke­
mias,31 breast, urothelial and renal carcinomas.40 As RNA was 
not available from this set of NSCLCs examined for methylation, 
we are unable to comment on whether the observed hypomethyla­
tion leads to overexpression of LINE-1 and Alu. To examine the 
potential epigenetic control of LINE-1 and Alu in lung cancer, we 
utilized decitabine and TSA (common inhibitors of methylation 
and histone deacetylation, respectively) on 2 lung cancer cell lines 
and a nontumorigenic bronchial epithelial cell line to verify hypo- 
methylation-mediated activation of transcription. In all 3 cell 
lines, the use of decitabine (which lead to experimentally con­
firmed hypomethylation of LINE-1 and Alu) resulted in increased 
transcription of both elements (Fig, 3). Notably, simultaneous use 
of TSA further increased transcription level. It has to be noted at 
this point that the observed increased expression of LINE and Alu 
could be partly due to incomplete elements encompassed in genes 
that are overexpressed in the presence of decitabine.
Although we are clearly demonstrating that expression of LINE 
and Alu is under epigenetic control in a lung cancer environment, 
it has to be noted that retrotransposition could be impaired by 
methylation-independent mechanisms. siRNAs produced by the
LINE-1 5'antisense promoter have been shown to inhibit its retro­
transposition.5,6 In addition, LINE and Alu retrotransposition is 
controlled by APOBEC3 proteins (41,42) and sequestration into 
stress granules.43 Last, it must also be noted that hvpomethylation 
of LINE and Alu is not necessarily unifonn,7,44 thus it is not 
totally clear to which extent our data can be extrapolated.
Thus, further investigation involving a new patient cohort with 
available DNA and RNA is required to confinn this as a mecha­
nism contributing to genomic instability. An alternative sugges­
tion, on the other hand, is that chromatin relaxation at such retro- 
element sites may promote illegitimate recombination leading to 
genomic instability?
Epigenetics appear to have a key role to play in anticancer 
therapies. DNMT inhibitors are increasingly used in clinical tri­
als.4 ,4<5 Recent studies provide very promising results47,48 as epi­
genetic modulation of drug resistance may be critical for improv­
ing cancer drug efficiency overall.49 It is, however, important to 
understand in detail the epigenetic reprogramming of cancer cells. 
In this direction, further to identify the most commonly hyperme- 
thylated genes, it is crucial to understand the impact of transpos­
able element hypomethylation in cancer biology. In addition, we 
need to understand how and to what extent DNA hypomethylation 
may be a critical adverse effect of epigenetic therapies.50
Findings in our study demonstrate for the first time in primary 
human lung tumors the relationship between retroelement hypo­
methylation and genomic instability. In addition, we provide evi­
dence that hypomethylation of LINE-1 and Alu elements in 
human lung cancer cell lines leads to enhanced transcription, 
which in combination with previous reports on retrotransposition- 
induced genomic instability points towards a more active role of 
the reactivation of such retroelenients in the pathogenesis of 
human tumors. Further work is required to fully elucidate the mo­
lecular mechanisms involved and to provide the basis for the bet­
ter clinical utilization of demethylating agents for the treatment of 
human cancer.
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The p73 gene possesses an extrinsic PI promoter and an intrinsic P2 
promoter, resulting in TAp73 and ANp73 isoforms, respectively. The ulti­
mate effect of p73 in oncogenesis is thought to depend on the apoptotic 
TA to antiapoptotic AN isoforms’ ratio. This study was aimed at identify­
ing novel transcription factors that affect TA isoform synthesis. With the 
use of bioinformatics tools, in vitro binding assays, and chromatin immu- 
noprecipitation analysis, a region extending -233 to -204 bp upstream of 
the transcription start site of the human p73 PI promoter, containing con­
served Spl-binding sites, was characterized. Treatment of cells with Spl 
RNAi and Spl inhibitor functionally suppress TAp73 expression, indicat­
ing positive regulation of PI by the Spl protein. Notably Spl inhibition or 
knockdown also reduces ANp73 protein levels. Therefore, Spl directly reg­
ulates TAp73 transcription and affects ANp73 levels in lung cancer. 
TAp73y was shown to be the only TA isoform overexpressed in several 
lung cancer cell lines and in 26 non-small cell lung cancers, consistent with 
Spl overexpression, thereby questioning the apoptotic role of this specific 
p73 isoform in lung cancer.
Introduction
Lung cancer is one of the most common and fatal 
types of cancer in developed countries. Despite scien­
tific advances, the overall number of associated deaths 
has only slightly decreased during the last 20 years [1]. 
The well-known tumour suppressor gene p53 has been 
found to be mutated in 70-90% of lung cancer cases 
and in less than 50% of all cancer cases [1]. However, 
the involvement of p73, its structural and functional
homologue, in this type of cancer is not clearly 
understood [2].
The p73 gene is a member of the p53 family that 
encodes an N-terminal transactivation domain (TA), 
a highly conserved DNA-binding domain (DBD), and 
a C-terminal oligomerization domain [3]. Despite its 
high degree of sequence similarity with p53, especially 
in the DBD, and its ability to activate various p53
Abbreviations
ChIP, chromatin immunoprecipitation; DBD, DNA-binding domain; EMSA, electrophoretic mobility shift assay; NSCLC, non-small cell lung 
cancer; siRNA, small interfering RNA; TA. transactivation domain; TSS, transcription start site; VEGF, vascular endothelial growth factor.
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targets [4] as well as to induce apoptosis in cancer cells 
[5], p73 has unique characteristics that differentiate it 
from a classical Knudson-type gene. Unlike p53„ p73 
rarely mutates in cancer [6], and p73~/- mice do not 
develop spontaneous tumours, but show severe abnor­
malities in neuronal development [7], The gene pro­
duces numerous isoforms as a result of: (a) alternative 
splicing in the 3'-end (leading to the formation of oc, (3, 
y, S, s, ^ and q isoforms) [8-12]; (b) the use of an 
extrinsic promoter (PI) and an alternative, intrinsic 
promoter (P2) in the 5'-end (leading to the formation 
of TA and AN classes of isoforms, respectively) [13]; 
and (c) alternative splicing in the 5'-end (resulting in 
truncated transcripts p73Aex2, p73Aex2/3, and AN'- 
p73, which partially or entirely lack the TA, collec­
tively called ATA) [14]. The numerous iso forms derive 
from several combinations between differential N-ter- 
minal domain and C-terminal domain [15].
Despite the rarity of p73 mutations, overexpression 
of p73 isoforms is common in several types of cancer 
[14,16], including lung cancer [2]. Elevated levels of 
expression of p73 isoforms have also been correlated 
with lung cancer, as ANp73 overexpression predicts a 
poorer prognosis in patients with squamous cell car­
cinoma and adenocarcinoma [17], In addition, TAp73 
is overexpressed in lung cancer tumour tissues 
[18,19].
The ‘two genes in one’ idea has been suggested for 
p73, whereby the same gene is thought to generate 
products with opposing roles, mainly the apoptotic TA 
isoform(s) and the antiapoptotic AN isofoims. In gen­
eral, TAp73 isoforms regulate the transcription of 
ANp73 isoforms, which, in turn, act as dominant nega­
tive regulators of both TAp73 and p53, thus giving a 
dominant negative feedback loop [13], Consequently, 
the ultimate effect of p73 isofoims in cancer progres­
sion is attributed to the TA/AN ratio, rather than the 
overexpression of a specific p73 isoform or a specific 
class of p73 isoforms per se [20,21],
In line with this concept, the selective promoter acti­
vation could result in the activation of either onco­
genic or tumour suppressor isoform(s) of this gene, 
thereby shifting the TA/AN equilibrium towards an 
oncogenic or a tumour suppressor direction. For 
example, the p73 PI promoter contains functional 
E2Fl-binding sites [22], through which the E2F1 tran­
scription factor induces TAp73 overexpression and 
consequent apoptosis [23,24]. It has been reported that 
the p73 PI promoter is not completely inactivated by 
site-directed mutagenesis of its functional E2F1 sites 
[23], implying that additional transcription factor(s) 
play a significant role in its regulation. This study 
focused on the identification of novel transcriptional
factors that control the use of the p73 PI promoter 
and, subsequently, the relative expression of p73 iso- 
forms in lung cancer by using lung cancer cell lines 
and tumour samples. Spl was found to activate the 
transcription of TAp73y in lung cancer via highly con­
served Spl-binding sites on the p73 PI promoter. In 
addition, TAp73y and Spl are co-overexpressed both 
in vitro and in situ in lung cancer. Spl also affected the 
ANp73 levels in lung cancer.
Results
The p73 PI promoter has multiple putative 
Sp1-binding sites
In order to identify transcription factors that control 
the use of the p73 PI promoter, we searched for con­
served binding sites located in regions of its sequence 
that show high homology among various species, 
including Dos taunts, Equus eaballus, Erinaceus europa- 
eus, Loxodonta africana, Macao a mulatto, Mas nmscu- 
lus, Ornithorhynchus anatinus, Otolemur garnettii. Pan 
troglodytes, Rattus norvegicus and Tupaia belangeri. 
The transcription start site (TSS) of the human 
transcripts ENST00000346387, ENST00000354437,
ENST00000357733, ENST00000378290, and ENST00 
000378295, which is located at chr 1:3558989 (Ensem- 
bl v54, May 2009), was selected. The analysis focused 
on the first 250 bp upstream of the TSS, which shows 
most conservation among mammals. Four conserved 
human p73 PI promoter regions (A-D), containing 
potential Spl-binding sites, were identified (Fig. 1). 
Region A is located -233 to -204 bp upstream of the 
human p73 PI TSS, and contains two putative Spl- 
binding elements. Regions B, C, and D, which are 
located -61 to -33, -20 to -1, and -4 to +20 bp 
upstream of the TSS, respectively, all contain one 
putative Spl-binding element. Our in silico prediction 
of candidate Spl motifs in regions A, C and D is in 
accordance with a previous study, in which matinspec- 
tor V2.2 at the TRANSFAC website was used [25], 
Furthermore, contra analysis also suggested another 
candidate Spl motif in region B. Our study demon­
strated a canonical, conserved TATA box at posi­
tion -32, based on the mapping of the TSS by 
Ensembl, which is identical to the TATA box previ­
ously described for the human p73V\ promoter [22].
Regions A, B and C on the p73 PI promoter can 
bind Spl in vitro
We evaluated the affinity of the in i///co-identified 
region A, B, C and D oligonucleotides for in vitro
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____________Region A______________________
-242 cgcgcgcca^aaggcgg----- cgggaaggaggcggggca------gagc|jcg-cccgg -196
cgcgcgccaaaagacgg----- cgggaaggaggcggggca------gagtgcgccccgg
cgcgcgccaaaagacgg----- cgggaaggaagcggggcg------gagcgcg-ccggc
cgcgcgccaaaaggcgg----- cgggaaggaggcggggc-------gagagcg-cccgg
tgcgcgccagacacggg----- cgggaaggaggcgcccct------gaggccg------
cgcgcgccaagcggcgg----- cgggaaggaggcgggag-------gagcggg-gccca
cacgtggcaggcggcagtgccgtcaggggagtcgcggagggctgaatgcgcgtg-ccccg
cgcgcgccaaacagcgg----- cgggaaggaggcggggc-------gggcgcg-tccgg
cgcgcgccaaaaggcgg----- cgggaaggaggcggggca------gagcgcg-cccgg
cgcgcgccaaacggcgg----- cgggaaggaggcggggca------gagcgcg-cccgg
cgcgcgccaagc-----------------agaggcgggag-------gagcaga-gcccg
cgcgcgccaaac-gcgg----- cgggaaggaggcggggcg------gagcgcgccccag
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Bos taurus 
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Mus musculus
Ornithorhynchus anatinus 
Otolemur garnettii 
Pan troglodytes 
Macaca mulatta 
Rattus norvegicus 
Tupaia belangeri
-195 gaccccgac-ttggacgcggccagctggagag-gcggagcgccgggaggagaccttggcc -139 
gaccccgac-tcggacgcggccagctgggggg-gcggagcgccggatggcgaccttggcc 
gaccccgacttcggacgcgtccagctgcggga-gcggagcgccgggctgcaaccttggtc 
gaccccgac-tcggacgcggccagctgggggg-gcggagcgccgcgcggcaacccgggtc 
gatcccg-c-tctgcaaaggccagctgcgagg-gcggagcgcgaggagacagcctcggcc 
gaccccgac-tcgggcagagccagctggggag-gcggggcgcgcgtgggagccaggggcc
gcccccggc-tccgggaggcgccatggtttgg-gcgagacg---- agatggcgcggaac
a—cccgac-tcggaagcggccagctgggggg-gcggagcgcc--gaggagaccttggcc 
gaccccgac-ttggacgcggccccttggacagtgcggagcgccgggaggagatcttgtcc 
gaccccgac-tcggacgcggccatctggggag-gcggagcgccgggaggagaccttggcc 
gaccccgac-tcgggcagagccagctggggag-gcggggcgcgcgtgggagcccggggcc 
gaccctgac-ac-gacgcggccagctggggg--gcggagcgccgggaggagaccttggcc
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Otolemur garnettii 
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Macaca mulatta 
Rattus norvegicus 
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-138 ------------------------------------ ccgcc-gcgactcggtggcccg-c -116
ctagcct-gg-----cgctgctgccccttgctcctcctgccaacggctgagcggcccg-c
ccggcctggg-----ccccgccgccccgcgctcctcccgcc-acgcctgagcggcccg-c
ccggcct-aa-----ccgcgccg-ccagcccttctccagcg-cgggctgagcggcccg-c
------- ggggacccgccgccgccctgtcccgcctcccgc-gcggtcga---gcccg-c
---------------- cgggtgg-ccggccctcctcccgcc-acggctgagt-gcccg-c
------------------------------------- tttg-gcaataaagaaagctg-t
------------------------------------ aggcc----------cggcccgcc
------------------------------------ ccgcc-gcgactcggtggcccg-c
------------------------------------ ccgcc-gcgactgggtggcccg-c
----------------ccggcgg-ccggccctcctcccgcc-acggctgagt-gcccg-c
tcggccc-gg---- cccggcag-cctggccctcctccgcg-gcggctgagtagcccg-c
Homo sapiens 
Bos taurus 
Equus caballus 
Erinaceus europaeus 
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Otolemur garnettii 
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Macaca mulatta 
Rattus norvegicus 
Tupaia belangeri
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Mus musculus
Ornithorhynchus anatinus 
Otolemur garnettii 
Pan troglodytes 
Macaca mulatta 
Rattus norvegicus 
Tupaia belangeri
Homo sapiens 
Bos taurus 
Equus caballus 
Erinaceus europaeus 
Loxodonta africana 
Mus musculus
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Otolemur garnettii 
Pan troglodytes 
Macaca mulatta 
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-115 gctgcct------------tcccgcgcgccgggcta-aaaaggcgctaacgcccgcggccg-cct -65
gctgcct-------tcccg-ccggccggctgcggaaggcgctaacgctggcggcta-ccc
gctgcct-------tcccgcccagcgggctgcggaaggcgctaacgcccgcggccg-ccc
gctacct-------tcccgcgcggccggctgcggaaggcgctaactcc-gcggcca-ccc
gccgcct------ tcccgcccg-caggctc-gaacagcgctaa-------ggccg-tgc
gctgcct-------tcccgccggtccgccaa-gaaaggcgctaa-gcctgcggcag-tcc
gcttgctggctaaatgcgacctccctcgtca-gagggaccat-----------ctg-tct
gctccct------------------------------------------------------
gctgcct-------tcccgcgcgcctggcta-taaaggtgctaacgcccgcggccg-cct
gctgcct-------tcccgcgcgccgggcta-aaaaggcgctaacgccggcggccg-cct
gctgcct-------tcccgccggtccgccga-gaaaggcgctaa-gcctgcgccag-ccc
gctgcct-------tcccgcctgccgggctgcaaaaggcgctaacgcccgcggccgcccc
__________Region B___________ TATA Box
-64 ac---- tjccccgcggcgcctcccctccccgcgccca|tat--aa|cccgcct|a----- gg- -18
c----- tccccgcggcgcctcccctccccgcgcccatat--aacccgcctt----- gg-
cc--- ttccccgcggcgcctccccgccccgcggccatat--aacccgcctc----- ga-
c----- tccccgcagcgcctcccctccccgcgcccatat--aactcgcctc----- gg-
c----- gccccgc-ccgcgccccctcaccgcgccgatat--aacccgc--------- g-
cc---tcgccgc—cgcctccctgctccgcacccttat---aacccgc-----------
ccgacgccctcaccccacaccccatctctacgcatgcatgggaggccacttccagagga-
ac---- tccccgcggcgcctcccctccccgcgccca tat--aacccgccta----- gg-
ac---- tccccgcggcgcctcccctccccgcgccca tat--aacccgccta----- gg-
cc--- tcgccgc—cgcctccctgccccacgcccatat---aacccgc-----------
cc---- tctccacgacgcctcccqtccccgcgcgca taa--aatccgcctc----- tgcRegion C I TSS ** Region D____________ _ ___j
-17 ggccgggcagcccg|ccctjgcctccccgcccg------------cgcaccc^cccggag-g
-cggccggagcccgccctgcctccgcgcccgcgcccgccaggccgcacccgcctctcg-t
-gccccgccgcccgccctaccttccggcccgcggccgcccaggcgcagccgcctcgcg-g
cggcccgccgcccgccctgcctccccgcccgaggccgcccggcttcaccggtctctcg-g
cgcccgccattctgcc----- tcccgtccg------ccagcgcgtgcccgccgctcgct
cgtcccgcatccag-----------------------------------------------
aaccttgccctctccccgacatc-------------------------------------
29
ggccgggcagcccgccctggctcgccgcccg----------- cgcgcccgcccagag-g
ggccgggccgcccgccctgcctccccgcccg----------- cgcacccgccccgag-g
cgtcccgcagcccgccc---- ctcagccca-----------------------------
cgcggggcagcccgccctgcttccccgcccgcggccgcaggtccgcacccgcctctag-g
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synthesized Spl protein using electrophoretic mobility 
shift assay (EMSA) experiments. In vitro, Spl can bind 
to region A, B and C oligonucleotides (Fig. 2A, 
lanes 6 and 11, and Fig. 2B, lane 6, respectively). 
Self-competition experiments, as well as competi­
tion experiments using an excess of unlabelled control 
oligonucleotide (containing a control Spl binding site) 
for region A radiolabelled oligonucleotide, abolished 
the formation of the Spl-radiolabelled region A oligo­
nucleotide complex (Fig. 2A, lanes 7 and 8, respec­
tively). The addition of the mSpl oligonucleotide 
(containing a mutated Spl binding site) did not affect 
protein-DNA binding (Fig. 2A, lane 9), whereas the 
addition of antibody against Spl strongly supershifted 
the Spl-DNA complex (Fig. 2A, lane 10). Similar 
experiments for regions B (Fig. 2A) and C (Fig. 2B) 
confirmed specific in vitro Spl-DNA binding. Notably, 
the binding activity of the region A oligonucleotide 
was markedly higher than those of all other oligonu­
cleotides that were tested, possibly indicating that both 
putative Spl binding elements in region A are active. 
Therefore, region A appears to be a better binding site 
for Spl. In contrast, region D failed to bind in vitro 
synthesized Spl protein (Fig. 2B, lanes 11-15), and it 
was excluded from further analysis.
Binding of endogenous Sp1 from lung cancer 
cell lines to the p73 PI promoter
In order to validate the ability of endogenous Spl to 
bind to the p73 PI promoter within the cellular 
environment, we performed additional EMSA experi­
ments using nuclear extracts from 11 representative 
lung cancer cell lines. We used only region A radiola­
belled oligonucleotide, as it was found to bind in vitro 
to Spl more effectively. We observed that the binding 
of endogenous Spl to region A in the fibroblast cell 
line IMR90 was almost equal to that in the normal 
HNBE cells (Fig. 2C, lanes 1 and 2). A marked 
increase in the level of region A oligonucleotide-Spl 
complexes was noted in the anaplastic carcinoma cell 
line (Fig. 2C, lane 3), and the levels of the complexes 
appeared to remain equivalently high in the small cell 
Inng cancer cell line (Fig. 2C, lane 4), the squamous 
cell carcinoma cell lines (Fig. 2C, lanes 5-7), the 
adenocarcinoma cell lines (Fig. 2C, lanes 8-10), and 
the large cell lung carcinoma cell line (Fig. 2C, 
lane 11). The region A oligonucleotide-Spl complex
was supershifted in the representative cell line A549 
(Fig. 2C, lane 12), demonstrating the specificity of 
region A for Spl of the nuclear cell lysates. The 
Spl-DNA binding pattern for the region A oligonu­
cleotide is consistent with that of the control oligo­
nucleotide (Fig. 2D).
Binding of Spl to the p73 PI promoter within the 
cellular environment is further supported by chromatin 
immunoprecipitation (ChIP) assays. Spl antibody 
immunoprecipitated the p73 PI promoter in A549 cells 
in a dose-dependent manner (Fig. 2E). In contrast, no 
PCR signal was observed when the irrelevant P-actin 
antibody was used for ChIP. The sheared and cross- 
linked DNA that was produced prior to the immuno- 
precipitation step (input) was used as a positive 
control PCR template.
TAp73 synthesis is regulated by Spl through 
region A in lung cancer ceil lines
Next, we tested the ability of Spl to regulate TAp73 
expression in vivo by treating the standard TAp73- 
expressing cell line A549 with either Spl small interfer­
ing RNA (siRNA) or an Spl protein inhibitor. The 
resulting changes in TAp73 expression were monitored 
by western blot analysis. The known Spl target vascu­
lar endothelial growth factor (VEGF) [26] was used as 
a positive control. A549 cells were transiently trans­
fected with Spl siRNA, and the nonsilencing control 
siRNA was the negative control for Spl siRNA inter­
ference. As shown in Fig. 3A, treatment with Spl 
siRNA resulted in the downregulation of TAp73 and 
VEGF levels as compared with the corresponding 
levels in the siRNA-untreated cells, revealing positive 
regulation of the p73 PI promoter by Spl. In contrast, 
TAp73 and VEGF levels were not affected by treat­
ment with negative control Spl siRNA. Similarly, 
TAp73 levels gradually decreased after a 48 h treat­
ment of A549 cells with increasing concentrations of 
the Spl inhibitor mithramycin A (Fig. 3B), which 
not only interferes with the transcription of genes 
containing GC-rich regions in their promoters, but 
also, at high concentrations, reduces recruitment of 
Spl to its own promoter [27].
We then performed transient transfection of A549 
cells with region A double-stranded phosphorothioate 
oligonucleotides, which are able to antagonize 
region A for Spl binding, in order to examine whether
Fig. 1. The PI p73 promoter has multiple putative Spl-binding sites, conserved among 12 mammalian species. Alignment using contra 
analysis revealed four conserved, putative Spl element-containing regions, spanning from -233 to -204 bp (region A), -61 to -33 bp 
(region B), -20 to -1 bp (region C) and -4 to +20 bp (region D) relative to the TSS of the human p73 PI promoter. The four regions are 
box-highlighted, and the human Spl-binding sites are yellow-shaded. The TATA box is also box-highlighted.
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Rg. 2. Spl binds to the p73 PI promoter both in vitro and in vivo. (A) The 32P-labelled region A target was incubated with the in vitro 
Spl protein either alone (lane 6) or in the presence of cold region A oligonucleotide (self-competition reaction) (lane 7), cold control oligo­
nucleotide (CON) (competition reaction with positive control) (lane 8), or cold mutant Spl oligonucleotide (mSpI) (competition reaction with 
negative control) (lane 9). In lane 10, the protein-DNA complexes are supershifted with polyclonal antibody against Spl (supershift reaction). 
Lanes 11-15 correspond to a similar set of reactions for the 32P-labelled region B target. Lanes 1-5 correspond to the positive control reac­
tions for the Spl-containing oligonucleotide (CON). (B) Lanes 6-10 correspond to a similar set of reactions for the 32P-labelled region C tar­
get, and lanes 11-15 correspond to a similar set of reactions for the 32P-labelled region D target. Lanes 1-5 correspond to the positive 
control reactions for the Spl-containing oligonucleotide (CON). EMSAs using in vitro Spl and region A, B, C or D oligonucleotides revealed 
that regions A, B and C can bind to Spl. (C) Lanes 1-11 contain radiolabelled region A oligonucleotide incubated with nuclear extracts from 
11 lung cancer cell lines and electrophoresed on polyacrylamide gel. The specificity of the region A oligonucleotide-SpI protein complex is 
confirmed by a supershift reaction with polyclonal antibody against Spl in the representative A549 cell line (lane 12). (D) Lanes 1-11 show 
the corresponding positive control EMSA experiments demonstrating specific binding of endogenous Spl of the same cell lines to radiola­
belled control Spl oligonucleotide (CON). The CON-Spl protein complex was supershifted in the representative cell line, A549 (lane 12). 
Unlabel., unlabelled oligonucleotides; 32P-label, 32P-labelled oligonucleotides; N/S, nonspecific DNA-protein complexes. (E) ChIP assay with 
DNA from A549 cells. Immunoprecipitation was performed with 2 pg and 6 pg of antibody against Spl. PCR primer pairs were specific for 
the -265 to +61 bp region of the p73 PI promoter. Chromatin incubated with antibody against p-actin was used as a negative immunopre­
cipitation control, whereas input was used as a positive PCR control.
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Rg. 3. Spl mediates TAp73 overexpression through PI activation. (A) Transient transfection with Spl siRNA results in the reduction of Spl 
and TAp73 levels in A549 cells. VEGF levels were used as a positive control for Spl siRNA interference, p-actin levels were used as a load­
ing control. Nonspecific Spl siRNA was used as a negative control. (B) A 48-h treatment of A549 cells with increasing concentrations of the 
Spl inhibitor mithramycin A results in reductions in Spl and TAp73 levels. VEGF levels were used as a positive control (C) A549 cells were 
transiently transfected with region A decoy, total protein extracts were prepared from these cells after 4. 12 and 24 h of decoy treatment, 
and the TAp73 levels were estimated by western blot analysis. (D) Similar transient transfection experiments with mutant Spl (mSpI) 
decoys were performed as a negative control of interference. The experiment was performed in triplicate. (E) TAp73 levels were quantified 
by imagequant and compared with the corresponding levels of the untreated cells. As shown in the graph, TAp73 levels decreased with time 
upon region A decoy treatment. (F) Quantification of the TAp73 levels and comparison with the corresponding levels of decoy-untreated cells 
(black bars) demonstrated no change in TAp73 levels of mSpI-treated cells over time (grey bars). The protein amounts in all experiments 
were normalized to p-actin.
region A of the p73 PI promoter is specifically 
responsible for Spl-mediated TAp73 expression in lung 
cancer cells. Mutant (mSpl) double-stranded phosp- 
horothioate oligonucleotides were used as the corre­
sponding negative control. Region A phosphorothioate 
oligonucleotides were able to reduce TAp73 expression 
over a 24 h treatment period (Fig. 3C,E), whereas 
mSpl phosphorothioate oligonucleotides failed to 
affect TAp73 expression (Fig. 3D,F). In contrast, 
region B and C phosphorothioate oligonucleotides had
a negligible effect on TAp73 expression, even after 
48 h of treatment (data not shown).
TAp73y and Spl are co-overexpressed in lung 
cancer cell lines and non-small cell lung cancers 
(NSCLCs)
Western blot analysis for TAp73 isoforms using total 
protein extracts from 15 lung cancer cell lines revealed 
that the abundantly expressed TAp73 isoform in all
FEBS Journal 277 (2010) 3014-3027 £> 2010 National Hellenic Research Foundation. Journal compilation © 2010 FEBS 3019
Spl activates p73 P1 promoter in lung cancer S. Logotheti et at.
tested cell lines was TAp73y, whereas TAp73ot and 
TAp73p were not detected. The level of TAp73y was 
low in the normal HNBE cells, slightly increased in 
the fetal lung fibroblast cell lines (CCL171 and 
IMR90), and substantially increased in the lung epithe­
lial anaplastic carcinoma cell line (CALU6), the small 
cell carcinoma cell line (DMS53), the squamous lung 
cancer cell lines (CRL5802, HTB182, HTB58, HTB59, 
and SKMES1). the adenocarcinoma cell lines (A549, 
CALU3, CRL5935, and SKLU1), and the large cell lung 
cancer cell line (CORL23). The corresponding Spl 
expression pattern was consistent with that of TAp73y 
(Fig. 4A), as well as with the Spl-DNA binding pattern 
revealed by the EMSA experiments. Quantification of 
TAp73y and Spl levels is shown in Fig. 4B.
To verify our findings in situ, we analysed the 
expression of TAp73 isoforms in a group of 26 lung 
cancer patients. TAp73y was exclusively overexpres­
sed in 68.42% (13/19) of squamous cell lung cancer
samples and in 57.14% (4/7) of adenocarcinoma sam­
ples as compared with their corresponding adjacent 
normal tissues. TAp73oc and TAp73P were undetect­
able in the tumour tissues of all patients. Spl levels 
were also examined, and Spl was found to be overex­
pressed in 57.89% (11/19) of squamous cell lung can­
cer samples and in 42.86% (3/7) of adenocarcinoma 
samples. Spl and TAp73y were co-overexpressed in 
42.86% (3/7) of adenocarcinoma samples, in 52.63% 
(10/19) of squamous cell lung cancer samples, and in 
50% (13/26) of total lung cancer samples. Figure 4C 
shows TAp73 and Spl levels in representative squa­
mous cell carcinoma and adenocarcinoma samples 
(Fig. SI). The mean TAp73y levels showed an 
approximately 12-fold increase in tumour tissues with 
respect to the corresponding normal levels. Similarly, 
an approximately eight-fold increase in the mean Spl 
levels was observed in the examined tumour samples 
(Fig. 4D).
Fig. 4. TAp73y and Spl are co-overexpressed in lung cancer cell lines and tumour samples. (A) Western blot analysis of total extracts from 
15 lung cancer cell lines revealed coelevation of Spl and TAp73y protein levels in these cells. In w'frotranslated TAp73a, TAp73P and 
TAp73y were used as controls for the identification of TAp73 isoforms, in vitro Spl was used as a control for the expression of Spl, and 
P-actin was used as a loading control. (B) Spl and TAp73y levels were quantified by imagequant and expressed relative to the normal HNBE 
cell line. (C) Western blot analysis demonstrated a significant increase in both TAp73y and Spl levels in the representative squamous cell 
carcinoma (patient No. 1) and adenocarcinoma (patient No. 18) samples as compared with the corresponding normal tissues. In w'fro-synthe- 
sized TAp73p and TAp73y were used as controls, for the identification of the exact TAp73 isoform expressed in these samples. (D) 
The mean levels of TAp73y and Spl in 26 NSCLCs samples were compared with the corresponding mean levels in the normal samples. Rel­
ative mean TAp73y levels showed an almost 12-fold increase (grey bars), and relative mean Spl levels showed a greater than eight-fold 
increase (black bars). The experiment was performed in triplicate.
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strated an increase in ANp73 in representative squamous cell carcinoma and adenocarcinoma samples relative to the adjacent normal 
tissues.
ANp73 levels are affected by Spl and enhanced 
in lung cancer cells
As the outcome of the action of TAp73 is dependent 
on the presence of the dominant negative ANp73 [13], 
an important issue to be considered is whether Spl 
also affects ANp73 levels in the context of lung cancer. 
It is also important to investigate whether ANp73 is 
co-overexpressed, along with TAp73y, in lung cancer. 
In this respect, we first assessed the effect of Spl 
siRNA treatment of A549 cells on ANp73 levels. As 
shown in Fig. 5A, ANp73 levels were markedly 
reduced in the Spl siRNA-treated A549 cells as com­
pared with the untreated cells, in contrast to the 
ANp73 levels of nonsilencing control-treated A549 
cells, which remained unchanged. Similarly, ANp73 
levels showed a marked decrease upon treatment of 
the A549 cell line with 400 nM mithramycin A 
(Fig. 5A). A contra analysis was performed in order 
to examine whether a direct interaction of Spl with 
the p73 P2 promoter is possible. Interestingly, our 
analysis showed a conserved region of 124 bp 
upstream of the AN-TP73 TSS. A highly conserved 
Spl candidate site was found at position-17 to -26. 
This sequence was flanked by two candidate TATA 
boxes at positions -3 to -9 and -26 to + 32. Another 
Spl site was identified at the 5/-end of the conserved 
promoter region (-115 to -124). The TSS was located 
at chr 1:3597096 (Ensemble v54. May 2009) of the 
AN-TP73 promoter (transcripts ENST00000378280 
and ENST00000378285) (data not shown).
Next, ANp73 levels were monitored in 12 lung can­
cer cell lines, as well as in four representative paired 
samples of the 26-membered panel of lung cancer 
patients. Figure 5B shows that ANp73 protein expres­
sion was low in the normal HNBE and fetal lung 
fibroblast CCL171 cell lines, whereas it was signifi­
cantly increased in the lung epithelial anaplastic 
carcinoma cell line (CALU6), in the squamous lung 
cancer cell lines (HTB59, HTB58, and SKMES1), in 
the adenocarcinoma cell lines (CALU3, CRL5935, 
A549, and SKLU1), and in the large cell lung cancer 
cell line (CORL23). In agreement with the data con­
cerning cell lines, as well as previous data on clinical 
samples [17,19], ANp73 was also overexpressed in the 
representative tumour samples as compared with their 
corresponding normal tissues (Fig. 5C). Thus, ANp73 
levels are not only enhanced in lung cancer cells, along 
with those of TAp73y, but are also affected by Spl.
Discussion
In the search for transcription factors that affect the use 
of the p73 PI promoter, we identified a region -233 to 
-204 bp upstream of the TSS of the human p73 PI pro­
moter containing conserved, functional Spl-binding 
sites. Reduction of the endogenous Spl levels or inhibi­
tion of Spl binding to this region downregulates TAp73 
expression in lung cancer cells. Importantly, Spl also 
affected the expression of ANp73 in lung cancer cells.
Spl has traditionally been considered to be a ubiqui­
tous transcription factor, responsible for the basal/
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constitutive activation of a wide range of viral and 
mammalian genes. However, novel data strongly corre­
late deregulated Spl expression with tumour develop­
ment, growth and metastasis, as it is significantly 
overexpressed in pancreatic, breast, thyroid and colon 
tumours, and it transactivates genes with a substantial 
role in cancer progression, cell cycle regulation, and 
antiapoptotic procedures [28]. Our study makes Spl the 
second transcription factor identified, so far, after 
E2F1 as directly controlling the p73 PI promoter. In 
addition, it indicates an association between Spl over­
expression and TAp73 overexpression in lung cancer.
Sp families of transcription factors can form com­
plexes with TAp73 isoforms [29], Recently, it was 
shown that TAp73 isoforms interfere with Spl tran­
scriptional activity, thus acting as repressors of Spl- 
mediated activation of genes, such as those encoding 
enhancer II of the core protein of hepatitis B virus 
[30], human telomerase reverse transcriptase [31,32], 
the potent angiogenic factor VEGF [33] and the cell 
cycle G2/M checkpoint controller cyclin B [34], It is 
proposed that this repression may be achieved via for­
mation of Spl-TAp73 complexes, resulting in the 
abrogation of Spl binding to corresponding elements 
on target gene promoters [30,32]. This tumour suppres­
sion mechanism parallels that of p53 [35,36]. The 
above-mentioned negative effect of p73 on Spl-medi­
ated transcription is specific only to the TAp73 iso­
forms, and not the ANp73 [31] or ATAp73 isoforms 
[30,32], and its efficiency fluctuates depending on the 
type of TAp73 isoform, with TAp73P being the most 
effective suppressor and TAp73y being the least effec­
tive [32]. It remains to be elucidated whether TAp73 
interference in the Spl-mediated transactivation of 
oncogenes also applies to lung cancer, suggesting that 
the interactions between Spl and TAp73 isoforms 
extend beyond the level of transcriptional control of 
the p73 PI promoter.
In this study, we also demonstrated that the full- 
length p73 isoform overexpressed in cancer cells both 
in vitro and in situ is TAp73y. TA isoforms were found 
to be elevated in lung cancer samples in the past, but 
the exact TAp73 isoform(s) overexpressed were not 
determined [2,19]. To the best of our knowledge, this 
is the first time that this particular isoform has been 
found to be specifically and exclusively overexpressed 
in cancer cells. Typically, TAp73 isoforms activate 
genes that mediate either cell cycle arrest or apoptosis, 
such as p21, box, mdm2, gadd45, cyclin G, 1GFBP3, 
and 14-3-3, and trigger cell death [5]. In vivo evidence 
supports the proposed role of TA isoforms as tumour 
suppressors, as TAp73~ ~ mice are tumour-prone and 
develop tumours upon treatment with carcinogens.
1 §1 131_______________ 310 345 360__________ 4S4 549
■ IIS
382 413 425 481
1 54 131 310 345 380 484 499
362
TA DBD OD SAM
[J Glu/Pro-rich region ^ Pro-rich region
] TAp73a 
TAp73p 
TAp73y
Fig. 6. Comparison between the primary structure of TAp73a, 
TAp73p. and TAp73y. Alternative splicing results in the loss of the 
Pro-rich domain and in the truncation of the Glu/Pro-rich domain, 
which contains a newly identified N-terminal transactivation domain. 
OD, oligodimerization domain; SAM, sterile at-motif (based on |40]).
with lung adenocarcinoma being the most frequent 
cancer diagnosed in these knockout animals [37]. 
Therefore, our finding raises questions about the pre­
sumed role of TAp73y in cancer, suggesting that its 
function may diverge from the traditionally proposed 
apoptotic function of TAp73 isoforms. Indeed, 
TAp73y has been almost ineffective in activating the 
p21Wafl/Cipl promoter and inhibiting colony forma­
tion of Saos cells, in contrast to the more efficient 
TAp73ot and TAp73P [9]. Similarly, it only poorly 
transactivates a p53-binding consensus sequence-con­
taining promoter in p5J-null cell lines [11],
The failure of TAp73y to exert the same drastic 
transactivation activities as the more extensively stud­
ied TAp73a and TAp73p might be associated with dif­
ferences in its C-terminal domain (Fig. 6). In this 
respect, a newly highlighted difference in TAp73y is 
that its C-terminal domain is basic and forms weak 
sequence-specific DNA-protein complexes, whereas the 
corresponding domains of TAp73a and TAp73p are 
neutral and form strong DNA-protein complexes, 
reflecting differential promoter binding and target gene 
transactivation [38]. Another difference in the C-termi- 
nal domain of TAp73y is that, owing to the excision 
of exon 11 during alternative splicing, it lacks most of 
the Glu/Pro-rich domain and the Pro-rich domain, 
which are located in a region extending from 382 to 
491 amino acids and are thought to enhance the trans­
activation activities of TAp73a and TAp73p [39,40]. In 
addition, lack of exon 11 in TAp73y results in the 
truncation of a second transactivation domain, located 
within amino acids 381-399, which was recently shown 
to regulate genes involved in cell cycle progression 
[41], The above data imply a transactivational deficit 
for TAp73y as compared with other TAp73 isoforms, 
which could influence its apoptotic function.
In agreement with previous clinical studies [19], we 
demonstrated that ANp73 levels are also elevated in
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lung cancer cell lines and in exemplary tumour sam­
ples. Furthermore, and for the first time, we showed 
that ANp73 levels are reduced in vitro upon inhibition 
or knockdown of the Spl transcription factor, The 
effect of Spl on ANp73 expression may be direct, as 
highly conserved, putative Spl-binding sites on the p73 
P2 promoter were identified by bioinformatic analysis. 
This possibly means that Spl controls both TAp73 
and ANp73 expression via regulation of their respec­
tive promoters. Alternatively, it is possible that this 
effect may be indirect, as the overexpression of 
P2-derived AN isoforms could be attributed to the 
overexpression of TAp73, which is known to activate 
the P2 promoter [13], In this case, downregulation of 
ANp73 expression upon Spl inhibition or reduction 
could be caused by subsequent downregulation of 
TAp73 expression. Furthermore, the possibility that 
the p73 PI promoter is able to produce a fraction of 
ANp73 molecules in lung cancer cannot be excluded, 
as the Pl-derived AN' transcripts, which have been 
reported to be expressed in lung cancer tumours [19], 
are also translated to ANp73 [14]. In other words, as 
ANp73 proteins are the translational products of both 
Pl-derived AN' and P2-derived AN transcripts, the 
decreased ANp73 levels may be attributed, at least in 
part, to the reduced activity of the p73 PI promoter. 
Finally, it is also possible that the influence of Spl on 
ANp73 levels might be the combinational and/or syn­
ergistic result of all the above-mentioned processes. 
Therefore, all of these issues should be addressed in 
the future.
Taken together, our findings make it clear that there 
is a link between the expression of Spl and p73 
isoforms in lung cancer. Not only does Spl have the 
potential to affect the TA and AN protein isoform 
levels, but its deregulated expression is also implicated 
in lung cancer. On the other hand, TAp73 overexpres­
sion in lung cancer could be linked to oncogene- 
induced DNA damage, as induction of p73 is DNA 
damage response-dependent [42,43]. The mechanisms 
that underlie the interplay between Spl and full-length 
or N-terminal-truncated p73 isoform(s) should be fur­
ther investigated.
Experimental procedures
Bioinformatics
The contra [44] web tool was used for tp73 PI promoter 
analysis, as follows. The direction of transcription of 
tp73 was identified, and the most upstream TSS of all tp73 
Ensembl [45] transcripts was selected. One thousand base 
pairs of the UCSC multiz 28-way 5000 upstream alignment.
homologous to the human tp73 PI promoter genomic 
sequences, were used for the initial analysis. The sequences 
were compared against the V$SPl_Q2_0i TRANSFAC 
position weight matrix of Spl target motifs with a core cut­
off of 0.90 and a similarity matrix cut-off of 0.75. The 
sequence alignment and its accompanying information 
regarding potential Spl sites were downloaded and viewed 
by jalview [46]. Through bioedit [47], the alignments were 
imported to Microsoft Word 2003 (http://www.micro 
soft.com/) for further manipulation.
Cell lines and culture conditions
The following human lung carcinoma cell lines used in this 
study were obtained from the American Type Culture Col­
lection (Rockville, MD, USA): HNBE, CCL171, IMR90, 
CALU6, DMS53, CRL5802, HTBIS2, HTB58, HTB59, 
SKMES1, A549, CALU3, CRL5935, SKLUl and 
CORL23. All cell lines were maintained in DMEM supple­
mented with 10% fetal bovine serum (Invitrogen, Carlsbad, 
CA, USA). To evaluate the effects of mithramycin A 
(Sigma-Aldrich, St Louis, MO, USA), 60-70% confluent 
cells were incubated with 50-400 hm mithramycin A in 
60-mm cell culture dishes for 48 h.
Patient characteristics and tumour specimens
Tumour specimens and their corresponding normal tissues 
were derived from 26 lung cancer patients, 18 males and 
eight females. Of the 26 patients, 19 were diagnosed with 
squamous cell carcinoma and seven with adenocarcinoma. 
The patients’ mean age was 68.6 years. All of the above- 
mentioned patients underwent surgical tumour excision at 
the Cardiothoracic Centre of Broadgreen, Liverpool, UK. 
The study protocol was approved by the Liverpool Ethics 
Committee and all of the patients provided written, 
informed consent.
Preparation of total cell lysates and nuclear 
extracts
For the preparation of total cell lysates, cells were lysed in 
lysis buffer (20 mmohL-1 Tris, pH 7.6, 0.5% Triton X-100, 
250 mmol L"1 NaCl, 3 mmoI-L_1 EDTA, 3 mmol-L"1 
EGTA, 10 g-mL-' Pefabloc, 2 mmol-L_t sodium ortho­
vanadate, 10 g-mL-1 aprotinin, 10 g-mL-1 leupeptin, and 
1 mmol-L-1 dithiothreitol). Lysates were incubated on ice 
for 30 min and then centrifuged at 8000 x g at 4 °C for 
10 min. The supernatant was aliquoted and stored at 
-70 °C.
For the preparation of nuclear extracts, cells were pel­
leted and homogenized in ice-cold hypotonic buffer (25 mM 
Tris, pH 7.5, 5 mM KCl, 0.5 mM MgCL, 0.5 mM dithiothre­
itol, 0.5 raM phenylmethanesulfonyl fluoride) with a Teflon-
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glass homogenizer. The nuclear fraction was pelleted, 
washed with isotonic buffer (25 him Tris, pH 7.5, 5 mM 
KC1, 0.5 mM MgCl2, 0.5 mM dithiothreitol, 1 mM phen- 
ylmethanesulfonyl fluoride, 0.2 mM sucrose) and lysed 
with extraction buffer (25 mM Tris, pH 7.5, 1 mM EDTA, 
0.1% Triton X-100, 0.5 mM dithiothreitol, 0.5 mM phen- 
ylmethanesulfonyl fluoride). Nuclear debris was removed 
by centrifugation at 55 000 g for 1 h at 4 °C. Estimations 
of the protein concentrations for both total cell lysates and 
nuclear extracts were performed using the Bio-Rad protein 
assay (Bio-Rad Laboratories, Hercules, CA, USA).
Protein extraction from tumour samples
Frozen tissue samples mixed with ice-cold RIPA buffer 
[1 x NaC!/Pi, 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium 
deoxycholate, 0.1% (v/v) SDS] (Sigma-Aldrich) containing 
protease inhibitors (Roche Applied Science, Hague Road, 
IN, USA) at a tissue/buffer volume ratio of 1 : 1. The mix­
ture was incubated on ice for 1 h and homogenized with 
frequent vortexing. The homogenate was centrifuged at 
13 000 g for 15 min at 4 °C, and the resulting supernatant 
was collected in a clean Eppendorf tube.
In vitro proteins
In vitro Spl was purchased from Promega (Madison, WI, 
USA). TAp73a, TAp73P and TAp73y were synthesized 
from the corresponding expression plasmids [9], using the 
TnT in vitro translation system (Promega).
EMSAs
Annealed oligonucleotides representing regions A, B, C and 
D of the human p73 PI promoter were used (Invitrogen). 
A consensus Spl-binding site and a mutant Spl-binding site 
were used as positive and negative control, respectively 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Oligo­
nucleotide sequences are summarized in Table 1. Annealed
oligonucleotides were end-labelled with [32P]ATP[yP], using 
T4 polynucleotide kinase (New England Biolabs, Ipwich, 
MA, USA), following the manufacturer’s instructions. 
Radiolabelled products were purified on Microspin G-25 
columns (GE Healthcare, Little Chalfont, UK), according 
to the manufacturer’s instructions. The reaction mixture 
was prepared by mixing 2000 c.p.m. of y-32P-labelled oligo­
nucleotide with 20 pg of nuclear cell protein in binding buf­
fer (50 mM Hepes, pH 8.0, 500 mM NaCl, 0.5 M
phenylmethanesulfonyl fluoride, 0.5 mg-mL^1 BSA, 20% 
glycerol, 1 mM EDTA) plus 1 mM dithiothreitol and 
150 pg-mL_1 poly(dl-dC) (Sigma-Aldrich), and left at room 
temperature for 30 min. The reaction mixtures were subse­
quently electrophoresed on a 6% polyacrylamide gel at 
150 V for 90 min, and the gel was dried and visualized by 
autoradiography. For the supershift assay, the reaction 
mixture was incubated with antibody against human Spl 
(PEP2) (Santa Cruz Biotechnology) for 30 min at 4 °C.
CHIP assay
Cells were crosslinked at a final concentration of 1 % form­
aldehyde for 10 min at 37 °C. Crosslinked cells were 
washed twice in ice-cold NaCl/P; and collected by centrifu­
gation for 5 min at 300 x g The pellet was resuspended in 
600 pL of buffer (50 mM Tris/HCl, pH 8.0, 85 mM KC1, 
0.5% NP40) and incubated for 10 min on ice. The solution 
was centrifuged for 5 min at 1700 x g, and the pellet was 
resuspended in 600 pL of lysis buffer (50 niM Hepes/KOH, 
pH 7.5, 150 mM NaCl, 1 mM EDTA, pH 8.0, 1% Tri­
ton X-100, 0.1% sodium deoxycholate, 0.1% SDS) contain­
ing protease inhibitors. Lysate was sonicated to shear DNA 
to an average fragment size of 500-1000 bp, and the debris 
was pelleted by centrifugation for 5 min at 11 000 x g and 
4 °C. The soluble chromatin material was further treated 
with salmon sperm DNA/protein A agarose 50% slurry 
(Upstate Biotechnology, Lake Placid, NY, USA). After 
overnight incubation with antibody against Spl (sc-59x) 
(Santa Cruz Biotechnology), the immune complexes were
Table 1. Oligonucleotides used in EMSA experiments. F, forward; R, reverse.
Name Position (relative to the TSS) Direction Oligonucleotides (5'- to 37
Region A -233 to -204 bp F aaaggcggcgggaaggaggcggggcagagc
R gctctgccccgcctccttcccgccgccttt
Region B -61 to -33 bp F cccgcggcgcctcccctccccgcgccca
R tgggcgcggggaggggaggcgccgcggg
Region C -20 to -1 bp F aggggccgggcagcccgccct
R agggcgggctgcccggcccct
Region D -4 to +20 bp F ccctgcctccccgcccgcgcaccc
R gggtgcgcgggcggggaggcaggg
Cold control oligonucleotide None F attcgatcggggcggggcgag
R ctcgccccgccccgatcgaat
mSpI None F attcgatcggttcggggcgag
R ctcgccccgaaccgatcgaat
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treated with 60 pL of salmon sperm DNA/protein A aga­
rose 50% slurry (Upstate Biotechnology) for 2 h at 4 °C. 
The beads were then washed sequentially for 5 min at room 
temperature in 1 mL of lysis buffer without SDS, in 1 mL 
of lysis buffer plus 500 mM NaCl, in 1 mL of buffer 
(10 mM Tris/HCl, pH 8.0, 1 dim EDTA, pH 8.0, 250 mM 
LiCl, 1% NP40, 1% sodium deoxycholate), and finally 
twice in Tris/EDTA. Immune complexes were eluted with 
200 pL of elution buffer (1% SDS, 50 mM Tris/HCl, 
pH 7.5, 10 mM EDTA) and incubated for 5 min at 65 °C. 
The pooled elutes were incubated with RNase for 1 h and 
with proteinase K for 4 h at 65 °C to reverse crosslinks. 
DNA was extracted by phenol/chloroform treatment and 
precipitated with 10 pg of glycogen and ethanol overnight 
at - 20 °C. The pelleted DNA was resuspended in 10 pL of 
nuclease free water and amplified by PCR. The PCR 
primers used were as follows: forward, 5'-TCG CCG GGC 
TCT GCA GGA G-3'; and reverse, 5'-GTT TCG CTG 
CGT CCC CTT CGC-3'.
siRNA transient transfection
Spl Validated Stealth RNAi DuoPak and its medium-GC 
content siRNA control (Invitrogen) were used for knock­
down of p73 and VEGF. A549 cells were harvested in six- 
well plates and transfected with Lipofectamine RNAiMAX 
according to the manufacturer’s instructions. Lipofecta- 
mine-containing medium was replaced after 6 h. Cells were 
collected following a 48-h incubation at 37 °C, and total 
proteins were isolated for western blot analysis.
Double-stranded oligonucleotide functional 
analysis
We used phosphorothioate oligonucleotides for regions A, B 
and C (Invitrogen) to transiently transfect the A549 cell line, 
as previously described [48]. Cells were harvested in six-well 
plates and transfected with 150 nM Spl-decoy oligonucleo­
tides, using Eugene transfection reagent (Roche Applied Sci­
ence), according to the manufacturer’s instructions. After 
4 h, the medium was replaced with fresh medium, without 
Eugene and oligonucleotides. The cells were collected 4, 12 
and 24 h after transfection, and total proteins extracted 
from these cells were subjected to western blot analysis.
Western blot analysis
Protein extracts (10 pg) were electrophoresed on an 8% 
SDS/polyacrylamide gel under reducing conditions, trans­
ferred to nitrocellulose membranes, and blocked for 2 h at 
room temperature. The blots were subsequently incubated 
overnight at 4 °C with the following primary antibodies: rab­
bit immunoglobulin against human Spl (PEP2) (Santa Cruz 
Biotechnology), mouse immunoglobulin against human 
P-actin (Abeam, Cambridge, UK), mouse immunoglobulin
against human full length p73 (which has been shown to rec­
ognize TAp73ct, TAp73p, and TAp73y [49]), rabbit immuno­
globulin against human VEGF (sc-507) (Santa Cruz 
Biotechnology), and mouse immunoglobulin against human 
ANp73 (Abeam), in 1 : 600, I : 1000, 1 : 4000, 1 : 500 and 
1 : 500 dilutions, respectively. The blots were incubated with 
the appropriate secondary horseradish peroxidase-conju­
gated antibodies (Santa Cruz, Santa Cruz, CA, USA) in cor­
responding dilutions of 1 : 8000, 1 : 5000, 1 : 10 000, 
1 : 3000 and 1 : 10 000 for 2 h at room temperature. Detec­
tion of protein levels was carried out using an enhanced 
chemiluminescence system (Pierce, Rockford, IL, USA). The 
protein amounts were normalized to p-actin and quantified 
using imagequant software (GE Healthcare, Little 
Chalfont, UK).
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